<?xml version="1.0" encoding="US-ASCII" ?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoXBRL; Version: 3.3b -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: http://www.novaworks.co -->
    <!-- Field: Doc-Info; Name: Source; Value: vista_10qxbrldec312012.xfr; Date: 2013/02/14T19:04:10 -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<xbrli:xbrl xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:dei="http://xbrl.sec.gov/dei/2012-01-31" xmlns:ref="http://www.xbrl.org/2006/ref" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:us-gaap="http://fasb.org/us-gaap/2012-01-31" xmlns:us-roles="http://fasb.org/us-roles/2012-01-31" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:num="http://www.xbrl.org/dtr/type/numeric" xmlns:us-types="http://fasb.org/us-types/2012-01-31" xmlns:VSTA="http://vistagen.com/20121231">
    <link:schemaRef xlink:href="vsta-20121231.xsd" xlink:type="simple" />
    <xbrli:context id="AsOf2013-02-12">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001411685</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2013-02-12</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2012-12-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001411685</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2012-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2012-03-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001411685</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2012-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2011-03-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001411685</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2011-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf1998-05-25">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001411685</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>1998-05-25</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2012-04-01to2012-12-31_PreModificationWarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001411685</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">VSTA:PreModificationWarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2012-04-01</xbrli:startDate>
        <xbrli:endDate>2012-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2012-04-01to2012-12-31_PostModificationWarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001411685</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">VSTA:PostModificationWarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2012-04-01</xbrli:startDate>
        <xbrli:endDate>2012-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2012-12-31_ShareBasedCompensationWarrantsOneMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001411685</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RangeAxis">VSTA:ShareBasedCompensationWarrantsOneMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2012-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2012-12-31_ShareBasedCompensationWarrantsTwoMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001411685</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RangeAxis">VSTA:ShareBasedCompensationWarrantsTwoMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2012-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2012-12-31_ShareBasedCompensationWarrantsFourMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001411685</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RangeAxis">VSTA:ShareBasedCompensationWarrantsFourMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2012-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2012-12-31_ShareBasedCompensationWarrantsFiveMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001411685</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RangeAxis">VSTA:ShareBasedCompensationWarrantsFiveMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2012-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2012-12-31_ShareBasedCompensationWarrantsSixMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001411685</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RangeAxis">VSTA:ShareBasedCompensationWarrantsSixMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2012-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2012-12-31_ShareBasedCompensationWarrantsSevenMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001411685</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RangeAxis">VSTA:ShareBasedCompensationWarrantsSevenMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2012-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2012-12-31_ShareBasedCompensationWarrantsEightMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001411685</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RangeAxis">VSTA:ShareBasedCompensationWarrantsEightMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2012-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2012-12-31_ShareBasedCompensationWarrantsNineMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001411685</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RangeAxis">VSTA:ShareBasedCompensationWarrantsNineMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2012-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2012-12-31_ShareBasedCompensationWarrantsElevenMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001411685</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RangeAxis">VSTA:ShareBasedCompensationWarrantsElevenMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2012-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2012-12-31_February2012ConvertibleNotes12PercentMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001411685</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">VSTA:February2012ConvertibleNotes12PercentMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2012-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2012-04-01to2012-04-30_InvestorRelationServicesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001411685</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">VSTA:InvestorRelationServicesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2012-04-01</xbrli:startDate>
        <xbrli:endDate>2012-04-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2012-06-01to2012-06-30_InvestorRelationsAndPublicCompanyServicesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001411685</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">VSTA:InvestorRelationsAndPublicCompanyServicesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2012-06-01</xbrli:startDate>
        <xbrli:endDate>2012-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2012-06-01to2012-06-30_AdditionalInvestorRelationsServicesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001411685</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">VSTA:AdditionalInvestorRelationsServicesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2012-06-01</xbrli:startDate>
        <xbrli:endDate>2012-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2012-05-15to2012-06-30_WarrantModificationsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001411685</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">VSTA:WarrantModificationsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2012-05-15</xbrli:startDate>
        <xbrli:endDate>2012-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2012-04-01to2012-06-30_ForegoingExercisesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001411685</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">VSTA:ForegoingExercisesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2012-04-01</xbrli:startDate>
        <xbrli:endDate>2012-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2012-06-29_PlatinumMember_SeriesAPreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001411685</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">VSTA:PlatinumMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2012-06-29</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2012-06-30_PlatinumMember_QualifiedFinancingMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001411685</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">VSTA:PlatinumMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">VSTA:QualifiedFinancingMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2012-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2011-10-01to2011-12-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001411685</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2011-10-01</xbrli:startDate>
        <xbrli:endDate>2011-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2011-04-01to2011-12-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001411685</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2011-04-01</xbrli:startDate>
        <xbrli:endDate>2011-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From1998-05-26to2012-12-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001411685</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>1998-05-26</xbrli:startDate>
        <xbrli:endDate>2012-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2012-12-31_CatoHoldingCompanyMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001411685</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">VSTA:CatoHoldingCompanyMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2012-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2012-04-01to2012-12-31_PreModificationMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001411685</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">VSTA:PreModificationMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2012-04-01</xbrli:startDate>
        <xbrli:endDate>2012-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2012-04-01to2012-12-31_PostModificationMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001411685</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">VSTA:PostModificationMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2012-04-01</xbrli:startDate>
        <xbrli:endDate>2012-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2012-10-01to2012-12-31_CatoBioVenturesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001411685</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">VSTA:CatoBioVenturesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2012-10-01</xbrli:startDate>
        <xbrli:endDate>2012-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2011-10-01to2011-12-31_CatoBioVenturesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001411685</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">VSTA:CatoBioVenturesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2011-10-01</xbrli:startDate>
        <xbrli:endDate>2011-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2011-04-01to2011-12-31_CatoBioVenturesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001411685</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">VSTA:CatoBioVenturesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2011-04-01</xbrli:startDate>
        <xbrli:endDate>2011-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2012-04-01to2012-12-31_CatoBioVenturesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001411685</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">VSTA:CatoBioVenturesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2012-04-01</xbrli:startDate>
        <xbrli:endDate>2012-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2012-04-01to2012-12-31_USNationalInstitutesOfHealthMember_NIHGrantRevenueMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001411685</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsAxis">VSTA:USNationalInstitutesOfHealthMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:DeferredRevenueArrangementTypeAxis">VSTA:NIHGrantRevenueMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2012-04-01</xbrli:startDate>
        <xbrli:endDate>2012-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2011-04-01to2011-12-31_USNationalInstitutesOfHealthMember_NIHGrantRevenueMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001411685</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsAxis">VSTA:USNationalInstitutesOfHealthMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:DeferredRevenueArrangementTypeAxis">VSTA:NIHGrantRevenueMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2011-04-01</xbrli:startDate>
        <xbrli:endDate>2011-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2012-12-31_CatoResearchLtdMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001411685</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">VSTA:CatoResearchLtdMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2012-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2012-12-31_IssuedToPlatinumOnTwoJulyTwoThousandTwelveMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001411685</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">VSTA:IssuedToPlatinumOnTwoJulyTwoThousandTwelveMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2012-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2012-12-31_IssuedToPlatinumOnThirtyAugustTwoThousandTwelveMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001411685</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">VSTA:IssuedToPlatinumOnThirtyAugustTwoThousandTwelveMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2012-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2012-12-31_SeniorNotesNonCurrentMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001411685</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">VSTA:SeniorNotesNonCurrentMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2012-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2012-12-31_NoteDiscountMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001411685</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">VSTA:NoteDiscountMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2012-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2012-12-31_SevenPercentNotesPayableAprilTwoThousandElevenMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001411685</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">VSTA:SevenPercentNotesPayableAprilTwoThousandElevenMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2012-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2012-12-31_SevenPercentNotesPayableAugustTwoThousandTwelveMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001411685</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">VSTA:SevenPercentNotesPayableAugustTwoThousandTwelveMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2012-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2012-12-31_SevenPercentNotesPayableMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001411685</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">VSTA:SevenPercentNotesPayableMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2012-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2012-12-31_CurrentPortionMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001411685</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">VSTA:CurrentPortionMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2012-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2012-12-31_SevenPercentNotesPayableNonCurrentPortionMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001411685</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">VSTA:SevenPercentNotesPayableNonCurrentPortionMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2012-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2012-12-31_BurrPilgerMayerMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001411685</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">VSTA:BurrPilgerMayerMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2012-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2012-12-31_DesjardinsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001411685</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">VSTA:DesjardinsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2012-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2012-12-31_McCarthyTetraultMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001411685</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">VSTA:McCarthyTetraultMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2012-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2012-12-31_MayTwoThousandElevenMorrisonFoersterMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001411685</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">VSTA:MayTwoThousandElevenMorrisonFoersterMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2012-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2012-12-31_AugustTwoThousandTwelveMorrisonAndFoersterNoteAMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001411685</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">VSTA:AugustTwoThousandTwelveMorrisonAndFoersterNoteAMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2012-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2012-12-31_AugustTwoThousandTwelveMorrisonAndFoersterNoteBMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001411685</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">VSTA:AugustTwoThousandTwelveMorrisonAndFoersterNoteBMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2012-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2012-12-31_NoteDiscountOneMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001411685</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">VSTA:NoteDiscountOneMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2012-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2012-12-31_SevenPointFivePercentNotesPayableMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001411685</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">VSTA:SevenPointFivePercentNotesPayableMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2012-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2012-12-31_CurrentPortionOneMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001411685</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">VSTA:CurrentPortionOneMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2012-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2012-12-31_NonCurrentPortionAndDiscountMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001411685</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">VSTA:NonCurrentPortionAndDiscountMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2012-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2012-12-31_FivePointEightPercentAndEightPercentNotesPayableToInsurancePremiumFinancingCompanyCurrentMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001411685</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">VSTA:FivePointEightPercentAndEightPercentNotesPayableToInsurancePremiumFinancingCompanyCurrentMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2012-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2012-12-31_TenPercentNotesPayableToVendorsForAccountsPayableConvertedToNotesPayableMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001411685</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">VSTA:TenPercentNotesPayableToVendorsForAccountsPayableConvertedToNotesPayableMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2012-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2012-12-31_CurrentPortionTwoMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001411685</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">VSTA:CurrentPortionTwoMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2012-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2012-12-31_NonCurrentPortionMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001411685</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">VSTA:NonCurrentPortionMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2012-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2012-12-31_TenPercentNotesPayableToUnrelatedPartiesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001411685</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">VSTA:TenPercentNotesPayableToUnrelatedPartiesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2012-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2012-12-31_CurrentPortionThreeMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001411685</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">VSTA:CurrentPortionThreeMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2012-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2012-12-31_NonCurrentPortionAndDiscountOneMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001411685</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">VSTA:NonCurrentPortionAndDiscountOneMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2012-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2012-12-31_SevenPercentNotePayableToCatoHoldingMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001411685</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">VSTA:SevenPercentNotePayableToCatoHoldingMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2012-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2012-12-31_NoteDiscountTwoMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001411685</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">VSTA:NoteDiscountTwoMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2012-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2012-12-31_NotesPayableToRelatedPartiesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001411685</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">VSTA:NotesPayableToRelatedPartiesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2012-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2012-12-31_CurrentPortionFourMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001411685</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">VSTA:CurrentPortionFourMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2012-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2012-12-31_NonCurrentPortionAndDiscountTwoMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001411685</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">VSTA:NonCurrentPortionAndDiscountTwoMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2012-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2012-03-31_IssuedToPlatinumOnTwoJulyTwoThousandTwelveMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001411685</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">VSTA:IssuedToPlatinumOnTwoJulyTwoThousandTwelveMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2012-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2012-03-31_IssuedToPlatinumOnThirtyAugustTwoThousandTwelveMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001411685</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">VSTA:IssuedToPlatinumOnThirtyAugustTwoThousandTwelveMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2012-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2012-03-31_SeniorNotesNonCurrentMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001411685</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">VSTA:SeniorNotesNonCurrentMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2012-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2012-03-31_FebruaryTwoThousandTwelveTwelvePercentConvertiblePromissoryNotesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001411685</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">VSTA:FebruaryTwoThousandTwelveTwelvePercentConvertiblePromissoryNotesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2012-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2012-03-31_NoteDiscountMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001411685</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">VSTA:NoteDiscountMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2012-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2012-03-31_TwelvePercentConvertibleNotesNetNnonCurrentMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001411685</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">VSTA:TwelvePercentConvertibleNotesNetNnonCurrentMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2012-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2012-03-31_SevenPercentNotesPayableAprilTwoThousandElevenMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001411685</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">VSTA:SevenPercentNotesPayableAprilTwoThousandElevenMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2012-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2012-03-31_SevenPercentNotesPayableAugustTwoThousandTwelveMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001411685</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">VSTA:SevenPercentNotesPayableAugustTwoThousandTwelveMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2012-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2012-03-31_SevenPercentNotesPayableMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001411685</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">VSTA:SevenPercentNotesPayableMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2012-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2012-03-31_CurrentPortionMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001411685</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">VSTA:CurrentPortionMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2012-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2012-03-31_SevenPercentNotesPayableNonCurrentPortionMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001411685</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">VSTA:SevenPercentNotesPayableNonCurrentPortionMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2012-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2012-03-31_BurrPilgerMayerMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001411685</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">VSTA:BurrPilgerMayerMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2012-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2012-03-31_DesjardinsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001411685</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">VSTA:DesjardinsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2012-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2012-03-31_McCarthyTetraultMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001411685</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">VSTA:McCarthyTetraultMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2012-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2012-03-31_MayTwoThousandElevenMorrisonFoersterMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001411685</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">VSTA:MayTwoThousandElevenMorrisonFoersterMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2012-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2012-03-31_AugustTwoThousandTwelveMorrisonAndFoersterNoteAMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001411685</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">VSTA:AugustTwoThousandTwelveMorrisonAndFoersterNoteAMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2012-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2012-03-31_AugustTwoThousandTwelveMorrisonAndFoersterNoteBMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001411685</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">VSTA:AugustTwoThousandTwelveMorrisonAndFoersterNoteBMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2012-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2012-03-31_NoteDiscountOneMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001411685</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">VSTA:NoteDiscountOneMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2012-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2012-03-31_SevenPointFivePercentNotesPayableMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001411685</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">VSTA:SevenPointFivePercentNotesPayableMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2012-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2012-03-31_CurrentPortionOneMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001411685</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">VSTA:CurrentPortionOneMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2012-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2012-03-31_NonCurrentPortionAndDiscountMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001411685</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">VSTA:NonCurrentPortionAndDiscountMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2012-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2012-03-31_FivePointEightPercentAndEightPercentNotesPayableToInsurancePremiumFinancingCompanyCurrentMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001411685</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">VSTA:FivePointEightPercentAndEightPercentNotesPayableToInsurancePremiumFinancingCompanyCurrentMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2012-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2012-03-31_TenPercentNotesPayableToVendorsForAccountsPayableConvertedToNotesPayableMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001411685</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">VSTA:TenPercentNotesPayableToVendorsForAccountsPayableConvertedToNotesPayableMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2012-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2012-03-31_CurrentPortionTwoMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001411685</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">VSTA:CurrentPortionTwoMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2012-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2012-03-31_NonCurrentPortionMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001411685</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">VSTA:NonCurrentPortionMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2012-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2012-03-31_TenPercentNotesPayableToUnrelatedPartiesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001411685</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">VSTA:TenPercentNotesPayableToUnrelatedPartiesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2012-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2012-03-31_CurrentPortionThreeMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001411685</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">VSTA:CurrentPortionThreeMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2012-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2012-03-31_NonCurrentPortionAndDiscountOneMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001411685</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">VSTA:NonCurrentPortionAndDiscountOneMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2012-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2012-03-31_SevenPercentNotePayableToCatoHoldingMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001411685</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">VSTA:SevenPercentNotePayableToCatoHoldingMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2012-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2012-03-31_NoteDiscountTwoMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001411685</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">VSTA:NoteDiscountTwoMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2012-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2012-03-31_NotesPayableToRelatedPartiesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001411685</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">VSTA:NotesPayableToRelatedPartiesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2012-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2012-03-31_CurrentPortionFourMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001411685</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">VSTA:CurrentPortionFourMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2012-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2012-03-31_NonCurrentPortionAndDiscountTwoMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001411685</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">VSTA:NonCurrentPortionAndDiscountTwoMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2012-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2012-12-31_FebruaryTwoThousandTwelveTwelvePercentConvertiblePromissoryNotesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001411685</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">VSTA:FebruaryTwoThousandTwelveTwelvePercentConvertiblePromissoryNotesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2012-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2012-12-31_TwelvePercentConvertibleNotesNetNnonCurrentMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001411685</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">VSTA:TwelvePercentConvertibleNotesNetNnonCurrentMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2012-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2012-12-31_ShareBasedCompensationWarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001411685</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RangeAxis">VSTA:ShareBasedCompensationWarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2012-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2011-12-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001411685</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2011-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2012-04-01to2012-12-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001411685</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2012-04-01</xbrli:startDate>
        <xbrli:endDate>2012-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2012-12-31_MaximumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001411685</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsByReportLineAxis">us-gaap:MaximumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2012-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2012-12-31_MinimumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001411685</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsByReportLineAxis">us-gaap:MinimumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2012-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2012-10-01to2012-12-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001411685</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2012-10-01</xbrli:startDate>
        <xbrli:endDate>2012-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:unit id="USD">
      <xbrli:measure>iso4217:USD</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="Shares">
      <xbrli:measure>xbrli:shares</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="USDPShares">
      <xbrli:divide>
        <xbrli:unitNumerator>
          <xbrli:measure>iso4217:USD</xbrli:measure>
        </xbrli:unitNumerator>
        <xbrli:unitDenominator>
          <xbrli:measure>xbrli:shares</xbrli:measure>
        </xbrli:unitDenominator>
      </xbrli:divide>
    </xbrli:unit>
    <xbrli:unit id="Percent">
      <xbrli:measure>xbrli:pure</xbrli:measure>
    </xbrli:unit>
    <us-gaap:ProceedsFromIssuanceOfCommonStock contextRef="From2012-05-15to2012-06-30_WarrantModificationsMember" unitRef="USD" decimals="0">257300</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromIssuanceOfCommonStock contextRef="From2011-04-01to2011-12-31" unitRef="USD" decimals="0">2528400</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromIssuanceOfCommonStock contextRef="From1998-05-26to2012-12-31" unitRef="USD" decimals="0">3280600</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromIssuanceOfCommonStock contextRef="From2012-04-01to2012-12-31" unitRef="USD" decimals="0">480600</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <VSTA:PreferredStockSeriesPerValue1 contextRef="AsOf2012-12-31" unitRef="USDPShares" decimals="INF">0.001</VSTA:PreferredStockSeriesPerValue1>
    <VSTA:PreferredStockSeriesPerValue1 contextRef="AsOf2012-03-31" unitRef="USDPShares" decimals="INF">0.001</VSTA:PreferredStockSeriesPerValue1>
    <VSTA:PreferredStockSeriesASharesAuthorized contextRef="AsOf2012-12-31" unitRef="USD" decimals="0">500000</VSTA:PreferredStockSeriesASharesAuthorized>
    <VSTA:PreferredStockSeriesASharesAuthorized contextRef="AsOf2012-03-31" unitRef="USD" decimals="0">500000</VSTA:PreferredStockSeriesASharesAuthorized>
    <VSTA:PreferredStockSeriesASharesIssued contextRef="AsOf2012-12-31" unitRef="USD" decimals="0">500000</VSTA:PreferredStockSeriesASharesIssued>
    <VSTA:PreferredStockSeriesASharesIssued contextRef="AsOf2012-03-31" unitRef="USD" decimals="0">437055</VSTA:PreferredStockSeriesASharesIssued>
    <VSTA:PreferredStockSeriesASharesOutstanding contextRef="AsOf2012-12-31" unitRef="USD" decimals="0">500000</VSTA:PreferredStockSeriesASharesOutstanding>
    <VSTA:PreferredStockSeriesASharesOutstanding contextRef="AsOf2012-03-31" unitRef="USD" decimals="0">437055</VSTA:PreferredStockSeriesASharesOutstanding>
    <us-gaap:CommonStockParOrStatedValuePerShare contextRef="AsOf2012-12-31" unitRef="USDPShares" decimals="INF">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare contextRef="AsOf2012-03-31" unitRef="USDPShares" decimals="INF">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare contextRef="AsOf2012-06-29_PlatinumMember_SeriesAPreferredStockMember" unitRef="USDPShares" decimals="INF">15</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized contextRef="AsOf2012-12-31" unitRef="Shares" decimals="INF">200000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized contextRef="AsOf2012-03-31" unitRef="Shares" decimals="INF">200000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesIssued contextRef="AsOf2012-12-31" unitRef="Shares" decimals="INF">22065095</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesIssued contextRef="AsOf2012-03-31" unitRef="Shares" decimals="INF">18704267</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding contextRef="AsOf2012-06-29_PlatinumMember_SeriesAPreferredStockMember" unitRef="Shares" decimals="INF">500000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:TreasuryStockShares contextRef="AsOf2012-12-31" unitRef="Shares" decimals="INF">2713308</us-gaap:TreasuryStockShares>
    <us-gaap:TreasuryStockShares contextRef="AsOf2012-03-31" unitRef="Shares" decimals="INF">2083858</us-gaap:TreasuryStockShares>
    <us-gaap:PreferredStockSharesIssued contextRef="AsOf2012-12-31" unitRef="Shares" decimals="INF">15000000</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesIssued contextRef="AsOf2012-06-29_PlatinumMember_SeriesAPreferredStockMember" unitRef="Shares" decimals="INF">62945</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesIssued contextRef="AsOf2011-12-31" unitRef="Shares" decimals="INF">4370550</us-gaap:PreferredStockSharesIssued>
    <VSTA:InvestorRelationsAndAwarenessServicesPaidByIssuanceOfCommonStockOrWarrants contextRef="AsOf2012-12-31" unitRef="USD" xsi:nil="true" />
    <VSTA:InvestorRelationsAndAwarenessServicesPaidByIssuanceOfCommonStockOrWarrants contextRef="AsOf2012-03-31" unitRef="USD" decimals="0">19700</VSTA:InvestorRelationsAndAwarenessServicesPaidByIssuanceOfCommonStockOrWarrants>
    <us-gaap:AccruedProfessionalFeesCurrent contextRef="AsOf2012-12-31" unitRef="USD" decimals="0">68300</us-gaap:AccruedProfessionalFeesCurrent>
    <us-gaap:AccruedProfessionalFeesCurrent contextRef="AsOf2012-03-31" unitRef="USD" decimals="0">107400</us-gaap:AccruedProfessionalFeesCurrent>
    <VSTA:MarketPricePerShare contextRef="From2012-04-01to2012-12-31_PreModificationWarrantsMember" unitRef="USDPShares" decimals="INF">1.95</VSTA:MarketPricePerShare>
    <VSTA:MarketPricePerShare contextRef="From2012-04-01to2012-12-31_PostModificationWarrantsMember" unitRef="USDPShares" decimals="INF">1.95</VSTA:MarketPricePerShare>
    <VSTA:MarketPricePerShare contextRef="From2012-04-01to2012-12-31_PreModificationMember" unitRef="USDPShares" decimals="INF">0.94</VSTA:MarketPricePerShare>
    <VSTA:MarketPricePerShare contextRef="From2012-04-01to2012-12-31_PostModificationMember" unitRef="USDPShares" decimals="INF">0.94</VSTA:MarketPricePerShare>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit contextRef="From2012-04-01to2012-12-31_PreModificationWarrantsMember" unitRef="USDPShares" decimals="INF">6</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit contextRef="From2012-04-01to2012-12-31_PostModificationWarrantsMember" unitRef="USDPShares" decimals="INF">0.5</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit>
    <VSTA:WeightedAverageFairValuePerShare contextRef="From2012-04-01to2012-12-31_PreModificationWarrantsMember" unitRef="USDPShares" decimals="INF">0.65</VSTA:WeightedAverageFairValuePerShare>
    <VSTA:WeightedAverageFairValuePerShare contextRef="From2012-04-01to2012-12-31_PostModificationWarrantsMember" unitRef="USDPShares" decimals="INF">1.46</VSTA:WeightedAverageFairValuePerShare>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate contextRef="From2012-04-01to2012-12-31_PreModificationWarrantsMember" unitRef="Percent" decimals="INF">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate contextRef="From2012-04-01to2012-12-31_PostModificationWarrantsMember" unitRef="Percent" decimals="INF">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum contextRef="From2012-04-01to2012-12-31_PreModificationWarrantsMember" unitRef="Percent" decimals="INF">0.857</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum contextRef="From2012-04-01to2012-12-31_PostModificationWarrantsMember" unitRef="Percent" decimals="INF">0.857</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum contextRef="From2012-04-01to2012-12-31_PreModificationWarrantsMember" unitRef="Percent" decimals="INF">0.745</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum contextRef="From2012-04-01to2012-12-31_PostModificationWarrantsMember" unitRef="Percent" decimals="INF">0.857</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum>
    <VSTA:ExpectedTermYearsMaximum contextRef="From2012-04-01to2012-12-31_PreModificationWarrantsMember">P2Y10M6D</VSTA:ExpectedTermYearsMaximum>
    <VSTA:ExpectedTermYearsMaximum contextRef="From2012-04-01to2012-12-31_PostModificationWarrantsMember">P1M13D</VSTA:ExpectedTermYearsMaximum>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="From2012-04-01to2012-12-31_PreModificationWarrantsMember">P7M13D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="From2012-04-01to2012-12-31_PostModificationWarrantsMember">P1M13D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum contextRef="From2012-04-01to2012-12-31_PreModificationWarrantsMember" unitRef="Percent" decimals="INF">0.0041</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum contextRef="From2012-04-01to2012-12-31_PostModificationWarrantsMember" unitRef="Percent" decimals="INF">0.0006</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum contextRef="From2012-04-01to2012-12-31_PreModificationWarrantsMember" unitRef="Percent" decimals="INF">.0029</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum contextRef="From2012-04-01to2012-12-31_PostModificationWarrantsMember" unitRef="Percent" decimals="INF">.0006</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="AsOf2012-12-31" unitRef="Shares" decimals="INF">4966771</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="AsOf2012-12-31_ShareBasedCompensationWarrantsOneMember" unitRef="Shares" decimals="INF">15428</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="AsOf2012-12-31_ShareBasedCompensationWarrantsTwoMember" unitRef="Shares" decimals="INF">2998809</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="AsOf2012-12-31_ShareBasedCompensationWarrantsFourMember" unitRef="Shares" decimals="INF">120280</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="AsOf2012-12-31_ShareBasedCompensationWarrantsFiveMember" unitRef="Shares" decimals="INF">4021570</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="AsOf2012-12-31_ShareBasedCompensationWarrantsSixMember" unitRef="Shares" decimals="INF">577784</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="AsOf2012-12-31_ShareBasedCompensationWarrantsSevenMember" unitRef="Shares" decimals="INF">604000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="AsOf2012-12-31_ShareBasedCompensationWarrantsEightMember" unitRef="Shares" decimals="INF">492004</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="AsOf2012-12-31_ShareBasedCompensationWarrantsNineMember" unitRef="Shares" decimals="INF">480134</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="AsOf2012-12-31_ShareBasedCompensationWarrantsElevenMember" unitRef="Shares" decimals="INF">563025</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="AsOf2012-12-31_ShareBasedCompensationWarrantsMember" unitRef="Shares" decimals="INF">9873034</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <VSTA:ExercisePrice contextRef="AsOf2012-12-31_ShareBasedCompensationWarrantsOneMember" unitRef="USDPShares" decimals="INF">0.88</VSTA:ExercisePrice>
    <VSTA:ExercisePrice contextRef="AsOf2012-12-31_ShareBasedCompensationWarrantsTwoMember" unitRef="USDPShares" decimals="INF">1.00</VSTA:ExercisePrice>
    <VSTA:ExercisePrice contextRef="AsOf2012-12-31_ShareBasedCompensationWarrantsFourMember" unitRef="USDPShares" decimals="INF">1.25</VSTA:ExercisePrice>
    <VSTA:ExercisePrice contextRef="AsOf2012-12-31_ShareBasedCompensationWarrantsFiveMember" unitRef="USDPShares" decimals="INF">1.50</VSTA:ExercisePrice>
    <VSTA:ExercisePrice contextRef="AsOf2012-12-31_ShareBasedCompensationWarrantsSixMember" unitRef="USDPShares" decimals="INF">1.75</VSTA:ExercisePrice>
    <VSTA:ExercisePrice contextRef="AsOf2012-12-31_ShareBasedCompensationWarrantsSevenMember" unitRef="USDPShares" decimals="INF">2.00</VSTA:ExercisePrice>
    <VSTA:ExercisePrice contextRef="AsOf2012-12-31_ShareBasedCompensationWarrantsEightMember" unitRef="USDPShares" decimals="INF">2.50</VSTA:ExercisePrice>
    <VSTA:ExercisePrice contextRef="AsOf2012-12-31_ShareBasedCompensationWarrantsNineMember" unitRef="USDPShares" decimals="INF">2.625</VSTA:ExercisePrice>
    <VSTA:ExercisePrice contextRef="AsOf2012-12-31_ShareBasedCompensationWarrantsElevenMember" unitRef="USDPShares" decimals="INF">3.00</VSTA:ExercisePrice>
    <us-gaap:ConvertibleNotesPayable contextRef="AsOf2012-12-31" unitRef="USD" decimals="0">4000000</us-gaap:ConvertibleNotesPayable>
    <us-gaap:ConvertibleNotesPayable contextRef="AsOf2012-06-29_PlatinumMember_SeriesAPreferredStockMember" unitRef="USD" decimals="0">500000</us-gaap:ConvertibleNotesPayable>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward contextRef="From2012-04-01to2012-04-30_InvestorRelationServicesMember" unitRef="Shares" decimals="INF">50000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward contextRef="From2012-06-01to2012-06-30_InvestorRelationsAndPublicCompanyServicesMember" unitRef="Shares" decimals="INF">100000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward contextRef="From2012-05-15to2012-06-30_WarrantModificationsMember" unitRef="Shares" decimals="INF">25000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward contextRef="From2012-04-01to2012-06-30_ForegoingExercisesMember" unitRef="Shares" decimals="INF">179857</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward>
    <VSTA:InvestmentWarrantsExercisePrice contextRef="From2012-04-01to2012-04-30_InvestorRelationServicesMember" unitRef="USDPShares" decimals="INF">2.80</VSTA:InvestmentWarrantsExercisePrice>
    <VSTA:InvestmentWarrantsExercisePrice contextRef="From2012-06-01to2012-06-30_InvestorRelationsAndPublicCompanyServicesMember" unitRef="USDPShares" decimals="INF">3</VSTA:InvestmentWarrantsExercisePrice>
    <VSTA:InvestmentWarrantsExercisePrice contextRef="From2012-04-01to2012-06-30_ForegoingExercisesMember" unitRef="USDPShares" decimals="INF">3</VSTA:InvestmentWarrantsExercisePrice>
    <us-gaap:StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants contextRef="From2012-04-01to2012-04-30_InvestorRelationServicesMember" unitRef="USD" decimals="0">69200</us-gaap:StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants>
    <us-gaap:StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants contextRef="From2012-06-01to2012-06-30_InvestorRelationsAndPublicCompanyServicesMember" unitRef="USD" decimals="0">25800</us-gaap:StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants>
    <us-gaap:StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants contextRef="From2012-04-01to2012-06-30_ForegoingExercisesMember" unitRef="USD" decimals="0">34800</us-gaap:StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants>
    <VSTA:SharePrice1 contextRef="From2012-04-01to2012-04-30_InvestorRelationServicesMember" unitRef="USDPShares" decimals="INF">2.74</VSTA:SharePrice1>
    <VSTA:SharePrice1 contextRef="From2012-06-01to2012-06-30_InvestorRelationsAndPublicCompanyServicesMember" unitRef="USDPShares" decimals="INF">0.85</VSTA:SharePrice1>
    <VSTA:SharePrice1 contextRef="From2012-06-01to2012-06-30_AdditionalInvestorRelationsServicesMember" unitRef="USDPShares" decimals="INF">0.85</VSTA:SharePrice1>
    <VSTA:SharePrice1 contextRef="From2012-04-01to2012-06-30_ForegoingExercisesMember" unitRef="USDPShares" decimals="INF">0.89</VSTA:SharePrice1>
    <VSTA:ShareBasedCompensationArrangementByShareBasedPaymentAwardPerShareWeightedAveragePriceOfSharesPurchased1 contextRef="From2012-04-01to2012-04-30_InvestorRelationServicesMember" unitRef="USDPShares" decimals="INF">2.8</VSTA:ShareBasedCompensationArrangementByShareBasedPaymentAwardPerShareWeightedAveragePriceOfSharesPurchased1>
    <VSTA:ShareBasedCompensationArrangementByShareBasedPaymentAwardPerShareWeightedAveragePriceOfSharesPurchased1 contextRef="From2012-06-01to2012-06-30_InvestorRelationsAndPublicCompanyServicesMember" unitRef="USDPShares" decimals="INF">3</VSTA:ShareBasedCompensationArrangementByShareBasedPaymentAwardPerShareWeightedAveragePriceOfSharesPurchased1>
    <VSTA:ShareBasedCompensationArrangementByShareBasedPaymentAwardPerShareWeightedAveragePriceOfSharesPurchased1 contextRef="From2012-05-15to2012-06-30_WarrantModificationsMember" unitRef="USDPShares" decimals="INF">2.24</VSTA:ShareBasedCompensationArrangementByShareBasedPaymentAwardPerShareWeightedAveragePriceOfSharesPurchased1>
    <VSTA:ShareBasedCompensationArrangementByShareBasedPaymentAwardPerShareWeightedAveragePriceOfSharesPurchased1 contextRef="From2012-04-01to2012-06-30_ForegoingExercisesMember" unitRef="USDPShares" decimals="INF">3</VSTA:ShareBasedCompensationArrangementByShareBasedPaymentAwardPerShareWeightedAveragePriceOfSharesPurchased1>
    <us-gaap:FairValueAssumptionsRiskFreeInterestRate contextRef="From2012-04-01to2012-04-30_InvestorRelationServicesMember" unitRef="Percent" decimals="INF">0.0050</us-gaap:FairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:FairValueAssumptionsRiskFreeInterestRate contextRef="From2012-06-01to2012-06-30_InvestorRelationsAndPublicCompanyServicesMember" unitRef="Percent" decimals="INF">0.0046</us-gaap:FairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:FairValueAssumptionsRiskFreeInterestRate contextRef="From2012-04-01to2012-06-30_ForegoingExercisesMember" unitRef="Percent" decimals="INF">0.0042</us-gaap:FairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:FairValueAssumptionsRiskFreeInterestRate contextRef="From2012-04-01to2012-12-31_PreModificationMember" unitRef="Percent" decimals="INF">0.25</us-gaap:FairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:FairValueAssumptionsRiskFreeInterestRate contextRef="From2012-04-01to2012-12-31_PostModificationMember" unitRef="Percent" decimals="INF">0.6</us-gaap:FairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:FairValueAssumptionsWeightedAverageVolatilityRate contextRef="From2012-04-01to2012-04-30_InvestorRelationServicesMember" unitRef="Percent" decimals="INF">0.7909</us-gaap:FairValueAssumptionsWeightedAverageVolatilityRate>
    <us-gaap:FairValueAssumptionsWeightedAverageVolatilityRate contextRef="From2012-06-01to2012-06-30_InvestorRelationsAndPublicCompanyServicesMember" unitRef="Percent" decimals="INF">0.8428</us-gaap:FairValueAssumptionsWeightedAverageVolatilityRate>
    <us-gaap:FairValueAssumptionsWeightedAverageVolatilityRate contextRef="From2012-04-01to2012-06-30_ForegoingExercisesMember" unitRef="Percent" decimals="INF">0.7804</us-gaap:FairValueAssumptionsWeightedAverageVolatilityRate>
    <us-gaap:FairValueAssumptionsExpectedDividendRate contextRef="From2012-04-01to2012-04-30_InvestorRelationServicesMember" unitRef="Percent" decimals="INF">0</us-gaap:FairValueAssumptionsExpectedDividendRate>
    <us-gaap:FairValueAssumptionsExpectedDividendRate contextRef="From2012-06-01to2012-06-30_InvestorRelationsAndPublicCompanyServicesMember" unitRef="Percent" decimals="INF">0</us-gaap:FairValueAssumptionsExpectedDividendRate>
    <us-gaap:FairValueAssumptionsExpectedDividendRate contextRef="From2012-04-01to2012-06-30_ForegoingExercisesMember" unitRef="Percent" decimals="INF">0</us-gaap:FairValueAssumptionsExpectedDividendRate>
    <us-gaap:FairValueAssumptionsExpectedDividendRate contextRef="From2012-04-01to2012-12-31_PreModificationMember" unitRef="Percent" decimals="INF">0</us-gaap:FairValueAssumptionsExpectedDividendRate>
    <us-gaap:FairValueAssumptionsExpectedDividendRate contextRef="From2012-04-01to2012-12-31_PostModificationMember" unitRef="Percent" decimals="INF">0</us-gaap:FairValueAssumptionsExpectedDividendRate>
    <VSTA:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant1 contextRef="From2012-06-01to2012-06-30_InvestorRelationsAndPublicCompanyServicesMember" unitRef="Shares" decimals="INF">280000</VSTA:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant1>
    <VSTA:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant1 contextRef="From2012-06-01to2012-06-30_AdditionalInvestorRelationsServicesMember" unitRef="Shares" decimals="INF">120000</VSTA:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant1>
    <VSTA:CommonStockValue1 contextRef="From2012-06-01to2012-06-30_InvestorRelationsAndPublicCompanyServicesMember" unitRef="USD" decimals="0">238000</VSTA:CommonStockValue1>
    <VSTA:CommonStockValue1 contextRef="From2012-06-01to2012-06-30_AdditionalInvestorRelationsServicesMember" unitRef="USD" decimals="0">102000</VSTA:CommonStockValue1>
    <VSTA:AmountsDueForServices contextRef="From2012-05-15to2012-06-30_WarrantModificationsMember" unitRef="USD" decimals="0">12500</VSTA:AmountsDueForServices>
    <VSTA:CommonStockPurchseDiscription contextRef="From2012-05-15to2012-06-30_WarrantModificationsMember">For every three discounted warrant shares exercised by the warrant holders, the Company granted a three-year warrant to purchase one share of its common stock at an exercise price of $3.00 per share.</VSTA:CommonStockPurchseDiscription>
    <VSTA:IncreasedValueOfWarrantsExercised contextRef="From2012-05-15to2012-06-30_WarrantModificationsMember" unitRef="USD" decimals="0">436400</VSTA:IncreasedValueOfWarrantsExercised>
    <VSTA:CommonStockOwned contextRef="AsOf2012-06-29_PlatinumMember_SeriesAPreferredStockMember" unitRef="Shares" decimals="INF">629450</VSTA:CommonStockOwned>
    <VSTA:SecuredConvertiblePromissoryNote1 contextRef="AsOf2012-06-29_PlatinumMember_SeriesAPreferredStockMember" unitRef="Percent" decimals="INF">0.10</VSTA:SecuredConvertiblePromissoryNote1>
    <VSTA:FinancingTransactionsGrossProceeds contextRef="AsOf2012-06-30_PlatinumMember_QualifiedFinancingMember" unitRef="USD" decimals="0">3</VSTA:FinancingTransactionsGrossProceeds>
    <VSTA:InvestmentInQualifiedFinancing contextRef="AsOf2012-06-30_PlatinumMember_QualifiedFinancingMember" unitRef="USD" decimals="0">500000</VSTA:InvestmentInQualifiedFinancing>
    <VSTA:AmountOfCommitmentsFromOtherInvestors contextRef="AsOf2012-06-30_PlatinumMember_QualifiedFinancingMember" unitRef="USD" decimals="0">3</VSTA:AmountOfCommitmentsFromOtherInvestors>
    <us-gaap:RegistrationPaymentArrangementAccrualCarryingValue contextRef="AsOf2012-12-31_February2012ConvertibleNotes12PercentMember" unitRef="USD" decimals="0">20700</us-gaap:RegistrationPaymentArrangementAccrualCarryingValue>
    <VSTA:ContractualTerm1 contextRef="From2012-04-01to2012-04-30_InvestorRelationServicesMember">P3Y</VSTA:ContractualTerm1>
    <VSTA:ContractualTerm1 contextRef="From2012-06-01to2012-06-30_InvestorRelationsAndPublicCompanyServicesMember">P3Y6M11D</VSTA:ContractualTerm1>
    <VSTA:ContractualTerm1 contextRef="From2012-04-01to2012-06-30_ForegoingExercisesMember">P3Y</VSTA:ContractualTerm1>
    <VSTA:PeriodOfCommitmentsFromOtherInvestors2 contextRef="AsOf2012-06-30_PlatinumMember_QualifiedFinancingMember">P90D</VSTA:PeriodOfCommitmentsFromOtherInvestors2>
    <us-gaap:ChemicalsRevenue contextRef="From2012-04-01to2012-12-31_USNationalInstitutesOfHealthMember_NIHGrantRevenueMember" unitRef="USD" decimals="0">187000</us-gaap:ChemicalsRevenue>
    <us-gaap:ChemicalsRevenue contextRef="From2011-04-01to2011-12-31_USNationalInstitutesOfHealthMember_NIHGrantRevenueMember" unitRef="USD" decimals="0">731000</us-gaap:ChemicalsRevenue>
    <us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost contextRef="From2012-10-01to2012-12-31_CatoBioVenturesMember" unitRef="USD" decimals="0">124700</us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost>
    <us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost contextRef="From2011-10-01to2011-12-31_CatoBioVenturesMember" unitRef="USD" decimals="0">360000</us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost>
    <us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost contextRef="From2011-04-01to2011-12-31_CatoBioVenturesMember" unitRef="USD" decimals="0">1019000</us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost>
    <us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost contextRef="From2012-04-01to2012-12-31_CatoBioVenturesMember" unitRef="USD" decimals="0">639300</us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost>
    <us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost contextRef="From2012-04-01to2012-12-31_USNationalInstitutesOfHealthMember_NIHGrantRevenueMember" unitRef="USD" decimals="0">639300</us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost>
    <us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost contextRef="From2011-04-01to2011-12-31_USNationalInstitutesOfHealthMember_NIHGrantRevenueMember" unitRef="USD" decimals="0">1019000</us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost>
    <us-gaap:InterestIncomeExpenseNet contextRef="From2012-10-01to2012-12-31_CatoBioVenturesMember" unitRef="USD" decimals="0">34700</us-gaap:InterestIncomeExpenseNet>
    <us-gaap:InterestIncomeExpenseNet contextRef="From2011-10-01to2011-12-31_CatoBioVenturesMember" unitRef="USD" decimals="0">9000</us-gaap:InterestIncomeExpenseNet>
    <us-gaap:InterestIncomeExpenseNet contextRef="From2011-04-01to2011-12-31_CatoBioVenturesMember" unitRef="USD" decimals="0">85000</us-gaap:InterestIncomeExpenseNet>
    <us-gaap:InterestIncomeExpenseNet contextRef="From2012-04-01to2012-12-31_CatoBioVenturesMember" unitRef="USD" decimals="0">51400</us-gaap:InterestIncomeExpenseNet>
    <VSTA:NotesPayableDiscount contextRef="AsOf2012-12-31" unitRef="USD" decimals="0">1205000</VSTA:NotesPayableDiscount>
    <VSTA:NotesPayableDiscount contextRef="AsOf2012-03-31" unitRef="USD" decimals="0">228900</VSTA:NotesPayableDiscount>
    <VSTA:NotesPayableDiscountRelatedParties contextRef="AsOf2012-12-31" unitRef="USD" decimals="0">157900</VSTA:NotesPayableDiscountRelatedParties>
    <VSTA:NotesPayableDiscountRelatedParties contextRef="AsOf2012-03-31" unitRef="USD" decimals="0">24300</VSTA:NotesPayableDiscountRelatedParties>
    <VSTA:ConvertibleNotesDiscount contextRef="AsOf2012-03-31" unitRef="USD" decimals="0">499300</VSTA:ConvertibleNotesDiscount>
    <VSTA:ExercisePricePerShareWeightedAvg contextRef="From2012-04-01to2012-12-31_PreModificationWarrantsMember" unitRef="USDPShares" decimals="INF">2.75</VSTA:ExercisePricePerShareWeightedAvg>
    <VSTA:ExercisePricePerShareWeightedAvg contextRef="From2012-04-01to2012-12-31_PostModificationWarrantsMember" unitRef="USDPShares" decimals="INF">.5</VSTA:ExercisePricePerShareWeightedAvg>
    <us-gaap:Revenues contextRef="From2011-10-01to2011-12-31" unitRef="USD" decimals="0">2400</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="From2011-04-01to2011-12-31" unitRef="USD" decimals="0">873300</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="From1998-05-26to2012-12-31" unitRef="USD" decimals="0">16370200</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="From2012-04-01to2012-12-31" unitRef="USD" decimals="0">200400</us-gaap:Revenues>
    <us-gaap:OtherSalesRevenueNet contextRef="From2011-10-01to2011-12-31" unitRef="USD" xsi:nil="true" />
    <us-gaap:OtherSalesRevenueNet contextRef="From2011-04-01to2011-12-31" unitRef="USD" xsi:nil="true" />
    <us-gaap:OtherSalesRevenueNet contextRef="From1998-05-26to2012-12-31" unitRef="USD" decimals="0">1123500</us-gaap:OtherSalesRevenueNet>
    <us-gaap:OtherSalesRevenueNet contextRef="From2012-04-01to2012-12-31" unitRef="USD" xsi:nil="true" />
    <VSTA:RevenueFromExternalCustomers contextRef="From2011-10-01to2011-12-31" unitRef="USD" xsi:nil="true" />
    <VSTA:RevenueFromExternalCustomers contextRef="From2011-04-01to2011-12-31" unitRef="USD" xsi:nil="true" />
    <VSTA:RevenueFromExternalCustomers contextRef="From1998-05-26to2012-12-31" unitRef="USD" decimals="0">2283600</VSTA:RevenueFromExternalCustomers>
    <VSTA:RevenueFromExternalCustomers contextRef="From2012-04-01to2012-12-31" unitRef="USD" xsi:nil="true" />
    <us-gaap:RevenueFromGrants contextRef="From2011-10-01to2011-12-31" unitRef="USD" decimals="0">2400</us-gaap:RevenueFromGrants>
    <us-gaap:RevenueFromGrants contextRef="From2011-04-01to2011-12-31" unitRef="USD" decimals="0">873300</us-gaap:RevenueFromGrants>
    <us-gaap:RevenueFromGrants contextRef="From1998-05-26to2012-12-31" unitRef="USD" decimals="0">12963100</us-gaap:RevenueFromGrants>
    <us-gaap:RevenueFromGrants contextRef="From2012-04-01to2012-12-31" unitRef="USD" decimals="0">200400</us-gaap:RevenueFromGrants>
    <us-gaap:OperatingIncomeLoss contextRef="From2011-10-01to2011-12-31" unitRef="USD" decimals="0">-2851100</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss contextRef="From2011-04-01to2011-12-31" unitRef="USD" decimals="0">-6256800</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss contextRef="From1998-05-26to2012-12-31" unitRef="USD" decimals="0">-49918700</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss contextRef="From2012-04-01to2012-12-31" unitRef="USD" decimals="0">-5322000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingExpenses contextRef="From2011-10-01to2011-12-31" unitRef="USD" decimals="0">2853500</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses contextRef="From2011-04-01to2011-12-31" unitRef="USD" decimals="0">7130100</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses contextRef="From1998-05-26to2012-12-31" unitRef="USD" decimals="0">66288900</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses contextRef="From2012-04-01to2012-12-31" unitRef="USD" decimals="0">5522400</us-gaap:OperatingExpenses>
    <us-gaap:GeneralAndAdministrativeExpense contextRef="From2011-10-01to2011-12-31" unitRef="USD" decimals="0">1547900</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense contextRef="From2011-04-01to2011-12-31" unitRef="USD" decimals="0">3569100</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense contextRef="From1998-05-26to2012-12-31" unitRef="USD" decimals="0">29548600</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense contextRef="From2012-04-01to2012-12-31" unitRef="USD" decimals="0">2430200</us-gaap:GeneralAndAdministrativeExpense>
    <VSTA:AcquiredInProcessResearchAndDevelopment contextRef="From2011-10-01to2011-12-31" unitRef="USD" xsi:nil="true" />
    <VSTA:AcquiredInProcessResearchAndDevelopment contextRef="From2011-04-01to2011-12-31" unitRef="USD" xsi:nil="true" />
    <VSTA:AcquiredInProcessResearchAndDevelopment contextRef="From1998-05-26to2012-12-31" unitRef="USD" decimals="0">7523200</VSTA:AcquiredInProcessResearchAndDevelopment>
    <VSTA:AcquiredInProcessResearchAndDevelopment contextRef="From2012-04-01to2012-12-31" unitRef="USD" xsi:nil="true" />
    <us-gaap:ResearchAndDevelopmentExpense contextRef="From2011-10-01to2011-12-31" unitRef="USD" decimals="0">1305600</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="From2011-04-01to2011-12-31" unitRef="USD" decimals="0">3561000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="From1998-05-26to2012-12-31" unitRef="USD" decimals="0">29217100</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="From2012-04-01to2012-12-31" unitRef="USD" decimals="0">3092200</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:InterestExpense contextRef="From2011-10-01to2011-12-31" unitRef="USD" decimals="0">-455500</us-gaap:InterestExpense>
    <us-gaap:InterestExpense contextRef="From2011-04-01to2011-12-31" unitRef="USD" decimals="0">-1637600</us-gaap:InterestExpense>
    <us-gaap:InterestExpense contextRef="From1998-05-26to2012-12-31" unitRef="USD" decimals="0">-10053200</us-gaap:InterestExpense>
    <us-gaap:InterestExpense contextRef="From2012-04-01to2012-12-31" unitRef="USD" decimals="0">-611700</us-gaap:InterestExpense>
    <us-gaap:NetIncomeLoss contextRef="From2011-10-01to2011-12-31" unitRef="USD" decimals="0">-4500100</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="From2011-04-01to2011-12-31" unitRef="USD" decimals="0">-9167500</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="From1998-05-26to2012-12-31" unitRef="USD" decimals="0">-63899100</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="From2012-04-01to2012-12-31" unitRef="USD" decimals="0">-9116600</us-gaap:NetIncomeLoss>
    <us-gaap:IncomeTaxExpenseBenefit contextRef="From2011-10-01to2011-12-31" unitRef="USD" xsi:nil="true" />
    <us-gaap:IncomeTaxExpenseBenefit contextRef="From2011-04-01to2011-12-31" unitRef="USD" decimals="0">-1600</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit contextRef="From1998-05-26to2012-12-31" unitRef="USD" decimals="0">-20500</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit contextRef="From2012-04-01to2012-12-31" unitRef="USD" decimals="0">-3700</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments contextRef="From2011-10-01to2011-12-31" unitRef="USD" decimals="0">-4500100</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments contextRef="From2011-04-01to2011-12-31" unitRef="USD" decimals="0">-9165900</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments contextRef="From1998-05-26to2012-12-31" unitRef="USD" decimals="0">-63878600</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments contextRef="From2012-04-01to2012-12-31" unitRef="USD" decimals="0">-9112900</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments>
    <us-gaap:OtherIncome contextRef="From2011-10-01to2011-12-31" unitRef="USD" xsi:nil="true" />
    <us-gaap:OtherIncome contextRef="From2011-04-01to2011-12-31" unitRef="USD" xsi:nil="true" />
    <us-gaap:OtherIncome contextRef="From1998-05-26to2012-12-31" unitRef="USD" decimals="0">47500</us-gaap:OtherIncome>
    <us-gaap:OtherIncome contextRef="From2012-04-01to2012-12-31" unitRef="USD" xsi:nil="true" />
    <us-gaap:GainsLossesOnExtinguishmentOfDebt contextRef="From2011-10-01to2011-12-31" unitRef="USD" decimals="0">-1193500</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt contextRef="From2011-04-01to2011-12-31" unitRef="USD" decimals="0">-1193500</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt contextRef="From1998-05-26to2012-12-31" unitRef="USD" decimals="0">-4730500</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt contextRef="From2012-04-01to2012-12-31" unitRef="USD" decimals="0">-3537000</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <VSTA:ChangeInPutAndNoteExtensionOptionAndWarrantLiabilities contextRef="From2011-10-01to2011-12-31" unitRef="USD" xsi:nil="true" />
    <VSTA:ChangeInPutAndNoteExtensionOptionAndWarrantLiabilities contextRef="From2011-04-01to2011-12-31" unitRef="USD" decimals="0">-78000</VSTA:ChangeInPutAndNoteExtensionOptionAndWarrantLiabilities>
    <VSTA:ChangeInPutAndNoteExtensionOptionAndWarrantLiabilities contextRef="From1998-05-26to2012-12-31" unitRef="USD" decimals="0">776300</VSTA:ChangeInPutAndNoteExtensionOptionAndWarrantLiabilities>
    <VSTA:ChangeInPutAndNoteExtensionOptionAndWarrantLiabilities contextRef="From2012-04-01to2012-12-31" unitRef="USD" decimals="0">357800</VSTA:ChangeInPutAndNoteExtensionOptionAndWarrantLiabilities>
    <us-gaap:EarningsPerShareDiluted contextRef="From2011-10-01to2011-12-31" unitRef="USDPShares" decimals="INF">-0.28</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted contextRef="From2011-04-01to2011-12-31" unitRef="USDPShares" decimals="INF">-0.65</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted contextRef="From2012-04-01to2012-12-31" unitRef="USDPShares" decimals="INF">-0.93</us-gaap:EarningsPerShareDiluted>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding contextRef="From2011-10-01to2011-12-31" unitRef="Shares" decimals="INF">16035861</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding contextRef="From2011-04-01to2011-12-31" unitRef="Shares" decimals="INF">14139007</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding contextRef="From2012-04-01to2012-12-31" unitRef="Shares" decimals="INF">17411993</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <VSTA:ComprehensiveLoss contextRef="From2011-10-01to2011-12-31" unitRef="USD" decimals="0">-4500100</VSTA:ComprehensiveLoss>
    <VSTA:ComprehensiveLoss contextRef="From2011-04-01to2011-12-31" unitRef="USD" decimals="0">-9167500</VSTA:ComprehensiveLoss>
    <VSTA:ComprehensiveLoss contextRef="From1998-05-26to2012-12-31" unitRef="USD" decimals="0">-63899100</VSTA:ComprehensiveLoss>
    <VSTA:ComprehensiveLoss contextRef="From2012-04-01to2012-12-31" unitRef="USD" decimals="0">-9116600</VSTA:ComprehensiveLoss>
    <us-gaap:ShareBasedCompensation contextRef="From2011-10-01to2011-12-31" unitRef="USD" decimals="0">468100</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation contextRef="From2011-04-01to2011-12-31" unitRef="USD" decimals="0">1447400</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation contextRef="From1998-05-26to2012-12-31" unitRef="USD" decimals="0">5316300</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation contextRef="From2012-04-01to2012-12-31" unitRef="USD" decimals="0">962000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation contextRef="From2012-10-01to2012-12-31" unitRef="USD" decimals="0">813700</us-gaap:ShareBasedCompensation>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="AsOf2012-12-31" unitRef="USD" decimals="0">24200</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="AsOf2012-03-31" unitRef="USD" decimals="0">81000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="AsOf2011-03-31" unitRef="USD" decimals="0">139300</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="AsOf1998-05-25" unitRef="USD" xsi:nil="true" />
    <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="AsOf2011-12-31" unitRef="USD" decimals="0">166400</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <VSTA:AwardedByU.S.NationalInstitutes contextRef="AsOf2012-12-31" unitRef="USD" decimals="INF">8800000</VSTA:AwardedByU.S.NationalInstitutes>
    <VSTA:OutstandingShares contextRef="AsOf2012-12-31" unitRef="Shares" decimals="INF">6836452</VSTA:OutstandingShares>
    <VSTA:OutstandingOptionsUnder2008And1999StockIncentivePlanAnd1998ScientificAdvisoryBoardPlan contextRef="AsOf2012-12-31" unitRef="Shares" decimals="INF">4966771</VSTA:OutstandingOptionsUnder2008And1999StockIncentivePlanAnd1998ScientificAdvisoryBoardPlan>
    <VSTA:OutstandingOptionsUnder2008And1999StockIncentivePlanAnd1998ScientificAdvisoryBoardPlan contextRef="AsOf2011-12-31" unitRef="Shares" decimals="INF">4806114</VSTA:OutstandingOptionsUnder2008And1999StockIncentivePlanAnd1998ScientificAdvisoryBoardPlan>
    <VSTA:OutstandingWarrantsToPurchaseCommonStock contextRef="AsOf2012-12-31" unitRef="Shares" decimals="INF">9873034</VSTA:OutstandingWarrantsToPurchaseCommonStock>
    <VSTA:OutstandingWarrantsToPurchaseCommonStock contextRef="AsOf2011-12-31" unitRef="Shares" decimals="INF">3451728</VSTA:OutstandingWarrantsToPurchaseCommonStock>
    <VSTA:Total contextRef="AsOf2012-12-31" unitRef="Shares" decimals="INF">41895003</VSTA:Total>
    <VSTA:Total contextRef="AsOf2011-12-31" unitRef="Shares" decimals="INF">12628392</VSTA:Total>
    <VSTA:February201212ConvertiblePromissoryNotesAndAccruedInterest1 contextRef="AsOf2012-12-31" unitRef="Shares" id="Foot-00-0" decimals="INF">4645198</VSTA:February201212ConvertiblePromissoryNotesAndAccruedInterest1>
    <VSTA:February201212ConvertiblePromissoryNotesAndAccruedInterest1 contextRef="AsOf2011-12-31" unitRef="Shares" xsi:nil="true" />
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice contextRef="AsOf2012-12-31" unitRef="USDPShares" decimals="INF">1.33</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:OtherPrepaidExpenseCurrent contextRef="AsOf2012-12-31" unitRef="USD" decimals="0">11600</us-gaap:OtherPrepaidExpenseCurrent>
    <us-gaap:OtherPrepaidExpenseCurrent contextRef="AsOf2012-03-31" unitRef="USD" decimals="0">6100</us-gaap:OtherPrepaidExpenseCurrent>
    <VSTA:LegalFees1 contextRef="AsOf2012-12-31" unitRef="USD" decimals="0">28900</VSTA:LegalFees1>
    <VSTA:LegalFees1 contextRef="AsOf2012-03-31" unitRef="USD" decimals="0">6100</VSTA:LegalFees1>
    <us-gaap:PrepaidInsurance contextRef="AsOf2012-12-31" unitRef="USD" decimals="0">42300</us-gaap:PrepaidInsurance>
    <us-gaap:PrepaidInsurance contextRef="AsOf2012-03-31" unitRef="USD" decimals="0">19000</us-gaap:PrepaidInsurance>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent contextRef="AsOf2012-12-31" unitRef="USD" decimals="0">82800</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent contextRef="AsOf2012-03-31" unitRef="USD" decimals="0">50900</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <VSTA:AccruedResearchAndDevelopmentExpenses contextRef="AsOf2012-12-31" unitRef="USD" xsi:nil="true" />
    <VSTA:AccruedResearchAndDevelopmentExpenses contextRef="AsOf2012-03-31" unitRef="USD" decimals="0">237500</VSTA:AccruedResearchAndDevelopmentExpenses>
    <us-gaap:AccruedVacationCurrent contextRef="AsOf2012-12-31" unitRef="USD" decimals="0">223400</us-gaap:AccruedVacationCurrent>
    <us-gaap:AccruedVacationCurrent contextRef="AsOf2012-03-31" unitRef="USD" decimals="0">229900</us-gaap:AccruedVacationCurrent>
    <VSTA:AccruedPlacementAgentFees contextRef="AsOf2012-12-31" unitRef="USD" decimals="0">50000</VSTA:AccruedPlacementAgentFees>
    <VSTA:AccruedPlacementAgentFees contextRef="AsOf2012-03-31" unitRef="USD" decimals="0">50000</VSTA:AccruedPlacementAgentFees>
    <VSTA:AccruedRegistrationRightsPayments contextRef="AsOf2012-12-31" unitRef="USD" decimals="0">29700</VSTA:AccruedRegistrationRightsPayments>
    <VSTA:AccruedRegistrationRightsPayments contextRef="AsOf2012-03-31" unitRef="USD" xsi:nil="true" />
    <us-gaap:OtherAccruedLiabilitiesCurrent contextRef="AsOf2012-12-31" unitRef="USD" decimals="0">10900</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent contextRef="AsOf2012-03-31" unitRef="USD" decimals="0">32500</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:UnsecuredLongTermDebt contextRef="AsOf2012-12-31_CatoHoldingCompanyMember" unitRef="USD" decimals="0">1009000</us-gaap:UnsecuredLongTermDebt>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber contextRef="AsOf2012-12-31_CatoHoldingCompanyMember" unitRef="Shares" decimals="INF">1009000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:FairValueAssumptionsExpectedVolatilityRate contextRef="From2012-04-01to2012-12-31_PreModificationMember" unitRef="Percent" decimals="INF">0.779</us-gaap:FairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:FairValueAssumptionsExpectedVolatilityRate contextRef="From2012-04-01to2012-12-31_PostModificationMember" unitRef="Percent" decimals="INF">0.888</us-gaap:FairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:FairValueAssumptionsExpectedTerm contextRef="From2012-04-01to2012-12-31_PreModificationMember">P2Y4M</us-gaap:FairValueAssumptionsExpectedTerm>
    <us-gaap:FairValueAssumptionsExpectedTerm contextRef="From2012-04-01to2012-12-31_PostModificationMember">P5Y14D</us-gaap:FairValueAssumptionsExpectedTerm>
    <VSTA:FairValueAssumptionsExercisePrice1 contextRef="From2012-04-01to2012-12-31_PreModificationMember" unitRef="USDPShares" decimals="INF">2</VSTA:FairValueAssumptionsExercisePrice1>
    <VSTA:FairValueAssumptionsExercisePrice1 contextRef="From2012-04-01to2012-12-31_PostModificationMember" unitRef="USDPShares" decimals="INF">2</VSTA:FairValueAssumptionsExercisePrice1>
    <VSTA:FairValuePerShare contextRef="From2012-04-01to2012-12-31_PreModificationMember" unitRef="USDPShares" decimals="INF">0.24</VSTA:FairValuePerShare>
    <VSTA:FairValuePerShare contextRef="From2012-04-01to2012-12-31_PostModificationMember" unitRef="USDPShares" decimals="INF">0.52</VSTA:FairValuePerShare>
    <VSTA:ExpirationDate contextRef="AsOf2012-12-31_ShareBasedCompensationWarrantsOneMember">5/11/2014</VSTA:ExpirationDate>
    <VSTA:ExpirationDate contextRef="AsOf2012-12-31_ShareBasedCompensationWarrantsTwoMember">9/15/2017</VSTA:ExpirationDate>
    <VSTA:ExpirationDate contextRef="AsOf2012-12-31_ShareBasedCompensationWarrantsFourMember">5/11/2014 to 12/31/2014</VSTA:ExpirationDate>
    <VSTA:ExpirationDate contextRef="AsOf2012-12-31_ShareBasedCompensationWarrantsFiveMember">12/31/2012 to 9/4/2017</VSTA:ExpirationDate>
    <VSTA:ExpirationDate contextRef="AsOf2012-12-31_ShareBasedCompensationWarrantsSixMember">12/31/2013</VSTA:ExpirationDate>
    <VSTA:ExpirationDate contextRef="AsOf2012-12-31_ShareBasedCompensationWarrantsSevenMember">8/3/2013 to 9/15/2017</VSTA:ExpirationDate>
    <VSTA:ExpirationDate contextRef="AsOf2012-12-31_ShareBasedCompensationWarrantsEightMember">05-11-2014</VSTA:ExpirationDate>
    <VSTA:ExpirationDate contextRef="AsOf2012-12-31_ShareBasedCompensationWarrantsNineMember">12/31/2013</VSTA:ExpirationDate>
    <VSTA:ExpirationDate contextRef="AsOf2012-12-31_ShareBasedCompensationWarrantsElevenMember">5/11/2015 to 2/13/2016</VSTA:ExpirationDate>
    <us-gaap:BusinessAcquisitionCostOfAcquiredEntityTransactionCosts contextRef="AsOf2012-12-31_CatoResearchLtdMember" unitRef="USD" decimals="0">895300</us-gaap:BusinessAcquisitionCostOfAcquiredEntityTransactionCosts>
    <VSTA:WarrantsExercisable contextRef="AsOf2012-12-31_CatoResearchLtdMember" unitRef="Shares" decimals="INF">1009000</VSTA:WarrantsExercisable>
    <VSTA:UnsecuredPromissoryNoteIssued2 contextRef="AsOf2012-12-31_CatoResearchLtdMember" unitRef="USD" decimals="0">1009000</VSTA:UnsecuredPromissoryNoteIssued2>
    <us-gaap:InvestmentOwnedBalancePrincipalAmount contextRef="AsOf2012-12-31_IssuedToPlatinumOnTwoJulyTwoThousandTwelveMember" unitRef="USD" decimals="0">500000</us-gaap:InvestmentOwnedBalancePrincipalAmount>
    <us-gaap:InvestmentOwnedBalancePrincipalAmount contextRef="AsOf2012-12-31_IssuedToPlatinumOnThirtyAugustTwoThousandTwelveMember" unitRef="USD" decimals="0">750000</us-gaap:InvestmentOwnedBalancePrincipalAmount>
    <us-gaap:InvestmentOwnedBalancePrincipalAmount contextRef="AsOf2012-12-31_SeniorNotesNonCurrentMember" unitRef="USD" decimals="0">1250000</us-gaap:InvestmentOwnedBalancePrincipalAmount>
    <us-gaap:InvestmentOwnedBalancePrincipalAmount contextRef="AsOf2012-12-31_NoteDiscountMember" unitRef="USD" decimals="0">-481300</us-gaap:InvestmentOwnedBalancePrincipalAmount>
    <us-gaap:InvestmentOwnedBalancePrincipalAmount contextRef="AsOf2012-12-31_SevenPercentNotesPayableAprilTwoThousandElevenMember" unitRef="USD" decimals="0">38500</us-gaap:InvestmentOwnedBalancePrincipalAmount>
    <us-gaap:InvestmentOwnedBalancePrincipalAmount contextRef="AsOf2012-12-31_SevenPercentNotesPayableAugustTwoThousandTwelveMember" unitRef="USD" decimals="0">60000</us-gaap:InvestmentOwnedBalancePrincipalAmount>
    <us-gaap:InvestmentOwnedBalancePrincipalAmount contextRef="AsOf2012-12-31_SevenPercentNotesPayableMember" unitRef="USD" decimals="0">98500</us-gaap:InvestmentOwnedBalancePrincipalAmount>
    <us-gaap:InvestmentOwnedBalancePrincipalAmount contextRef="AsOf2012-12-31_CurrentPortionMember" unitRef="USD" decimals="0">-43000</us-gaap:InvestmentOwnedBalancePrincipalAmount>
    <us-gaap:InvestmentOwnedBalancePrincipalAmount contextRef="AsOf2012-12-31_SevenPercentNotesPayableNonCurrentPortionMember" unitRef="USD" decimals="0">55500</us-gaap:InvestmentOwnedBalancePrincipalAmount>
    <us-gaap:InvestmentOwnedBalancePrincipalAmount contextRef="AsOf2012-12-31_BurrPilgerMayerMember" unitRef="USD" decimals="0">91800</us-gaap:InvestmentOwnedBalancePrincipalAmount>
    <us-gaap:InvestmentOwnedBalancePrincipalAmount contextRef="AsOf2012-12-31_DesjardinsMember" unitRef="USD" decimals="0">214500</us-gaap:InvestmentOwnedBalancePrincipalAmount>
    <us-gaap:InvestmentOwnedBalancePrincipalAmount contextRef="AsOf2012-12-31_McCarthyTetraultMember" unitRef="USD" decimals="0">441700</us-gaap:InvestmentOwnedBalancePrincipalAmount>
    <us-gaap:InvestmentOwnedBalancePrincipalAmount contextRef="AsOf2012-12-31_MayTwoThousandElevenMorrisonFoersterMember" unitRef="USD" xsi:nil="true" />
    <us-gaap:InvestmentOwnedBalancePrincipalAmount contextRef="AsOf2012-12-31_AugustTwoThousandTwelveMorrisonAndFoersterNoteAMember" unitRef="USD" decimals="0">991200</us-gaap:InvestmentOwnedBalancePrincipalAmount>
    <us-gaap:InvestmentOwnedBalancePrincipalAmount contextRef="AsOf2012-12-31_AugustTwoThousandTwelveMorrisonAndFoersterNoteBMember" unitRef="USD" decimals="0">1379400</us-gaap:InvestmentOwnedBalancePrincipalAmount>
    <us-gaap:InvestmentOwnedBalancePrincipalAmount contextRef="AsOf2012-12-31_NoteDiscountOneMember" unitRef="USD" decimals="0">-1600400</us-gaap:InvestmentOwnedBalancePrincipalAmount>
    <us-gaap:InvestmentOwnedBalancePrincipalAmount contextRef="AsOf2012-12-31_SevenPointFivePercentNotesPayableMember" unitRef="USD" decimals="0">1518200</us-gaap:InvestmentOwnedBalancePrincipalAmount>
    <us-gaap:InvestmentOwnedBalancePrincipalAmount contextRef="AsOf2012-12-31_CurrentPortionOneMember" unitRef="USD" decimals="0">-531000</us-gaap:InvestmentOwnedBalancePrincipalAmount>
    <us-gaap:InvestmentOwnedBalancePrincipalAmount contextRef="AsOf2012-12-31_NonCurrentPortionAndDiscountMember" unitRef="USD" decimals="0">987200</us-gaap:InvestmentOwnedBalancePrincipalAmount>
    <us-gaap:InvestmentOwnedBalancePrincipalAmount contextRef="AsOf2012-12-31_FivePointEightPercentAndEightPercentNotesPayableToInsurancePremiumFinancingCompanyCurrentMember" unitRef="USD" decimals="0">40300</us-gaap:InvestmentOwnedBalancePrincipalAmount>
    <us-gaap:InvestmentOwnedBalancePrincipalAmount contextRef="AsOf2012-12-31_TenPercentNotesPayableToVendorsForAccountsPayableConvertedToNotesPayableMember" unitRef="USD" decimals="0">158900</us-gaap:InvestmentOwnedBalancePrincipalAmount>
    <us-gaap:InvestmentOwnedBalancePrincipalAmount contextRef="AsOf2012-12-31_CurrentPortionTwoMember" unitRef="USD" decimals="0">-145400</us-gaap:InvestmentOwnedBalancePrincipalAmount>
    <us-gaap:InvestmentOwnedBalancePrincipalAmount contextRef="AsOf2012-12-31_NonCurrentPortionMember" unitRef="USD" decimals="0">13500</us-gaap:InvestmentOwnedBalancePrincipalAmount>
    <us-gaap:InvestmentOwnedBalancePrincipalAmount contextRef="AsOf2012-12-31_TenPercentNotesPayableToUnrelatedPartiesMember" unitRef="USD" decimals="0">1815900</us-gaap:InvestmentOwnedBalancePrincipalAmount>
    <us-gaap:InvestmentOwnedBalancePrincipalAmount contextRef="AsOf2012-12-31_CurrentPortionThreeMember" unitRef="USD" decimals="0">-759700</us-gaap:InvestmentOwnedBalancePrincipalAmount>
    <us-gaap:InvestmentOwnedBalancePrincipalAmount contextRef="AsOf2012-12-31_NonCurrentPortionAndDiscountOneMember" unitRef="USD" decimals="0">1056200</us-gaap:InvestmentOwnedBalancePrincipalAmount>
    <us-gaap:InvestmentOwnedBalancePrincipalAmount contextRef="AsOf2012-12-31_SevenPercentNotePayableToCatoHoldingMember" unitRef="USD" decimals="0">293400</us-gaap:InvestmentOwnedBalancePrincipalAmount>
    <us-gaap:InvestmentOwnedBalancePrincipalAmount contextRef="AsOf2012-12-31_NoteDiscountTwoMember" unitRef="USD" decimals="0">-18000</us-gaap:InvestmentOwnedBalancePrincipalAmount>
    <us-gaap:InvestmentOwnedBalancePrincipalAmount contextRef="AsOf2012-12-31_NotesPayableToRelatedPartiesMember" unitRef="USD" decimals="0">275400</us-gaap:InvestmentOwnedBalancePrincipalAmount>
    <us-gaap:InvestmentOwnedBalancePrincipalAmount contextRef="AsOf2012-12-31_CurrentPortionFourMember" unitRef="USD" decimals="0">-237200</us-gaap:InvestmentOwnedBalancePrincipalAmount>
    <us-gaap:InvestmentOwnedBalancePrincipalAmount contextRef="AsOf2012-12-31_NonCurrentPortionAndDiscountTwoMember" unitRef="USD" decimals="0">38200</us-gaap:InvestmentOwnedBalancePrincipalAmount>
    <us-gaap:InvestmentOwnedBalancePrincipalAmount contextRef="AsOf2012-03-31_IssuedToPlatinumOnTwoJulyTwoThousandTwelveMember" unitRef="USD" xsi:nil="true" />
    <us-gaap:InvestmentOwnedBalancePrincipalAmount contextRef="AsOf2012-03-31_IssuedToPlatinumOnThirtyAugustTwoThousandTwelveMember" unitRef="USD" xsi:nil="true" />
    <us-gaap:InvestmentOwnedBalancePrincipalAmount contextRef="AsOf2012-03-31_SeniorNotesNonCurrentMember" unitRef="USD" xsi:nil="true" />
    <us-gaap:InvestmentOwnedBalancePrincipalAmount contextRef="AsOf2012-03-31_FebruaryTwoThousandTwelveTwelvePercentConvertiblePromissoryNotesMember" unitRef="USD" decimals="0">500000</us-gaap:InvestmentOwnedBalancePrincipalAmount>
    <us-gaap:InvestmentOwnedBalancePrincipalAmount contextRef="AsOf2012-03-31_NoteDiscountMember" unitRef="USD" decimals="0">-499300</us-gaap:InvestmentOwnedBalancePrincipalAmount>
    <us-gaap:InvestmentOwnedBalancePrincipalAmount contextRef="AsOf2012-03-31_TwelvePercentConvertibleNotesNetNnonCurrentMember" unitRef="USD" decimals="0">700</us-gaap:InvestmentOwnedBalancePrincipalAmount>
    <us-gaap:InvestmentOwnedBalancePrincipalAmount contextRef="AsOf2012-03-31_SevenPercentNotesPayableAprilTwoThousandElevenMember" unitRef="USD" decimals="0">63800</us-gaap:InvestmentOwnedBalancePrincipalAmount>
    <us-gaap:InvestmentOwnedBalancePrincipalAmount contextRef="AsOf2012-03-31_SevenPercentNotesPayableAugustTwoThousandTwelveMember" unitRef="USD" xsi:nil="true" />
    <us-gaap:InvestmentOwnedBalancePrincipalAmount contextRef="AsOf2012-03-31_SevenPercentNotesPayableMember" unitRef="USD" decimals="0">63800</us-gaap:InvestmentOwnedBalancePrincipalAmount>
    <us-gaap:InvestmentOwnedBalancePrincipalAmount contextRef="AsOf2012-03-31_CurrentPortionMember" unitRef="USD" decimals="0">-63800</us-gaap:InvestmentOwnedBalancePrincipalAmount>
    <us-gaap:InvestmentOwnedBalancePrincipalAmount contextRef="AsOf2012-03-31_SevenPercentNotesPayableNonCurrentPortionMember" unitRef="USD" xsi:nil="true" />
    <us-gaap:InvestmentOwnedBalancePrincipalAmount contextRef="AsOf2012-03-31_BurrPilgerMayerMember" unitRef="USD" decimals="0">93400</us-gaap:InvestmentOwnedBalancePrincipalAmount>
    <us-gaap:InvestmentOwnedBalancePrincipalAmount contextRef="AsOf2012-03-31_DesjardinsMember" unitRef="USD" decimals="0">224300</us-gaap:InvestmentOwnedBalancePrincipalAmount>
    <us-gaap:InvestmentOwnedBalancePrincipalAmount contextRef="AsOf2012-03-31_McCarthyTetraultMember" unitRef="USD" decimals="0">459400</us-gaap:InvestmentOwnedBalancePrincipalAmount>
    <us-gaap:InvestmentOwnedBalancePrincipalAmount contextRef="AsOf2012-03-31_MayTwoThousandElevenMorrisonFoersterMember" unitRef="USD" decimals="0">2420100</us-gaap:InvestmentOwnedBalancePrincipalAmount>
    <us-gaap:InvestmentOwnedBalancePrincipalAmount contextRef="AsOf2012-03-31_AugustTwoThousandTwelveMorrisonAndFoersterNoteAMember" unitRef="USD" xsi:nil="true" />
    <us-gaap:InvestmentOwnedBalancePrincipalAmount contextRef="AsOf2012-03-31_AugustTwoThousandTwelveMorrisonAndFoersterNoteBMember" unitRef="USD" xsi:nil="true" />
    <us-gaap:InvestmentOwnedBalancePrincipalAmount contextRef="AsOf2012-03-31_NoteDiscountOneMember" unitRef="USD" decimals="0">-228900</us-gaap:InvestmentOwnedBalancePrincipalAmount>
    <us-gaap:InvestmentOwnedBalancePrincipalAmount contextRef="AsOf2012-03-31_SevenPointFivePercentNotesPayableMember" unitRef="USD" decimals="0">2968300</us-gaap:InvestmentOwnedBalancePrincipalAmount>
    <us-gaap:InvestmentOwnedBalancePrincipalAmount contextRef="AsOf2012-03-31_CurrentPortionOneMember" unitRef="USD" decimals="0">-367700</us-gaap:InvestmentOwnedBalancePrincipalAmount>
    <us-gaap:InvestmentOwnedBalancePrincipalAmount contextRef="AsOf2012-03-31_NonCurrentPortionAndDiscountMember" unitRef="USD" decimals="0">2600600</us-gaap:InvestmentOwnedBalancePrincipalAmount>
    <us-gaap:InvestmentOwnedBalancePrincipalAmount contextRef="AsOf2012-03-31_FivePointEightPercentAndEightPercentNotesPayableToInsurancePremiumFinancingCompanyCurrentMember" unitRef="USD" decimals="0">4600</us-gaap:InvestmentOwnedBalancePrincipalAmount>
    <us-gaap:InvestmentOwnedBalancePrincipalAmount contextRef="AsOf2012-03-31_TenPercentNotesPayableToVendorsForAccountsPayableConvertedToNotesPayableMember" unitRef="USD" decimals="0">165400</us-gaap:InvestmentOwnedBalancePrincipalAmount>
    <us-gaap:InvestmentOwnedBalancePrincipalAmount contextRef="AsOf2012-03-31_CurrentPortionTwoMember" unitRef="USD" decimals="0">-146000</us-gaap:InvestmentOwnedBalancePrincipalAmount>
    <us-gaap:InvestmentOwnedBalancePrincipalAmount contextRef="AsOf2012-03-31_NonCurrentPortionMember" unitRef="USD" decimals="0">19400</us-gaap:InvestmentOwnedBalancePrincipalAmount>
    <us-gaap:InvestmentOwnedBalancePrincipalAmount contextRef="AsOf2012-03-31_TenPercentNotesPayableToUnrelatedPartiesMember" unitRef="USD" decimals="0">3202100</us-gaap:InvestmentOwnedBalancePrincipalAmount>
    <us-gaap:InvestmentOwnedBalancePrincipalAmount contextRef="AsOf2012-03-31_CurrentPortionThreeMember" unitRef="USD" decimals="0">-582100</us-gaap:InvestmentOwnedBalancePrincipalAmount>
    <us-gaap:InvestmentOwnedBalancePrincipalAmount contextRef="AsOf2012-03-31_NonCurrentPortionAndDiscountOneMember" unitRef="USD" decimals="0">2620000</us-gaap:InvestmentOwnedBalancePrincipalAmount>
    <us-gaap:InvestmentOwnedBalancePrincipalAmount contextRef="AsOf2012-03-31_SevenPercentNotePayableToCatoHoldingMember" unitRef="USD" decimals="0">293300</us-gaap:InvestmentOwnedBalancePrincipalAmount>
    <us-gaap:InvestmentOwnedBalancePrincipalAmount contextRef="AsOf2012-03-31_NoteDiscountTwoMember" unitRef="USD" decimals="0">-24300</us-gaap:InvestmentOwnedBalancePrincipalAmount>
    <us-gaap:InvestmentOwnedBalancePrincipalAmount contextRef="AsOf2012-03-31_NotesPayableToRelatedPartiesMember" unitRef="USD" decimals="0">269000</us-gaap:InvestmentOwnedBalancePrincipalAmount>
    <us-gaap:InvestmentOwnedBalancePrincipalAmount contextRef="AsOf2012-03-31_CurrentPortionFourMember" unitRef="USD" decimals="0">-168200</us-gaap:InvestmentOwnedBalancePrincipalAmount>
    <us-gaap:InvestmentOwnedBalancePrincipalAmount contextRef="AsOf2012-03-31_NonCurrentPortionAndDiscountTwoMember" unitRef="USD" decimals="0">100800</us-gaap:InvestmentOwnedBalancePrincipalAmount>
    <us-gaap:InvestmentOwnedBalancePrincipalAmount contextRef="AsOf2012-12-31_FebruaryTwoThousandTwelveTwelvePercentConvertiblePromissoryNotesMember" unitRef="USD" decimals="0">500000</us-gaap:InvestmentOwnedBalancePrincipalAmount>
    <us-gaap:InvestmentOwnedBalancePrincipalAmount contextRef="AsOf2012-12-31_TwelvePercentConvertibleNotesNetNnonCurrentMember" unitRef="USD" decimals="0">18700</us-gaap:InvestmentOwnedBalancePrincipalAmount>
    <VSTA:InvestmentOwnedAccruedInterest1 contextRef="AsOf2012-12-31_IssuedToPlatinumOnTwoJulyTwoThousandTwelveMember" unitRef="USD" decimals="0">12400</VSTA:InvestmentOwnedAccruedInterest1>
    <VSTA:InvestmentOwnedAccruedInterest1 contextRef="AsOf2012-12-31_IssuedToPlatinumOnThirtyAugustTwoThousandTwelveMember" unitRef="USD" decimals="0">6300</VSTA:InvestmentOwnedAccruedInterest1>
    <VSTA:InvestmentOwnedAccruedInterest1 contextRef="AsOf2012-12-31_SeniorNotesNonCurrentMember" unitRef="USD" decimals="0">18700</VSTA:InvestmentOwnedAccruedInterest1>
    <VSTA:InvestmentOwnedAccruedInterest1 contextRef="AsOf2012-12-31_NoteDiscountMember" unitRef="USD" xsi:nil="true" />
    <VSTA:InvestmentOwnedAccruedInterest1 contextRef="AsOf2012-12-31_SevenPercentNotesPayableAprilTwoThousandElevenMember" unitRef="USD" decimals="0">200</VSTA:InvestmentOwnedAccruedInterest1>
    <VSTA:InvestmentOwnedAccruedInterest1 contextRef="AsOf2012-12-31_SevenPercentNotesPayableAugustTwoThousandTwelveMember" unitRef="USD" decimals="0">400</VSTA:InvestmentOwnedAccruedInterest1>
    <VSTA:InvestmentOwnedAccruedInterest1 contextRef="AsOf2012-12-31_SevenPercentNotesPayableMember" unitRef="USD" decimals="0">600</VSTA:InvestmentOwnedAccruedInterest1>
    <VSTA:InvestmentOwnedAccruedInterest1 contextRef="AsOf2012-12-31_CurrentPortionMember" unitRef="USD" decimals="0">-600</VSTA:InvestmentOwnedAccruedInterest1>
    <VSTA:InvestmentOwnedAccruedInterest1 contextRef="AsOf2012-12-31_SevenPercentNotesPayableNonCurrentPortionMember" unitRef="USD" xsi:nil="true" />
    <VSTA:InvestmentOwnedAccruedInterest1 contextRef="AsOf2012-12-31_BurrPilgerMayerMember" unitRef="USD" decimals="0">1200</VSTA:InvestmentOwnedAccruedInterest1>
    <VSTA:InvestmentOwnedAccruedInterest1 contextRef="AsOf2012-12-31_DesjardinsMember" unitRef="USD" decimals="0">10700</VSTA:InvestmentOwnedAccruedInterest1>
    <VSTA:InvestmentOwnedAccruedInterest1 contextRef="AsOf2012-12-31_McCarthyTetraultMember" unitRef="USD" decimals="0">22000</VSTA:InvestmentOwnedAccruedInterest1>
    <VSTA:InvestmentOwnedAccruedInterest1 contextRef="AsOf2012-12-31_MayTwoThousandElevenMorrisonFoersterMember" unitRef="USD" xsi:nil="true" />
    <VSTA:InvestmentOwnedAccruedInterest1 contextRef="AsOf2012-12-31_AugustTwoThousandTwelveMorrisonAndFoersterNoteAMember" unitRef="USD" xsi:nil="true" />
    <VSTA:InvestmentOwnedAccruedInterest1 contextRef="AsOf2012-12-31_AugustTwoThousandTwelveMorrisonAndFoersterNoteBMember" unitRef="USD" decimals="0">8300</VSTA:InvestmentOwnedAccruedInterest1>
    <VSTA:InvestmentOwnedAccruedInterest1 contextRef="AsOf2012-12-31_NoteDiscountOneMember" unitRef="USD" xsi:nil="true" />
    <VSTA:InvestmentOwnedAccruedInterest1 contextRef="AsOf2012-12-31_SevenPointFivePercentNotesPayableMember" unitRef="USD" decimals="0">42200</VSTA:InvestmentOwnedAccruedInterest1>
    <VSTA:InvestmentOwnedAccruedInterest1 contextRef="AsOf2012-12-31_CurrentPortionOneMember" unitRef="USD" decimals="0">-33900</VSTA:InvestmentOwnedAccruedInterest1>
    <VSTA:InvestmentOwnedAccruedInterest1 contextRef="AsOf2012-12-31_NonCurrentPortionAndDiscountMember" unitRef="USD" decimals="0">8300</VSTA:InvestmentOwnedAccruedInterest1>
    <VSTA:InvestmentOwnedAccruedInterest1 contextRef="AsOf2012-12-31_FivePointEightPercentAndEightPercentNotesPayableToInsurancePremiumFinancingCompanyCurrentMember" unitRef="USD" xsi:nil="true" />
    <VSTA:InvestmentOwnedAccruedInterest1 contextRef="AsOf2012-12-31_TenPercentNotesPayableToVendorsForAccountsPayableConvertedToNotesPayableMember" unitRef="USD" decimals="0">20800</VSTA:InvestmentOwnedAccruedInterest1>
    <VSTA:InvestmentOwnedAccruedInterest1 contextRef="AsOf2012-12-31_CurrentPortionTwoMember" unitRef="USD" decimals="0">-20800</VSTA:InvestmentOwnedAccruedInterest1>
    <VSTA:InvestmentOwnedAccruedInterest1 contextRef="AsOf2012-12-31_NonCurrentPortionMember" unitRef="USD" xsi:nil="true" />
    <VSTA:InvestmentOwnedAccruedInterest1 contextRef="AsOf2012-12-31_TenPercentNotesPayableToUnrelatedPartiesMember" unitRef="USD" decimals="0">63600</VSTA:InvestmentOwnedAccruedInterest1>
    <VSTA:InvestmentOwnedAccruedInterest1 contextRef="AsOf2012-12-31_CurrentPortionThreeMember" unitRef="USD" decimals="0">-55300</VSTA:InvestmentOwnedAccruedInterest1>
    <VSTA:InvestmentOwnedAccruedInterest1 contextRef="AsOf2012-12-31_NonCurrentPortionAndDiscountOneMember" unitRef="USD" decimals="0">8300</VSTA:InvestmentOwnedAccruedInterest1>
    <VSTA:InvestmentOwnedAccruedInterest1 contextRef="AsOf2012-12-31_SevenPercentNotePayableToCatoHoldingMember" unitRef="USD" decimals="0">17200</VSTA:InvestmentOwnedAccruedInterest1>
    <VSTA:InvestmentOwnedAccruedInterest1 contextRef="AsOf2012-12-31_NoteDiscountTwoMember" unitRef="USD" xsi:nil="true" />
    <VSTA:InvestmentOwnedAccruedInterest1 contextRef="AsOf2012-12-31_NotesPayableToRelatedPartiesMember" unitRef="USD" decimals="0">17200</VSTA:InvestmentOwnedAccruedInterest1>
    <VSTA:InvestmentOwnedAccruedInterest1 contextRef="AsOf2012-12-31_CurrentPortionFourMember" unitRef="USD" decimals="0">-17200</VSTA:InvestmentOwnedAccruedInterest1>
    <VSTA:InvestmentOwnedAccruedInterest1 contextRef="AsOf2012-12-31_NonCurrentPortionAndDiscountTwoMember" unitRef="USD" xsi:nil="true" />
    <VSTA:InvestmentOwnedAccruedInterest1 contextRef="AsOf2012-03-31_IssuedToPlatinumOnTwoJulyTwoThousandTwelveMember" unitRef="USD" xsi:nil="true" />
    <VSTA:InvestmentOwnedAccruedInterest1 contextRef="AsOf2012-03-31_IssuedToPlatinumOnThirtyAugustTwoThousandTwelveMember" unitRef="USD" xsi:nil="true" />
    <VSTA:InvestmentOwnedAccruedInterest1 contextRef="AsOf2012-03-31_SeniorNotesNonCurrentMember" unitRef="USD" xsi:nil="true" />
    <VSTA:InvestmentOwnedAccruedInterest1 contextRef="AsOf2012-03-31_FebruaryTwoThousandTwelveTwelvePercentConvertiblePromissoryNotesMember" unitRef="USD" decimals="0">5300</VSTA:InvestmentOwnedAccruedInterest1>
    <VSTA:InvestmentOwnedAccruedInterest1 contextRef="AsOf2012-03-31_NoteDiscountMember" unitRef="USD" xsi:nil="true" />
    <VSTA:InvestmentOwnedAccruedInterest1 contextRef="AsOf2012-03-31_TwelvePercentConvertibleNotesNetNnonCurrentMember" unitRef="USD" decimals="0">5300</VSTA:InvestmentOwnedAccruedInterest1>
    <VSTA:InvestmentOwnedAccruedInterest1 contextRef="AsOf2012-03-31_SevenPercentNotesPayableAprilTwoThousandElevenMember" unitRef="USD" decimals="0">400</VSTA:InvestmentOwnedAccruedInterest1>
    <VSTA:InvestmentOwnedAccruedInterest1 contextRef="AsOf2012-03-31_SevenPercentNotesPayableAugustTwoThousandTwelveMember" unitRef="USD" xsi:nil="true" />
    <VSTA:InvestmentOwnedAccruedInterest1 contextRef="AsOf2012-03-31_SevenPercentNotesPayableMember" unitRef="USD" decimals="0">400</VSTA:InvestmentOwnedAccruedInterest1>
    <VSTA:InvestmentOwnedAccruedInterest1 contextRef="AsOf2012-03-31_CurrentPortionMember" unitRef="USD" decimals="0">-400</VSTA:InvestmentOwnedAccruedInterest1>
    <VSTA:InvestmentOwnedAccruedInterest1 contextRef="AsOf2012-03-31_SevenPercentNotesPayableNonCurrentPortionMember" unitRef="USD" xsi:nil="true" />
    <VSTA:InvestmentOwnedAccruedInterest1 contextRef="AsOf2012-03-31_BurrPilgerMayerMember" unitRef="USD" decimals="0">1100</VSTA:InvestmentOwnedAccruedInterest1>
    <VSTA:InvestmentOwnedAccruedInterest1 contextRef="AsOf2012-03-31_DesjardinsMember" unitRef="USD" decimals="0">2800</VSTA:InvestmentOwnedAccruedInterest1>
    <VSTA:InvestmentOwnedAccruedInterest1 contextRef="AsOf2012-03-31_McCarthyTetraultMember" unitRef="USD" decimals="0">5700</VSTA:InvestmentOwnedAccruedInterest1>
    <VSTA:InvestmentOwnedAccruedInterest1 contextRef="AsOf2012-03-31_MayTwoThousandElevenMorrisonFoersterMember" unitRef="USD" decimals="0">37900</VSTA:InvestmentOwnedAccruedInterest1>
    <VSTA:InvestmentOwnedAccruedInterest1 contextRef="AsOf2012-03-31_AugustTwoThousandTwelveMorrisonAndFoersterNoteAMember" unitRef="USD" xsi:nil="true" />
    <VSTA:InvestmentOwnedAccruedInterest1 contextRef="AsOf2012-03-31_AugustTwoThousandTwelveMorrisonAndFoersterNoteBMember" unitRef="USD" xsi:nil="true" />
    <VSTA:InvestmentOwnedAccruedInterest1 contextRef="AsOf2012-03-31_NoteDiscountOneMember" unitRef="USD" xsi:nil="true" />
    <VSTA:InvestmentOwnedAccruedInterest1 contextRef="AsOf2012-03-31_SevenPointFivePercentNotesPayableMember" unitRef="USD" decimals="0">47500</VSTA:InvestmentOwnedAccruedInterest1>
    <VSTA:InvestmentOwnedAccruedInterest1 contextRef="AsOf2012-03-31_CurrentPortionOneMember" unitRef="USD" xsi:nil="true" />
    <VSTA:InvestmentOwnedAccruedInterest1 contextRef="AsOf2012-03-31_NonCurrentPortionAndDiscountMember" unitRef="USD" decimals="0">47500</VSTA:InvestmentOwnedAccruedInterest1>
    <VSTA:InvestmentOwnedAccruedInterest1 contextRef="AsOf2012-03-31_FivePointEightPercentAndEightPercentNotesPayableToInsurancePremiumFinancingCompanyCurrentMember" unitRef="USD" xsi:nil="true" />
    <VSTA:InvestmentOwnedAccruedInterest1 contextRef="AsOf2012-03-31_TenPercentNotesPayableToVendorsForAccountsPayableConvertedToNotesPayableMember" unitRef="USD" decimals="0">16800</VSTA:InvestmentOwnedAccruedInterest1>
    <VSTA:InvestmentOwnedAccruedInterest1 contextRef="AsOf2012-03-31_CurrentPortionTwoMember" unitRef="USD" xsi:nil="true" />
    <VSTA:InvestmentOwnedAccruedInterest1 contextRef="AsOf2012-03-31_NonCurrentPortionMember" unitRef="USD" decimals="0">16800</VSTA:InvestmentOwnedAccruedInterest1>
    <VSTA:InvestmentOwnedAccruedInterest1 contextRef="AsOf2012-03-31_TenPercentNotesPayableToUnrelatedPartiesMember" unitRef="USD" decimals="0">64700</VSTA:InvestmentOwnedAccruedInterest1>
    <VSTA:InvestmentOwnedAccruedInterest1 contextRef="AsOf2012-03-31_CurrentPortionThreeMember" unitRef="USD" decimals="0">-400</VSTA:InvestmentOwnedAccruedInterest1>
    <VSTA:InvestmentOwnedAccruedInterest1 contextRef="AsOf2012-03-31_NonCurrentPortionAndDiscountOneMember" unitRef="USD" decimals="0">64300</VSTA:InvestmentOwnedAccruedInterest1>
    <VSTA:InvestmentOwnedAccruedInterest1 contextRef="AsOf2012-03-31_SevenPercentNotePayableToCatoHoldingMember" unitRef="USD" decimals="0">6900</VSTA:InvestmentOwnedAccruedInterest1>
    <VSTA:InvestmentOwnedAccruedInterest1 contextRef="AsOf2012-03-31_NoteDiscountTwoMember" unitRef="USD" xsi:nil="true" />
    <VSTA:InvestmentOwnedAccruedInterest1 contextRef="AsOf2012-03-31_NotesPayableToRelatedPartiesMember" unitRef="USD" decimals="0">6900</VSTA:InvestmentOwnedAccruedInterest1>
    <VSTA:InvestmentOwnedAccruedInterest1 contextRef="AsOf2012-03-31_CurrentPortionFourMember" unitRef="USD" xsi:nil="true" />
    <VSTA:InvestmentOwnedAccruedInterest1 contextRef="AsOf2012-03-31_NonCurrentPortionAndDiscountTwoMember" unitRef="USD" decimals="0">6900</VSTA:InvestmentOwnedAccruedInterest1>
    <VSTA:InvestmentOwnedAccruedInterest1 contextRef="AsOf2012-12-31_FebruaryTwoThousandTwelveTwelvePercentConvertiblePromissoryNotesMember" unitRef="USD" decimals="0">35400</VSTA:InvestmentOwnedAccruedInterest1>
    <VSTA:InvestmentOwnedAccruedInterest1 contextRef="AsOf2012-12-31_TwelvePercentConvertibleNotesNetNnonCurrentMember" unitRef="USD" decimals="0">35400</VSTA:InvestmentOwnedAccruedInterest1>
    <VSTA:AggregateInvestmentOwnedAmount contextRef="AsOf2012-12-31_IssuedToPlatinumOnTwoJulyTwoThousandTwelveMember" unitRef="USD" decimals="0">512400</VSTA:AggregateInvestmentOwnedAmount>
    <VSTA:AggregateInvestmentOwnedAmount contextRef="AsOf2012-12-31_IssuedToPlatinumOnThirtyAugustTwoThousandTwelveMember" unitRef="USD" decimals="0">756300</VSTA:AggregateInvestmentOwnedAmount>
    <VSTA:AggregateInvestmentOwnedAmount contextRef="AsOf2012-12-31_SeniorNotesNonCurrentMember" unitRef="USD" decimals="0">1268700</VSTA:AggregateInvestmentOwnedAmount>
    <VSTA:AggregateInvestmentOwnedAmount contextRef="AsOf2012-12-31_NoteDiscountMember" unitRef="USD" decimals="0">-481300</VSTA:AggregateInvestmentOwnedAmount>
    <VSTA:AggregateInvestmentOwnedAmount contextRef="AsOf2012-12-31_SevenPercentNotesPayableAprilTwoThousandElevenMember" unitRef="USD" decimals="0">38700</VSTA:AggregateInvestmentOwnedAmount>
    <VSTA:AggregateInvestmentOwnedAmount contextRef="AsOf2012-12-31_SevenPercentNotesPayableAugustTwoThousandTwelveMember" unitRef="USD" decimals="0">60400</VSTA:AggregateInvestmentOwnedAmount>
    <VSTA:AggregateInvestmentOwnedAmount contextRef="AsOf2012-12-31_SevenPercentNotesPayableMember" unitRef="USD" decimals="0">99100</VSTA:AggregateInvestmentOwnedAmount>
    <VSTA:AggregateInvestmentOwnedAmount contextRef="AsOf2012-12-31_CurrentPortionMember" unitRef="USD" decimals="0">-43600</VSTA:AggregateInvestmentOwnedAmount>
    <VSTA:AggregateInvestmentOwnedAmount contextRef="AsOf2012-12-31_SevenPercentNotesPayableNonCurrentPortionMember" unitRef="USD" decimals="0">55500</VSTA:AggregateInvestmentOwnedAmount>
    <VSTA:AggregateInvestmentOwnedAmount contextRef="AsOf2012-12-31_BurrPilgerMayerMember" unitRef="USD" decimals="0">93000</VSTA:AggregateInvestmentOwnedAmount>
    <VSTA:AggregateInvestmentOwnedAmount contextRef="AsOf2012-12-31_DesjardinsMember" unitRef="USD" decimals="0">225200</VSTA:AggregateInvestmentOwnedAmount>
    <VSTA:AggregateInvestmentOwnedAmount contextRef="AsOf2012-12-31_McCarthyTetraultMember" unitRef="USD" decimals="0">463700</VSTA:AggregateInvestmentOwnedAmount>
    <VSTA:AggregateInvestmentOwnedAmount contextRef="AsOf2012-12-31_MayTwoThousandElevenMorrisonFoersterMember" unitRef="USD" xsi:nil="true" />
    <VSTA:AggregateInvestmentOwnedAmount contextRef="AsOf2012-12-31_AugustTwoThousandTwelveMorrisonAndFoersterNoteAMember" unitRef="USD" decimals="0">991200</VSTA:AggregateInvestmentOwnedAmount>
    <VSTA:AggregateInvestmentOwnedAmount contextRef="AsOf2012-12-31_AugustTwoThousandTwelveMorrisonAndFoersterNoteBMember" unitRef="USD" decimals="0">1387700</VSTA:AggregateInvestmentOwnedAmount>
    <VSTA:AggregateInvestmentOwnedAmount contextRef="AsOf2012-12-31_NoteDiscountOneMember" unitRef="USD" decimals="0">-1600400</VSTA:AggregateInvestmentOwnedAmount>
    <VSTA:AggregateInvestmentOwnedAmount contextRef="AsOf2012-12-31_SevenPointFivePercentNotesPayableMember" unitRef="USD" decimals="0">1560400</VSTA:AggregateInvestmentOwnedAmount>
    <VSTA:AggregateInvestmentOwnedAmount contextRef="AsOf2012-12-31_CurrentPortionOneMember" unitRef="USD" decimals="0">-564900</VSTA:AggregateInvestmentOwnedAmount>
    <VSTA:AggregateInvestmentOwnedAmount contextRef="AsOf2012-12-31_NonCurrentPortionAndDiscountMember" unitRef="USD" decimals="0">995500</VSTA:AggregateInvestmentOwnedAmount>
    <VSTA:AggregateInvestmentOwnedAmount contextRef="AsOf2012-12-31_FivePointEightPercentAndEightPercentNotesPayableToInsurancePremiumFinancingCompanyCurrentMember" unitRef="USD" decimals="0">40300</VSTA:AggregateInvestmentOwnedAmount>
    <VSTA:AggregateInvestmentOwnedAmount contextRef="AsOf2012-12-31_TenPercentNotesPayableToVendorsForAccountsPayableConvertedToNotesPayableMember" unitRef="USD" decimals="0">179700</VSTA:AggregateInvestmentOwnedAmount>
    <VSTA:AggregateInvestmentOwnedAmount contextRef="AsOf2012-12-31_CurrentPortionTwoMember" unitRef="USD" decimals="0">-166200</VSTA:AggregateInvestmentOwnedAmount>
    <VSTA:AggregateInvestmentOwnedAmount contextRef="AsOf2012-12-31_NonCurrentPortionMember" unitRef="USD" decimals="0">13500</VSTA:AggregateInvestmentOwnedAmount>
    <VSTA:AggregateInvestmentOwnedAmount contextRef="AsOf2012-12-31_TenPercentNotesPayableToUnrelatedPartiesMember" unitRef="USD" decimals="0">1879500</VSTA:AggregateInvestmentOwnedAmount>
    <VSTA:AggregateInvestmentOwnedAmount contextRef="AsOf2012-12-31_CurrentPortionThreeMember" unitRef="USD" decimals="0">-815000</VSTA:AggregateInvestmentOwnedAmount>
    <VSTA:AggregateInvestmentOwnedAmount contextRef="AsOf2012-12-31_NonCurrentPortionAndDiscountOneMember" unitRef="USD" decimals="0">1064500</VSTA:AggregateInvestmentOwnedAmount>
    <VSTA:AggregateInvestmentOwnedAmount contextRef="AsOf2012-12-31_SevenPercentNotePayableToCatoHoldingMember" unitRef="USD" decimals="0">310600</VSTA:AggregateInvestmentOwnedAmount>
    <VSTA:AggregateInvestmentOwnedAmount contextRef="AsOf2012-12-31_NoteDiscountTwoMember" unitRef="USD" decimals="0">-18000</VSTA:AggregateInvestmentOwnedAmount>
    <VSTA:AggregateInvestmentOwnedAmount contextRef="AsOf2012-12-31_NotesPayableToRelatedPartiesMember" unitRef="USD" decimals="0">292600</VSTA:AggregateInvestmentOwnedAmount>
    <VSTA:AggregateInvestmentOwnedAmount contextRef="AsOf2012-12-31_CurrentPortionFourMember" unitRef="USD" decimals="0">-254400</VSTA:AggregateInvestmentOwnedAmount>
    <VSTA:AggregateInvestmentOwnedAmount contextRef="AsOf2012-12-31_NonCurrentPortionAndDiscountTwoMember" unitRef="USD" decimals="0">38200</VSTA:AggregateInvestmentOwnedAmount>
    <VSTA:AggregateInvestmentOwnedAmount contextRef="AsOf2012-03-31_IssuedToPlatinumOnTwoJulyTwoThousandTwelveMember" unitRef="USD" xsi:nil="true" />
    <VSTA:AggregateInvestmentOwnedAmount contextRef="AsOf2012-03-31_IssuedToPlatinumOnThirtyAugustTwoThousandTwelveMember" unitRef="USD" xsi:nil="true" />
    <VSTA:AggregateInvestmentOwnedAmount contextRef="AsOf2012-03-31_SeniorNotesNonCurrentMember" unitRef="USD" xsi:nil="true" />
    <VSTA:AggregateInvestmentOwnedAmount contextRef="AsOf2012-03-31_FebruaryTwoThousandTwelveTwelvePercentConvertiblePromissoryNotesMember" unitRef="USD" decimals="0">505300</VSTA:AggregateInvestmentOwnedAmount>
    <VSTA:AggregateInvestmentOwnedAmount contextRef="AsOf2012-03-31_NoteDiscountMember" unitRef="USD" decimals="0">-499300</VSTA:AggregateInvestmentOwnedAmount>
    <VSTA:AggregateInvestmentOwnedAmount contextRef="AsOf2012-03-31_TwelvePercentConvertibleNotesNetNnonCurrentMember" unitRef="USD" decimals="0">6000</VSTA:AggregateInvestmentOwnedAmount>
    <VSTA:AggregateInvestmentOwnedAmount contextRef="AsOf2012-03-31_SevenPercentNotesPayableAprilTwoThousandElevenMember" unitRef="USD" decimals="0">64200</VSTA:AggregateInvestmentOwnedAmount>
    <VSTA:AggregateInvestmentOwnedAmount contextRef="AsOf2012-03-31_SevenPercentNotesPayableAugustTwoThousandTwelveMember" unitRef="USD" xsi:nil="true" />
    <VSTA:AggregateInvestmentOwnedAmount contextRef="AsOf2012-03-31_SevenPercentNotesPayableMember" unitRef="USD" decimals="0">64200</VSTA:AggregateInvestmentOwnedAmount>
    <VSTA:AggregateInvestmentOwnedAmount contextRef="AsOf2012-03-31_CurrentPortionMember" unitRef="USD" decimals="0">-64200</VSTA:AggregateInvestmentOwnedAmount>
    <VSTA:AggregateInvestmentOwnedAmount contextRef="AsOf2012-03-31_SevenPercentNotesPayableNonCurrentPortionMember" unitRef="USD" xsi:nil="true" />
    <VSTA:AggregateInvestmentOwnedAmount contextRef="AsOf2012-03-31_BurrPilgerMayerMember" unitRef="USD" decimals="0">94500</VSTA:AggregateInvestmentOwnedAmount>
    <VSTA:AggregateInvestmentOwnedAmount contextRef="AsOf2012-03-31_DesjardinsMember" unitRef="USD" decimals="0">227100</VSTA:AggregateInvestmentOwnedAmount>
    <VSTA:AggregateInvestmentOwnedAmount contextRef="AsOf2012-03-31_McCarthyTetraultMember" unitRef="USD" decimals="0">465100</VSTA:AggregateInvestmentOwnedAmount>
    <VSTA:AggregateInvestmentOwnedAmount contextRef="AsOf2012-03-31_MayTwoThousandElevenMorrisonFoersterMember" unitRef="USD" decimals="0">2458000</VSTA:AggregateInvestmentOwnedAmount>
    <VSTA:AggregateInvestmentOwnedAmount contextRef="AsOf2012-03-31_AugustTwoThousandTwelveMorrisonAndFoersterNoteAMember" unitRef="USD" xsi:nil="true" />
    <VSTA:AggregateInvestmentOwnedAmount contextRef="AsOf2012-03-31_AugustTwoThousandTwelveMorrisonAndFoersterNoteBMember" unitRef="USD" xsi:nil="true" />
    <VSTA:AggregateInvestmentOwnedAmount contextRef="AsOf2012-03-31_NoteDiscountOneMember" unitRef="USD" decimals="0">-228900</VSTA:AggregateInvestmentOwnedAmount>
    <VSTA:AggregateInvestmentOwnedAmount contextRef="AsOf2012-03-31_SevenPointFivePercentNotesPayableMember" unitRef="USD" decimals="0">3015800</VSTA:AggregateInvestmentOwnedAmount>
    <VSTA:AggregateInvestmentOwnedAmount contextRef="AsOf2012-03-31_CurrentPortionOneMember" unitRef="USD" decimals="0">-367700</VSTA:AggregateInvestmentOwnedAmount>
    <VSTA:AggregateInvestmentOwnedAmount contextRef="AsOf2012-03-31_NonCurrentPortionAndDiscountMember" unitRef="USD" decimals="0">2648100</VSTA:AggregateInvestmentOwnedAmount>
    <VSTA:AggregateInvestmentOwnedAmount contextRef="AsOf2012-03-31_FivePointEightPercentAndEightPercentNotesPayableToInsurancePremiumFinancingCompanyCurrentMember" unitRef="USD" decimals="0">4600</VSTA:AggregateInvestmentOwnedAmount>
    <VSTA:AggregateInvestmentOwnedAmount contextRef="AsOf2012-03-31_TenPercentNotesPayableToVendorsForAccountsPayableConvertedToNotesPayableMember" unitRef="USD" decimals="0">182200</VSTA:AggregateInvestmentOwnedAmount>
    <VSTA:AggregateInvestmentOwnedAmount contextRef="AsOf2012-03-31_CurrentPortionTwoMember" unitRef="USD" decimals="0">-146000</VSTA:AggregateInvestmentOwnedAmount>
    <VSTA:AggregateInvestmentOwnedAmount contextRef="AsOf2012-03-31_NonCurrentPortionMember" unitRef="USD" decimals="0">36200</VSTA:AggregateInvestmentOwnedAmount>
    <VSTA:AggregateInvestmentOwnedAmount contextRef="AsOf2012-03-31_TenPercentNotesPayableToUnrelatedPartiesMember" unitRef="USD" decimals="0">3266800</VSTA:AggregateInvestmentOwnedAmount>
    <VSTA:AggregateInvestmentOwnedAmount contextRef="AsOf2012-03-31_CurrentPortionThreeMember" unitRef="USD" decimals="0">-582500</VSTA:AggregateInvestmentOwnedAmount>
    <VSTA:AggregateInvestmentOwnedAmount contextRef="AsOf2012-03-31_NonCurrentPortionAndDiscountOneMember" unitRef="USD" decimals="0">2684300</VSTA:AggregateInvestmentOwnedAmount>
    <VSTA:AggregateInvestmentOwnedAmount contextRef="AsOf2012-03-31_SevenPercentNotePayableToCatoHoldingMember" unitRef="USD" decimals="0">300200</VSTA:AggregateInvestmentOwnedAmount>
    <VSTA:AggregateInvestmentOwnedAmount contextRef="AsOf2012-03-31_NoteDiscountTwoMember" unitRef="USD" decimals="0">-24300</VSTA:AggregateInvestmentOwnedAmount>
    <VSTA:AggregateInvestmentOwnedAmount contextRef="AsOf2012-03-31_NotesPayableToRelatedPartiesMember" unitRef="USD" decimals="0">275900</VSTA:AggregateInvestmentOwnedAmount>
    <VSTA:AggregateInvestmentOwnedAmount contextRef="AsOf2012-03-31_CurrentPortionFourMember" unitRef="USD" decimals="0">-168200</VSTA:AggregateInvestmentOwnedAmount>
    <VSTA:AggregateInvestmentOwnedAmount contextRef="AsOf2012-03-31_NonCurrentPortionAndDiscountTwoMember" unitRef="USD" decimals="0">107700</VSTA:AggregateInvestmentOwnedAmount>
    <VSTA:AggregateInvestmentOwnedAmount contextRef="AsOf2012-12-31_FebruaryTwoThousandTwelveTwelvePercentConvertiblePromissoryNotesMember" unitRef="USD" decimals="0">535400</VSTA:AggregateInvestmentOwnedAmount>
    <VSTA:AggregateInvestmentOwnedAmount contextRef="AsOf2012-12-31_TwelvePercentConvertibleNotesNetNnonCurrentMember" unitRef="USD" decimals="0">54100</VSTA:AggregateInvestmentOwnedAmount>
    <VSTA:ConversionRateSeriesPreferredShares contextRef="AsOf2012-12-31">10</VSTA:ConversionRateSeriesPreferredShares>
    <VSTA:SeriesPreferredShareParValue contextRef="AsOf2012-12-31" unitRef="USDPShares" decimals="INF">0.001</VSTA:SeriesPreferredShareParValue>
    <VSTA:SeriesPreferredStockShares contextRef="AsOf2012-12-31" unitRef="Shares" decimals="INF">500000</VSTA:SeriesPreferredStockShares>
    <VSTA:NumberOfPreferredSharesAuthorizedFollowingAmendment contextRef="AsOf2012-12-31" unitRef="Shares" decimals="INF">10000000</VSTA:NumberOfPreferredSharesAuthorizedFollowingAmendment>
    <VSTA:NumberOfSharesAuthorizedFollowingAmendment contextRef="AsOf2012-12-31" unitRef="Shares" decimals="INF">200000000</VSTA:NumberOfSharesAuthorizedFollowingAmendment>
    <VSTA:OutstandingShareRepresentation contextRef="AsOf2012-12-31" unitRef="Percent" decimals="INF">.9</VSTA:OutstandingShareRepresentation>
    <VSTA:SharesOutstandingAtMerger contextRef="AsOf2012-12-31" unitRef="Shares" decimals="INF">784500</VSTA:SharesOutstandingAtMerger>
    <VSTA:ShareRepurchase contextRef="AsOf2012-12-31" unitRef="Shares" decimals="INF">5064207</VSTA:ShareRepurchase>
    <VSTA:July2012PlantinumNotePrincipalAmount contextRef="AsOf2012-12-31" unitRef="USD" decimals="0">500000</VSTA:July2012PlantinumNotePrincipalAmount>
    <VSTA:August2012PlantinumNotePrincipalAmount contextRef="AsOf2012-12-31" unitRef="USD" decimals="0">750000</VSTA:August2012PlantinumNotePrincipalAmount>
    <VSTA:CashExpenditureMaximum contextRef="AsOf2012-12-31" unitRef="USD" decimals="0">6000000</VSTA:CashExpenditureMaximum>
    <VSTA:CashExpenditureMinimum contextRef="AsOf2012-12-31" unitRef="USD" decimals="0">4000000</VSTA:CashExpenditureMinimum>
    <VSTA:OriginalPrincipleBalanceOfNotes contextRef="AsOf2012-12-31" unitRef="USD" decimals="0">4000000</VSTA:OriginalPrincipleBalanceOfNotes>
    <VSTA:IssuedWarrantToPurchaseCommonStock contextRef="AsOf2012-12-31" unitRef="Shares" decimals="INF">560000</VSTA:IssuedWarrantToPurchaseCommonStock>
    <VSTA:RepaymentOfDebtInPercentage contextRef="AsOf2012-12-31" unitRef="Percent" decimals="INF">.25</VSTA:RepaymentOfDebtInPercentage>
    <us-gaap:WarrantsAndRightsOutstanding contextRef="AsOf2012-12-31" unitRef="USD" decimals="0">424100</us-gaap:WarrantsAndRightsOutstanding>
    <VSTA:July2012PlatinumNoteAmount contextRef="AsOf2012-12-31_February2012ConvertibleNotes12PercentMember" unitRef="USD" decimals="0">500000</VSTA:July2012PlatinumNoteAmount>
    <VSTA:August2012PlatinumNote contextRef="AsOf2012-12-31_February2012ConvertibleNotes12PercentMember" unitRef="USD" decimals="0">750000</VSTA:August2012PlatinumNote>
    <VSTA:JulyAndAugustNoteRate contextRef="AsOf2012-12-31_February2012ConvertibleNotes12PercentMember" unitRef="Percent" decimals="INF">.10</VSTA:JulyAndAugustNoteRate>
    <VSTA:ExpectedGrossNoteProceeds contextRef="AsOf2012-12-31_February2012ConvertibleNotes12PercentMember" unitRef="USD" decimals="0">3250000</VSTA:ExpectedGrossNoteProceeds>
    <VSTA:February2012Note contextRef="AsOf2012-12-31_February2012ConvertibleNotes12PercentMember" unitRef="USD" decimals="0">500000</VSTA:February2012Note>
    <VSTA:FebruaryNoteRate contextRef="AsOf2012-12-31_February2012ConvertibleNotes12PercentMember" unitRef="Percent" decimals="INF">.12</VSTA:FebruaryNoteRate>
    <VSTA:WarrantValue contextRef="AsOf2012-12-31_February2012ConvertibleNotes12PercentMember" unitRef="USDPShares" decimals="INF">2.75</VSTA:WarrantValue>
    <VSTA:AggregateShareValue contextRef="AsOf2012-12-31_February2012ConvertibleNotes12PercentMember" unitRef="USD" decimals="0">272724</VSTA:AggregateShareValue>
    <VSTA:RegistrationRightsAgreementLiability contextRef="AsOf2012-12-31_February2012ConvertibleNotes12PercentMember" unitRef="USD" decimals="0">20700</VSTA:RegistrationRightsAgreementLiability>
    <VSTA:SeniorSecuredConvertibleNotesPayableDiscount contextRef="AsOf2012-12-31" unitRef="USD" decimals="0">985500</VSTA:SeniorSecuredConvertibleNotesPayableDiscount>
    <VSTA:SeniorSecuredConvertibleNotesPayableDiscount contextRef="AsOf2012-03-31" unitRef="USD" xsi:nil="true" />
    <us-gaap:NetCashProvidedByUsedInInvestingActivities contextRef="From2011-04-01to2011-12-31" unitRef="USD" decimals="0">-13400</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities contextRef="From1998-05-26to2012-12-31" unitRef="USD" decimals="0">-811900</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities contextRef="From2012-04-01to2012-12-31" unitRef="USD" decimals="0">-131100</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:PaymentsToAcquireMachineryAndEquipment contextRef="From2011-04-01to2011-12-31" unitRef="USD" decimals="0">13400</us-gaap:PaymentsToAcquireMachineryAndEquipment>
    <us-gaap:PaymentsToAcquireMachineryAndEquipment contextRef="From1998-05-26to2012-12-31" unitRef="USD" decimals="0">811900</us-gaap:PaymentsToAcquireMachineryAndEquipment>
    <us-gaap:PaymentsToAcquireMachineryAndEquipment contextRef="From2012-04-01to2012-12-31" unitRef="USD" decimals="0">131100</us-gaap:PaymentsToAcquireMachineryAndEquipment>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="From2011-04-01to2011-12-31" unitRef="USD" decimals="0">-2847200</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="From1998-05-26to2012-12-31" unitRef="USD" decimals="0">-20001700</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="From2012-04-01to2012-12-31" unitRef="USD" decimals="0">-2493200</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:IncreaseDecreaseInDeferredRevenue contextRef="From2011-04-01to2011-12-31" unitRef="USD" decimals="0">-45700</us-gaap:IncreaseDecreaseInDeferredRevenue>
    <us-gaap:IncreaseDecreaseInDeferredRevenue contextRef="From1998-05-26to2012-12-31" unitRef="USD" xsi:nil="true" />
    <us-gaap:IncreaseDecreaseInDeferredRevenue contextRef="From2012-04-01to2012-12-31" unitRef="USD" decimals="0">-13200</us-gaap:IncreaseDecreaseInDeferredRevenue>
    <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities contextRef="From2011-04-01to2011-12-31" unitRef="USD" decimals="0">1267800</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities contextRef="From1998-05-26to2012-12-31" unitRef="USD" decimals="0">17595000</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities contextRef="From2012-04-01to2012-12-31" unitRef="USD" decimals="0">1014400</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInDepositOtherAssets contextRef="From2011-04-01to2011-12-31" unitRef="USD" xsi:nil="true" />
    <us-gaap:IncreaseDecreaseInDepositOtherAssets contextRef="From1998-05-26to2012-12-31" unitRef="USD" decimals="0">-29000</us-gaap:IncreaseDecreaseInDepositOtherAssets>
    <us-gaap:IncreaseDecreaseInDepositOtherAssets contextRef="From2012-04-01to2012-12-31" unitRef="USD" xsi:nil="true" />
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets contextRef="From2011-04-01to2011-12-31" unitRef="USD" decimals="0">458100</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets contextRef="From1998-05-26to2012-12-31" unitRef="USD" decimals="0">-21000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets contextRef="From2012-04-01to2012-12-31" unitRef="USD" decimals="0">-16500</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInAccountsReceivable contextRef="From2011-04-01to2011-12-31" unitRef="USD" decimals="0">34400</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInAccountsReceivable contextRef="From1998-05-26to2012-12-31" unitRef="USD" xsi:nil="true" />
    <us-gaap:IncreaseDecreaseInAccountsReceivable contextRef="From2012-04-01to2012-12-31" unitRef="USD" decimals="0">106200</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:GainLossOnSaleOfPropertyPlantEquipment contextRef="From2011-04-01to2011-12-31" unitRef="USD" xsi:nil="true" />
    <us-gaap:GainLossOnSaleOfPropertyPlantEquipment contextRef="From1998-05-26to2012-12-31" unitRef="USD" decimals="0">-16800</us-gaap:GainLossOnSaleOfPropertyPlantEquipment>
    <us-gaap:GainLossOnSaleOfPropertyPlantEquipment contextRef="From2012-04-01to2012-12-31" unitRef="USD" xsi:nil="true" />
    <VSTA:ConsultingServicesByRelatedPartiesSettledByIssuingPromissoryNotes contextRef="From2011-04-01to2011-12-31" unitRef="USD" xsi:nil="true" />
    <VSTA:ConsultingServicesByRelatedPartiesSettledByIssuingPromissoryNotes contextRef="From1998-05-26to2012-12-31" unitRef="USD" decimals="0">44600</VSTA:ConsultingServicesByRelatedPartiesSettledByIssuingPromissoryNotes>
    <VSTA:ConsultingServicesByRelatedPartiesSettledByIssuingPromissoryNotes contextRef="From2012-04-01to2012-12-31" unitRef="USD" xsi:nil="true" />
    <VSTA:FairValueOfCommonStockIssuedForNoteTermModification contextRef="From2011-04-01to2011-12-31" unitRef="USD" xsi:nil="true" />
    <VSTA:FairValueOfCommonStockIssuedForNoteTermModification contextRef="From1998-05-26to2012-12-31" unitRef="USD" decimals="0">22400</VSTA:FairValueOfCommonStockIssuedForNoteTermModification>
    <VSTA:FairValueOfCommonStockIssuedForNoteTermModification contextRef="From2012-04-01to2012-12-31" unitRef="USD" xsi:nil="true" />
    <VSTA:FairValueOfAdditionalWarrantsGrantedUnderDiscountedWarrantExerciseProgram contextRef="From2011-04-01to2011-12-31" unitRef="USD" xsi:nil="true" />
    <VSTA:FairValueOfAdditionalWarrantsGrantedUnderDiscountedWarrantExerciseProgram contextRef="From1998-05-26to2012-12-31" unitRef="USD" decimals="0">174000</VSTA:FairValueOfAdditionalWarrantsGrantedUnderDiscountedWarrantExerciseProgram>
    <VSTA:FairValueOfAdditionalWarrantsGrantedUnderDiscountedWarrantExerciseProgram contextRef="From2012-04-01to2012-12-31" unitRef="USD" decimals="0">35900</VSTA:FairValueOfAdditionalWarrantsGrantedUnderDiscountedWarrantExerciseProgram>
    <VSTA:FairValueOfWarrantsGrantedForServicesFollowingMerger contextRef="From2011-04-01to2011-12-31" unitRef="USD" xsi:nil="true" />
    <VSTA:FairValueOfWarrantsGrantedForServicesFollowingMerger contextRef="From1998-05-26to2012-12-31" unitRef="USD" decimals="0">714500</VSTA:FairValueOfWarrantsGrantedForServicesFollowingMerger>
    <VSTA:FairValueOfWarrantsGrantedForServicesFollowingMerger contextRef="From2012-04-01to2012-12-31" unitRef="USD" decimals="0">150000</VSTA:FairValueOfWarrantsGrantedForServicesFollowingMerger>
    <VSTA:FairValueOfCommonStockGrantedForServicesFollowingMerger contextRef="From2011-04-01to2011-12-31" unitRef="USD" xsi:nil="true" />
    <VSTA:FairValueOfCommonStockGrantedForServicesFollowingMerger contextRef="From1998-05-26to2012-12-31" unitRef="USD" decimals="0">792000</VSTA:FairValueOfCommonStockGrantedForServicesFollowingMerger>
    <VSTA:FairValueOfCommonStockGrantedForServicesFollowingMerger contextRef="From2012-04-01to2012-12-31" unitRef="USD" decimals="0">340000</VSTA:FairValueOfCommonStockGrantedForServicesFollowingMerger>
    <us-gaap:IssuanceOfStockAndWarrantsForServicesOrClaims contextRef="From2011-04-01to2011-12-31" unitRef="USD" decimals="0">131300</us-gaap:IssuanceOfStockAndWarrantsForServicesOrClaims>
    <us-gaap:IssuanceOfStockAndWarrantsForServicesOrClaims contextRef="From1998-05-26to2012-12-31" unitRef="USD" decimals="0">1056600</us-gaap:IssuanceOfStockAndWarrantsForServicesOrClaims>
    <us-gaap:IssuanceOfStockAndWarrantsForServicesOrClaims contextRef="From2012-04-01to2012-12-31" unitRef="USD" xsi:nil="true" />
    <VSTA:ExpenseRelatedToModificationOfWarrants contextRef="From2011-04-01to2011-12-31" unitRef="USD" decimals="0">741700</VSTA:ExpenseRelatedToModificationOfWarrants>
    <VSTA:ExpenseRelatedToModificationOfWarrants contextRef="From1998-05-26to2012-12-31" unitRef="USD" decimals="0">1182400</VSTA:ExpenseRelatedToModificationOfWarrants>
    <VSTA:ExpenseRelatedToModificationOfWarrants contextRef="From2012-04-01to2012-12-31" unitRef="USD" decimals="0">440700</VSTA:ExpenseRelatedToModificationOfWarrants>
    <VSTA:ChangeInPutAndNoteTermExtensionOptionAndWarrantLiabilities contextRef="From2011-04-01to2011-12-31" unitRef="USD" decimals="0">77900</VSTA:ChangeInPutAndNoteTermExtensionOptionAndWarrantLiabilities>
    <VSTA:ChangeInPutAndNoteTermExtensionOptionAndWarrantLiabilities contextRef="From1998-05-26to2012-12-31" unitRef="USD" decimals="0">-776400</VSTA:ChangeInPutAndNoteTermExtensionOptionAndWarrantLiabilities>
    <VSTA:ChangeInPutAndNoteTermExtensionOptionAndWarrantLiabilities contextRef="From2012-04-01to2012-12-31" unitRef="USD" decimals="0">-357800</VSTA:ChangeInPutAndNoteTermExtensionOptionAndWarrantLiabilities>
    <VSTA:LossOnSettlementsOfAccountsPayable contextRef="From2011-04-01to2011-12-31" unitRef="USD" xsi:nil="true" />
    <VSTA:LossOnSettlementsOfAccountsPayable contextRef="From1998-05-26to2012-12-31" unitRef="USD" decimals="0">78300</VSTA:LossOnSettlementsOfAccountsPayable>
    <VSTA:LossOnSettlementsOfAccountsPayable contextRef="From2012-04-01to2012-12-31" unitRef="USD" decimals="0">78300</VSTA:LossOnSettlementsOfAccountsPayable>
    <VSTA:LossOnEarlyExtinguishmentOfDebt contextRef="From2011-04-01to2011-12-31" unitRef="USD" decimals="0">1193500</VSTA:LossOnEarlyExtinguishmentOfDebt>
    <VSTA:LossOnEarlyExtinguishmentOfDebt contextRef="From1998-05-26to2012-12-31" unitRef="USD" decimals="0">4730500</VSTA:LossOnEarlyExtinguishmentOfDebt>
    <VSTA:LossOnEarlyExtinguishmentOfDebt contextRef="From2012-04-01to2012-12-31" unitRef="USD" decimals="0">3537000</VSTA:LossOnEarlyExtinguishmentOfDebt>
    <VSTA:AmortizationOfDiscountsOnFebruary201212ConvertibleNotes contextRef="From2011-04-01to2011-12-31" unitRef="USD" xsi:nil="true" />
    <VSTA:AmortizationOfDiscountsOnFebruary201212ConvertibleNotes contextRef="From1998-05-26to2012-12-31" unitRef="USD" decimals="0">22700</VSTA:AmortizationOfDiscountsOnFebruary201212ConvertibleNotes>
    <VSTA:AmortizationOfDiscountsOnFebruary201212ConvertibleNotes contextRef="From2012-04-01to2012-12-31" unitRef="USD" decimals="0">26900</VSTA:AmortizationOfDiscountsOnFebruary201212ConvertibleNotes>
    <VSTA:AmortizationOfDiscountsOnAugust2010ShortTermNotes contextRef="From2011-04-01to2011-12-31" unitRef="USD" decimals="0">14300</VSTA:AmortizationOfDiscountsOnAugust2010ShortTermNotes>
    <VSTA:AmortizationOfDiscountsOnAugust2010ShortTermNotes contextRef="From1998-05-26to2012-12-31" unitRef="USD" decimals="0">572000</VSTA:AmortizationOfDiscountsOnAugust2010ShortTermNotes>
    <VSTA:AmortizationOfDiscountsOnAugust2010ShortTermNotes contextRef="From2012-04-01to2012-12-31" unitRef="USD" xsi:nil="true" />
    <VSTA:AmortizationOfDiscountsOnPlatinumNotes contextRef="From2011-04-01to2011-12-31" unitRef="USD" decimals="0">908900</VSTA:AmortizationOfDiscountsOnPlatinumNotes>
    <VSTA:AmortizationOfDiscountsOnPlatinumNotes contextRef="From1998-05-26to2012-12-31" unitRef="USD" decimals="0">3553200</VSTA:AmortizationOfDiscountsOnPlatinumNotes>
    <VSTA:AmortizationOfDiscountsOnPlatinumNotes contextRef="From2012-04-01to2012-12-31" unitRef="USD" decimals="0">4500</VSTA:AmortizationOfDiscountsOnPlatinumNotes>
    <VSTA:AmortizationOfDiscountsOn77.5And10Notes contextRef="From2011-04-01to2011-12-31" unitRef="USD" decimals="0">57200</VSTA:AmortizationOfDiscountsOn77.5And10Notes>
    <VSTA:AmortizationOfDiscountsOn77.5And10Notes contextRef="From1998-05-26to2012-12-31" unitRef="USD" decimals="0">580000</VSTA:AmortizationOfDiscountsOn77.5And10Notes>
    <VSTA:AmortizationOfDiscountsOn77.5And10Notes contextRef="From2012-04-01to2012-12-31" unitRef="USD" decimals="0">320800</VSTA:AmortizationOfDiscountsOn77.5And10Notes>
    <VSTA:AmortizationOfImputedDiscountOnNonInterestBearingNotes contextRef="From2011-04-01to2011-12-31" unitRef="USD" xsi:nil="true" />
    <VSTA:AmortizationOfImputedDiscountOnNonInterestBearingNotes contextRef="From1998-05-26to2012-12-31" unitRef="USD" decimals="0">45000</VSTA:AmortizationOfImputedDiscountOnNonInterestBearingNotes>
    <VSTA:AmortizationOfImputedDiscountOnNonInterestBearingNotes contextRef="From2012-04-01to2012-12-31" unitRef="USD" xsi:nil="true" />
    <us-gaap:DepreciationAndAmortization contextRef="From2011-04-01to2011-12-31" unitRef="USD" decimals="0">33500</us-gaap:DepreciationAndAmortization>
    <us-gaap:DepreciationAndAmortization contextRef="From1998-05-26to2012-12-31" unitRef="USD" decimals="0">764700</us-gaap:DepreciationAndAmortization>
    <us-gaap:DepreciationAndAmortization contextRef="From2012-04-01to2012-12-31" unitRef="USD" decimals="0">21000</us-gaap:DepreciationAndAmortization>
    <us-gaap:ProfitLoss contextRef="From2011-04-01to2011-12-31" unitRef="USD" decimals="0">-9167500</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss contextRef="From1998-05-26to2012-12-31" unitRef="USD" decimals="0">-63899100</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss contextRef="From2012-04-01to2012-12-31" unitRef="USD" decimals="0">-9116600</us-gaap:ProfitLoss>
    <VSTA:InterestIncomeOnNoteReceivableForStockPurchase contextRef="From1998-05-26to2012-12-31" unitRef="USD" decimals="0">-26800</VSTA:InterestIncomeOnNoteReceivableForStockPurchase>
    <VSTA:InterestIncomeOnNoteReceivableForStockPurchase contextRef="From2012-04-01to2012-12-31" unitRef="USD" decimals="0">-26800</VSTA:InterestIncomeOnNoteReceivableForStockPurchase>
    <us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease contextRef="From2011-04-01to2011-12-31" unitRef="USD" decimals="0">27100</us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease>
    <us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease contextRef="From1998-05-26to2012-12-31" unitRef="USD" decimals="0">24200</us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease>
    <us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease contextRef="From2012-04-01to2012-12-31" unitRef="USD" decimals="0">-56800</us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities contextRef="From2011-04-01to2011-12-31" unitRef="USD" decimals="0">2887700</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities contextRef="From1998-05-26to2012-12-31" unitRef="USD" decimals="0">20837800</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities contextRef="From2012-04-01to2012-12-31" unitRef="USD" decimals="0">2567500</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:RepaymentsOfNotesPayable contextRef="From2011-04-01to2011-12-31" unitRef="USD" decimals="0">-653500</us-gaap:RepaymentsOfNotesPayable>
    <us-gaap:RepaymentsOfNotesPayable contextRef="From1998-05-26to2012-12-31" unitRef="USD" decimals="0">-1714400</us-gaap:RepaymentsOfNotesPayable>
    <us-gaap:RepaymentsOfNotesPayable contextRef="From2012-04-01to2012-12-31" unitRef="USD" decimals="0">-382000</us-gaap:RepaymentsOfNotesPayable>
    <us-gaap:RepaymentsOfLongTermCapitalLeaseObligations contextRef="From2011-04-01to2011-12-31" unitRef="USD" decimals="0">-24300</us-gaap:RepaymentsOfLongTermCapitalLeaseObligations>
    <us-gaap:RepaymentsOfLongTermCapitalLeaseObligations contextRef="From1998-05-26to2012-12-31" unitRef="USD" decimals="0">-115800</us-gaap:RepaymentsOfLongTermCapitalLeaseObligations>
    <us-gaap:RepaymentsOfLongTermCapitalLeaseObligations contextRef="From2012-04-01to2012-12-31" unitRef="USD" decimals="0">-15300</us-gaap:RepaymentsOfLongTermCapitalLeaseObligations>
    <VSTA:NetProceedsFromIssuanceOfFebruary201212ConvertibleNotesAndWarrants contextRef="From2011-04-01to2011-12-31" unitRef="USD" xsi:nil="true" />
    <VSTA:NetProceedsFromIssuanceOfFebruary201212ConvertibleNotesAndWarrants contextRef="From1998-05-26to2012-12-31" unitRef="USD" decimals="0">466500</VSTA:NetProceedsFromIssuanceOfFebruary201212ConvertibleNotesAndWarrants>
    <VSTA:NetProceedsFromIssuanceOfFebruary201212ConvertibleNotesAndWarrants contextRef="From2012-04-01to2012-12-31" unitRef="USD" xsi:nil="true" />
    <VSTA:NetProceedsFromIssuanceOfAugust2010ShortTermNotesAndWarrants contextRef="From2011-04-01to2011-12-31" unitRef="USD" xsi:nil="true" />
    <VSTA:NetProceedsFromIssuanceOfAugust2010ShortTermNotesAndWarrants contextRef="From1998-05-26to2012-12-31" unitRef="USD" decimals="0">800000</VSTA:NetProceedsFromIssuanceOfAugust2010ShortTermNotesAndWarrants>
    <VSTA:NetProceedsFromIssuanceOfAugust2010ShortTermNotesAndWarrants contextRef="From2012-04-01to2012-12-31" unitRef="USD" xsi:nil="true" />
    <VSTA:ProceedsFromIssuanceOf7NotesPayable contextRef="From2011-04-01to2011-12-31" unitRef="USD" xsi:nil="true" />
    <VSTA:ProceedsFromIssuanceOf7NotesPayable contextRef="From1998-05-26to2012-12-31" unitRef="USD" decimals="0">55000</VSTA:ProceedsFromIssuanceOf7NotesPayable>
    <VSTA:ProceedsFromIssuanceOf7NotesPayable contextRef="From2012-04-01to2012-12-31" unitRef="USD" xsi:nil="true" />
    <VSTA:NetProceedsFromIssuanceOf20062007NotesAndWarrants contextRef="From2011-04-01to2011-12-31" unitRef="USD" xsi:nil="true" />
    <VSTA:NetProceedsFromIssuanceOf20062007NotesAndWarrants contextRef="From1998-05-26to2012-12-31" unitRef="USD" decimals="0">1025000</VSTA:NetProceedsFromIssuanceOf20062007NotesAndWarrants>
    <VSTA:NetProceedsFromIssuanceOf20062007NotesAndWarrants contextRef="From2012-04-01to2012-12-31" unitRef="USD" xsi:nil="true" />
    <VSTA:NetProceedsFromIssuanceOf20082010NotesAndWarrants contextRef="From2011-04-01to2011-12-31" unitRef="USD" xsi:nil="true" />
    <VSTA:NetProceedsFromIssuanceOf20082010NotesAndWarrants contextRef="From1998-05-26to2012-12-31" unitRef="USD" decimals="0">2971800</VSTA:NetProceedsFromIssuanceOf20082010NotesAndWarrants>
    <VSTA:NetProceedsFromIssuanceOf20082010NotesAndWarrants contextRef="From2012-04-01to2012-12-31" unitRef="USD" xsi:nil="true" />
    <VSTA:NetProceedsFromIssuanceOfPlatinumNotesAndWarrants contextRef="From2011-04-01to2011-12-31" unitRef="USD" xsi:nil="true" />
    <VSTA:NetProceedsFromIssuanceOfPlatinumNotesAndWarrants contextRef="From1998-05-26to2012-12-31" unitRef="USD" decimals="0">5922100</VSTA:NetProceedsFromIssuanceOfPlatinumNotesAndWarrants>
    <VSTA:NetProceedsFromIssuanceOfPlatinumNotesAndWarrants contextRef="From2012-04-01to2012-12-31" unitRef="USD" decimals="0">2222100</VSTA:NetProceedsFromIssuanceOfPlatinumNotesAndWarrants>
    <VSTA:NetProceedsFromIssuanceOf10ConvertibleNotesAndWarrants contextRef="From2011-04-01to2011-12-31" unitRef="USD" xsi:nil="true" />
    <VSTA:NetProceedsFromIssuanceOf10ConvertibleNotesAndWarrants contextRef="From1998-05-26to2012-12-31" unitRef="USD" decimals="0">1655000</VSTA:NetProceedsFromIssuanceOf10ConvertibleNotesAndWarrants>
    <VSTA:NetProceedsFromIssuanceOf10ConvertibleNotesAndWarrants contextRef="From2012-04-01to2012-12-31" unitRef="USD" xsi:nil="true" />
    <VSTA:NetProceedsFromIssuanceOf7ConvertibleNotes contextRef="From2011-04-01to2011-12-31" unitRef="USD" xsi:nil="true" />
    <VSTA:NetProceedsFromIssuanceOf7ConvertibleNotes contextRef="From1998-05-26to2012-12-31" unitRef="USD" decimals="0">575000</VSTA:NetProceedsFromIssuanceOf7ConvertibleNotes>
    <VSTA:NetProceedsFromIssuanceOf7ConvertibleNotes contextRef="From2012-04-01to2012-12-31" unitRef="USD" xsi:nil="true" />
    <VSTA:ProceedsFromIssuanceOf7NotePayableToFoundingStockholder contextRef="From2011-04-01to2011-12-31" unitRef="USD" xsi:nil="true" />
    <VSTA:ProceedsFromIssuanceOf7NotePayableToFoundingStockholder contextRef="From1998-05-26to2012-12-31" unitRef="USD" decimals="0">90000</VSTA:ProceedsFromIssuanceOf7NotePayableToFoundingStockholder>
    <VSTA:ProceedsFromIssuanceOf7NotePayableToFoundingStockholder contextRef="From2012-04-01to2012-12-31" unitRef="USD" xsi:nil="true" />
    <us-gaap:ProceedsFromUnsecuredLinesOfCredit contextRef="From2011-04-01to2011-12-31" unitRef="USD" xsi:nil="true" />
    <us-gaap:ProceedsFromUnsecuredLinesOfCredit contextRef="From1998-05-26to2012-12-31" unitRef="USD" decimals="0">200000</us-gaap:ProceedsFromUnsecuredLinesOfCredit>
    <us-gaap:ProceedsFromUnsecuredLinesOfCredit contextRef="From2012-04-01to2012-12-31" unitRef="USD" xsi:nil="true" />
    <VSTA:ProceedsFromExerciseOfModifiedWarrantsMayjune2012AndUnderDiscountedWarrantExerciseProgram2011 contextRef="From2011-04-01to2011-12-31" unitRef="USD" decimals="0">1037100</VSTA:ProceedsFromExerciseOfModifiedWarrantsMayjune2012AndUnderDiscountedWarrantExerciseProgram2011>
    <VSTA:ProceedsFromExerciseOfModifiedWarrantsMayjune2012AndUnderDiscountedWarrantExerciseProgram2011 contextRef="From1998-05-26to2012-12-31" unitRef="USD" decimals="0">1428400</VSTA:ProceedsFromExerciseOfModifiedWarrantsMayjune2012AndUnderDiscountedWarrantExerciseProgram2011>
    <VSTA:ProceedsFromExerciseOfModifiedWarrantsMayjune2012AndUnderDiscountedWarrantExerciseProgram2011 contextRef="From2012-04-01to2012-12-31" unitRef="USD" decimals="0">262100</VSTA:ProceedsFromExerciseOfModifiedWarrantsMayjune2012AndUnderDiscountedWarrantExerciseProgram2011>
    <us-gaap:ProceedsFromIssuanceOfPreferredStockAndPreferenceStock contextRef="From2011-04-01to2011-12-31" unitRef="USD" xsi:nil="true" />
    <us-gaap:ProceedsFromIssuanceOfPreferredStockAndPreferenceStock contextRef="From1998-05-26to2012-12-31" unitRef="USD" decimals="0">4198600</us-gaap:ProceedsFromIssuanceOfPreferredStockAndPreferenceStock>
    <us-gaap:ProceedsFromIssuanceOfPreferredStockAndPreferenceStock contextRef="From2012-04-01to2012-12-31" unitRef="USD" xsi:nil="true" />
    <us-gaap:LiabilitiesAndStockholdersEquity contextRef="AsOf2012-12-31" unitRef="USD" decimals="0">326000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity contextRef="AsOf2012-03-31" unitRef="USD" decimals="0">341600</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2012-12-31" unitRef="USD" decimals="0">-10522400</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2012-03-31" unitRef="USD" decimals="0">-5705600</us-gaap:StockholdersEquity>
    <us-gaap:RetainedEarningsAccumulatedDeficit contextRef="AsOf2012-12-31" unitRef="USD" decimals="0">-63899100</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit contextRef="AsOf2012-03-31" unitRef="USD" decimals="0">-54782500</us-gaap:RetainedEarningsAccumulatedDeficit>
    <VSTA:NotesReceivableFromSaleOfCommonStockToOthers contextRef="AsOf2012-12-31" unitRef="USD" decimals="0">-256000</VSTA:NotesReceivableFromSaleOfCommonStockToOthers>
    <VSTA:NotesReceivableFromSaleOfCommonStockToOthers contextRef="AsOf2012-03-31" unitRef="USD" decimals="0">-250000</VSTA:NotesReceivableFromSaleOfCommonStockToOthers>
    <us-gaap:TreasuryStockValue contextRef="AsOf2012-12-31" unitRef="USD" decimals="0">-3968100</us-gaap:TreasuryStockValue>
    <us-gaap:TreasuryStockValue contextRef="AsOf2012-03-31" unitRef="USD" decimals="0">-3231700</us-gaap:TreasuryStockValue>
    <us-gaap:AdditionalPaidInCapital contextRef="AsOf2012-12-31" unitRef="USD" decimals="0">57578200</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AdditionalPaidInCapital contextRef="AsOf2012-03-31" unitRef="USD" decimals="0">52539500</us-gaap:AdditionalPaidInCapital>
    <us-gaap:CommonStockValue contextRef="AsOf2012-12-31" unitRef="USD" decimals="0">22100</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue contextRef="AsOf2012-03-31" unitRef="USD" decimals="0">18700</us-gaap:CommonStockValue>
    <us-gaap:PreferredStockValue contextRef="AsOf2012-12-31" unitRef="USD" decimals="0">500</us-gaap:PreferredStockValue>
    <us-gaap:PreferredStockValue contextRef="AsOf2012-03-31" unitRef="USD" decimals="0">400</us-gaap:PreferredStockValue>
    <us-gaap:Liabilities contextRef="AsOf2012-12-31" unitRef="USD" decimals="0">10848400</us-gaap:Liabilities>
    <us-gaap:Liabilities contextRef="AsOf2012-03-31" unitRef="USD" decimals="0">6047200</us-gaap:Liabilities>
    <us-gaap:LiabilitiesNoncurrent contextRef="AsOf2012-12-31" unitRef="USD" decimals="0">8272400</us-gaap:LiabilitiesNoncurrent>
    <us-gaap:LiabilitiesNoncurrent contextRef="AsOf2012-03-31" unitRef="USD" decimals="0">2864700</us-gaap:LiabilitiesNoncurrent>
    <us-gaap:CapitalLeaseObligationsNoncurrent contextRef="AsOf2012-12-31" unitRef="USD" decimals="0">8000</us-gaap:CapitalLeaseObligationsNoncurrent>
    <us-gaap:CapitalLeaseObligationsNoncurrent contextRef="AsOf2012-03-31" unitRef="USD" decimals="0">9700</us-gaap:CapitalLeaseObligationsNoncurrent>
    <VSTA:AccruedOfficersCompensation contextRef="AsOf2012-12-31" unitRef="USD" decimals="0">57000</VSTA:AccruedOfficersCompensation>
    <VSTA:AccruedOfficersCompensation contextRef="AsOf2012-03-31" unitRef="USD" decimals="0">57000</VSTA:AccruedOfficersCompensation>
    <us-gaap:AccountsPayableAndAccruedLiabilitiesNoncurrent contextRef="AsOf2012-12-31" unitRef="USD" decimals="0">3910400</us-gaap:AccountsPayableAndAccruedLiabilitiesNoncurrent>
    <us-gaap:AccountsPayableAndAccruedLiabilitiesNoncurrent contextRef="AsOf2012-03-31" unitRef="USD" xsi:nil="true" />
    <VSTA:NotesPayableAndAccruedInterestToRelatedPartiesNonCurrent contextRef="AsOf2012-12-31" unitRef="USD" decimals="0">1051700</VSTA:NotesPayableAndAccruedInterestToRelatedPartiesNonCurrent>
    <VSTA:NotesPayableAndAccruedInterestToRelatedPartiesNonCurrent contextRef="AsOf2012-03-31" unitRef="USD" decimals="0">107700</VSTA:NotesPayableAndAccruedInterestToRelatedPartiesNonCurrent>
    <VSTA:NotesPayableAndAccruedInterest contextRef="AsOf2012-12-31" unitRef="USD" decimals="0">1907800</VSTA:NotesPayableAndAccruedInterest>
    <VSTA:NotesPayableAndAccruedInterest contextRef="AsOf2012-03-31" unitRef="USD" decimals="0">2684300</VSTA:NotesPayableAndAccruedInterest>
    <VSTA:ConvertiblePromissoryNotesNetOfCurrentPortion contextRef="AsOf2012-12-31" unitRef="USD" xsi:nil="true" />
    <VSTA:ConvertiblePromissoryNotesNetOfCurrentPortion contextRef="AsOf2012-03-31" unitRef="USD" decimals="0">6000</VSTA:ConvertiblePromissoryNotesNetOfCurrentPortion>
    <VSTA:SeniorSecuredConvertiblePromisoryNotesAndAccruedInterest contextRef="AsOf2012-12-31" unitRef="USD" decimals="0">1337500</VSTA:SeniorSecuredConvertiblePromisoryNotesAndAccruedInterest>
    <VSTA:SeniorSecuredConvertiblePromisoryNotesAndAccruedInterest contextRef="AsOf2012-03-31" unitRef="USD" xsi:nil="true" />
    <us-gaap:LiabilitiesCurrent contextRef="AsOf2012-12-31" unitRef="USD" decimals="0">2576000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent contextRef="AsOf2012-03-31" unitRef="USD" decimals="0">3182500</us-gaap:LiabilitiesCurrent>
    <VSTA:DeferredRevenues contextRef="AsOf2012-12-31" unitRef="USD" xsi:nil="true" />
    <VSTA:DeferredRevenues contextRef="AsOf2012-03-31" unitRef="USD" decimals="0">13200</VSTA:DeferredRevenues>
    <us-gaap:CapitalLeaseObligationsCurrent contextRef="AsOf2012-12-31" unitRef="USD" decimals="0">7300</us-gaap:CapitalLeaseObligationsCurrent>
    <us-gaap:CapitalLeaseObligationsCurrent contextRef="AsOf2012-03-31" unitRef="USD" decimals="0">10500</us-gaap:CapitalLeaseObligationsCurrent>
    <VSTA:NotesPayableAndAccruedInterestToRelatedParties contextRef="AsOf2012-12-31" unitRef="USD" decimals="0">112000</VSTA:NotesPayableAndAccruedInterestToRelatedParties>
    <VSTA:NotesPayableAndAccruedInterestToRelatedParties contextRef="AsOf2012-03-31" unitRef="USD" decimals="0">168200</VSTA:NotesPayableAndAccruedInterestToRelatedParties>
    <us-gaap:NotesAndLoansPayableCurrent contextRef="AsOf2012-12-31" unitRef="USD" decimals="0">822100</us-gaap:NotesAndLoansPayableCurrent>
    <us-gaap:NotesAndLoansPayableCurrent contextRef="AsOf2012-03-31" unitRef="USD" decimals="0">582500</us-gaap:NotesAndLoansPayableCurrent>
    <us-gaap:AccruedLiabilitiesCurrent contextRef="AsOf2012-12-31" unitRef="USD" decimals="0">382300</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent contextRef="AsOf2012-03-31" unitRef="USD" decimals="0">657300</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccountsPayableCurrent contextRef="AsOf2012-12-31" unitRef="USD" decimals="0">1252300</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent contextRef="AsOf2012-03-31" unitRef="USD" decimals="0">1750800</us-gaap:AccountsPayableCurrent>
    <us-gaap:Assets contextRef="AsOf2012-12-31" unitRef="USD" decimals="0">326000</us-gaap:Assets>
    <us-gaap:Assets contextRef="AsOf2012-03-31" unitRef="USD" decimals="0">341600</us-gaap:Assets>
    <us-gaap:OtherAssetsNoncurrent contextRef="AsOf2012-12-31" unitRef="USD" decimals="0">29800</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent contextRef="AsOf2012-03-31" unitRef="USD" decimals="0">29000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:PropertyPlantAndEquipmentNet contextRef="AsOf2012-12-31" unitRef="USD" decimals="0">189200</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet contextRef="AsOf2012-03-31" unitRef="USD" decimals="0">74500</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:AssetsCurrent contextRef="AsOf2012-12-31" unitRef="USD" decimals="0">107000</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent contextRef="AsOf2012-03-31" unitRef="USD" decimals="0">238100</us-gaap:AssetsCurrent>
    <us-gaap:PrepaidExpenseCurrent contextRef="AsOf2012-12-31" unitRef="USD" decimals="0">82800</us-gaap:PrepaidExpenseCurrent>
    <us-gaap:PrepaidExpenseCurrent contextRef="AsOf2012-03-31" unitRef="USD" decimals="0">50900</us-gaap:PrepaidExpenseCurrent>
    <us-gaap:ReceivablesNetCurrent contextRef="AsOf2012-12-31" unitRef="USD" xsi:nil="true" />
    <us-gaap:ReceivablesNetCurrent contextRef="AsOf2012-03-31" unitRef="USD" decimals="0">106200</us-gaap:ReceivablesNetCurrent>
    <VSTA:ConversionTotalSeriesPreferredToCommonStock contextRef="AsOf2012-12-31" unitRef="Shares" decimals="INF">15000000</VSTA:ConversionTotalSeriesPreferredToCommonStock>
    <VSTA:ConversionToWarrantWarrantValue contextRef="AsOf2012-12-31" unitRef="Shares" decimals="INF">7500000</VSTA:ConversionToWarrantWarrantValue>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights contextRef="AsOf2012-12-31" unitRef="USDPShares" decimals="INF">1.5</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights>
    <VSTA:October2012PlatinumNotePrincipalAmount contextRef="AsOf2012-12-31" unitRef="USD" decimals="0">2000000</VSTA:October2012PlatinumNotePrincipalAmount>
    <VSTA:October2012PlatinumNotePrincipalAmount contextRef="AsOf2012-12-31_February2012ConvertibleNotes12PercentMember" unitRef="USD" decimals="0">2000000</VSTA:October2012PlatinumNotePrincipalAmount>
    <VSTA:October2012PlatinumNoteTranchAmount contextRef="AsOf2012-12-31" unitRef="USD" decimals="0">500000</VSTA:October2012PlatinumNoteTranchAmount>
    <VSTA:October2012PlatinumNoteTranchAmount contextRef="AsOf2012-12-31_February2012ConvertibleNotes12PercentMember" unitRef="USD" decimals="0">500000</VSTA:October2012PlatinumNoteTranchAmount>
    <VSTA:October2012PlatinumNoteGrossProceeds contextRef="AsOf2012-12-31" unitRef="USD" decimals="0">1000000</VSTA:October2012PlatinumNoteGrossProceeds>
    <VSTA:October2012PlatinumNoteGrossProceeds contextRef="AsOf2012-12-31_February2012ConvertibleNotes12PercentMember" unitRef="USD" decimals="0">1000000</VSTA:October2012PlatinumNoteGrossProceeds>
    <VSTA:PrivatePlacements contextRef="AsOf2012-12-31" unitRef="Shares" decimals="INF">951256</VSTA:PrivatePlacements>
    <VSTA:PrivatePlacements contextRef="AsOf2012-12-31_February2012ConvertibleNotes12PercentMember" unitRef="Shares" decimals="INF">951256</VSTA:PrivatePlacements>
    <VSTA:ProceedsFromIssuancesOfPrivatePlacement contextRef="AsOf2012-12-31" unitRef="USD" decimals="0">475600</VSTA:ProceedsFromIssuancesOfPrivatePlacement>
    <VSTA:ProceedsFromIssuancesOfPrivatePlacement contextRef="AsOf2012-12-31_February2012ConvertibleNotes12PercentMember" unitRef="USD" decimals="0">475600</VSTA:ProceedsFromIssuancesOfPrivatePlacement>
    <VSTA:PrivatePlacementUnitPrice contextRef="AsOf2012-12-31" unitRef="USDPShares" decimals="INF">.50</VSTA:PrivatePlacementUnitPrice>
    <VSTA:PrivatePlacementUnitPrice contextRef="AsOf2012-12-31_February2012ConvertibleNotes12PercentMember" unitRef="USDPShares" decimals="INF">0.50</VSTA:PrivatePlacementUnitPrice>
    <VSTA:FinancingRequiredToSellNote contextRef="AsOf2012-12-31" unitRef="USD" decimals="0">524400</VSTA:FinancingRequiredToSellNote>
    <VSTA:FinancingRequiredToSellNote contextRef="AsOf2012-12-31_February2012ConvertibleNotes12PercentMember" unitRef="USD" decimals="0">524400</VSTA:FinancingRequiredToSellNote>
    <VSTA:WarrantSharesIssuableUponExerciseNotePurchaseAndExchangeAgreement contextRef="AsOf2012-12-31" unitRef="Shares" decimals="INF">7500000</VSTA:WarrantSharesIssuableUponExerciseNotePurchaseAndExchangeAgreement>
    <VSTA:WarrantSharesIssuableUponExerciseNotePurchaseAndExchangeAgreement contextRef="AsOf2011-12-31" unitRef="Shares" xsi:nil="true" />
    <us-gaap:TemporaryEquityRedemptionPricePerShare contextRef="AsOf2012-12-31_MaximumMember" unitRef="USDPShares" decimals="INF">.51</us-gaap:TemporaryEquityRedemptionPricePerShare>
    <us-gaap:TemporaryEquityRedemptionPricePerShare contextRef="AsOf2012-12-31_MinimumMember" unitRef="USDPShares" decimals="INF">.71</us-gaap:TemporaryEquityRedemptionPricePerShare>
    <VSTA:MarketPriceOnDateOfGrant contextRef="AsOf2012-12-31_MaximumMember" unitRef="USDPShares" decimals="INF">.51</VSTA:MarketPriceOnDateOfGrant>
    <VSTA:MarketPriceOnDateOfGrant contextRef="AsOf2012-12-31_MinimumMember" unitRef="USDPShares" decimals="INF">.71</VSTA:MarketPriceOnDateOfGrant>
    <VSTA:FairValueAssumptionsRiskFreeInterestRates contextRef="AsOf2012-12-31_MaximumMember" unitRef="Percent" decimals="INF">.00895</VSTA:FairValueAssumptionsRiskFreeInterestRates>
    <VSTA:FairValueAssumptionsRiskFreeInterestRates contextRef="AsOf2012-12-31_MinimumMember" unitRef="Percent" decimals="INF">.0174</VSTA:FairValueAssumptionsRiskFreeInterestRates>
    <VSTA:ExpectedYears contextRef="AsOf2012-12-31_MaximumMember" unitRef="Percent" decimals="INF">6.25</VSTA:ExpectedYears>
    <VSTA:ExpectedYears contextRef="AsOf2012-12-31_MinimumMember" unitRef="Percent" decimals="INF">10</VSTA:ExpectedYears>
    <VSTA:ShareBasedCompensationArrangementByShareBasedPaymentAwardVolatilityRate contextRef="AsOf2012-12-31_MaximumMember" unitRef="Percent" decimals="INF">.829</VSTA:ShareBasedCompensationArrangementByShareBasedPaymentAwardVolatilityRate>
    <VSTA:ShareBasedCompensationArrangementByShareBasedPaymentAwardVolatilityRate contextRef="AsOf2012-12-31_MinimumMember" unitRef="Percent" decimals="INF">.854</VSTA:ShareBasedCompensationArrangementByShareBasedPaymentAwardVolatilityRate>
    <VSTA:OptionsOutstandingAtBeginningOfPeriod contextRef="From2012-04-01to2012-12-31" unitRef="Shares" decimals="INF">4805771</VSTA:OptionsOutstandingAtBeginningOfPeriod>
    <VSTA:OptionsGranted contextRef="From2012-04-01to2012-12-31" unitRef="Shares" decimals="INF">1075550</VSTA:OptionsGranted>
    <VSTA:OptionsForfeited contextRef="From2012-04-01to2012-12-31" unitRef="Shares" decimals="INF">-870550</VSTA:OptionsForfeited>
    <VSTA:OptionsExpired contextRef="From2012-04-01to2012-12-31" unitRef="Shares" decimals="INF">-44000</VSTA:OptionsExpired>
    <VSTA:OptionsOutstandingAtBeginningOfPeriods contextRef="From2012-04-01to2012-12-31" unitRef="USDPShares" decimals="INF">1.53</VSTA:OptionsOutstandingAtBeginningOfPeriods>
    <VSTA:OptionsGranteds contextRef="From2012-04-01to2012-12-31" unitRef="USDPShares" decimals="INF">0.72</VSTA:OptionsGranteds>
    <VSTA:OptionsForfeiteds contextRef="From2012-04-01to2012-12-31" unitRef="USDPShares" decimals="INF">1.72</VSTA:OptionsForfeiteds>
    <VSTA:OptionsExpireds contextRef="From2012-04-01to2012-12-31" unitRef="USDPShares" decimals="INF">0.79</VSTA:OptionsExpireds>
    <VSTA:OptionsOutstandingAtEndOfPeriods contextRef="From2012-04-01to2012-12-31" unitRef="USDPShares" decimals="INF">1.33</VSTA:OptionsOutstandingAtEndOfPeriods>
    <VSTA:OptionsExercisableAtEndOfPeriods contextRef="From2012-04-01to2012-12-31" unitRef="USDPShares" decimals="INF">1.36</VSTA:OptionsExercisableAtEndOfPeriods>
    <VSTA:CrlNoteInterestRate contextRef="From2012-10-01to2012-12-31_CatoBioVenturesMember" unitRef="Percent" decimals="INF">.075</VSTA:CrlNoteInterestRate>
    <VSTA:CrlNoteIntrestExpense contextRef="From2012-10-01to2012-12-31_CatoBioVenturesMember" unitRef="USD" decimals="0">26300</VSTA:CrlNoteIntrestExpense>
    <VSTA:CrlNoteIntrestExpense contextRef="From2012-04-01to2012-12-31_CatoBioVenturesMember" unitRef="USD" decimals="0">23600</VSTA:CrlNoteIntrestExpense>
    <VSTA:NetLossAttributableToCommonStockholders contextRef="From2011-10-01to2011-12-31" unitRef="USD" decimals="0">-4500100</VSTA:NetLossAttributableToCommonStockholders>
    <VSTA:NetLossAttributableToCommonStockholders contextRef="From2011-04-01to2011-12-31" unitRef="USD" decimals="0">-9167500</VSTA:NetLossAttributableToCommonStockholders>
    <VSTA:NetLossAttributableToCommonStockholders contextRef="From1998-05-26to2012-12-31" unitRef="USD" decimals="0">-71024100</VSTA:NetLossAttributableToCommonStockholders>
    <VSTA:NetLossAttributableToCommonStockholders contextRef="From2012-04-01to2012-12-31" unitRef="USD" decimals="0">-16241600</VSTA:NetLossAttributableToCommonStockholders>
    <VSTA:DeemedDividendOnSeriesPreferredStock contextRef="From2011-10-01to2011-12-31" unitRef="USD" xsi:nil="true" />
    <VSTA:DeemedDividendOnSeriesPreferredStock contextRef="From2011-04-01to2011-12-31" unitRef="USD" xsi:nil="true" />
    <VSTA:DeemedDividendOnSeriesPreferredStock contextRef="From1998-05-26to2012-12-31" unitRef="USD" decimals="0">-7125000</VSTA:DeemedDividendOnSeriesPreferredStock>
    <VSTA:DeemedDividendOnSeriesPreferredStock contextRef="From2012-04-01to2012-12-31" unitRef="USD" decimals="0">-7125000</VSTA:DeemedDividendOnSeriesPreferredStock>
    <VSTA:FairValuePerShareAtGrantDate contextRef="AsOf2012-12-31_MaximumMember" unitRef="USDPShares" decimals="INF">0</VSTA:FairValuePerShareAtGrantDate>
    <VSTA:FairValuePerShareAtGrantDate contextRef="AsOf2012-12-31_MinimumMember" unitRef="USDPShares" decimals="INF">1</VSTA:FairValuePerShareAtGrantDate>
    <dei:EntityRegistrantName contextRef="From2012-04-01to2012-12-31">VistaGen Therapeutics, Inc.</dei:EntityRegistrantName>
    <dei:EntityCentralIndexKey contextRef="From2012-04-01to2012-12-31">0001411685</dei:EntityCentralIndexKey>
    <dei:DocumentType contextRef="From2012-04-01to2012-12-31">10-Q</dei:DocumentType>
    <dei:DocumentPeriodEndDate contextRef="From2012-04-01to2012-12-31">2012-12-31</dei:DocumentPeriodEndDate>
    <dei:AmendmentFlag contextRef="From2012-04-01to2012-12-31">false</dei:AmendmentFlag>
    <dei:CurrentFiscalYearEndDate contextRef="From2012-04-01to2012-12-31">--03-31</dei:CurrentFiscalYearEndDate>
    <dei:EntityWellKnownSeasonedIssuer contextRef="From2012-04-01to2012-12-31">No</dei:EntityWellKnownSeasonedIssuer>
    <dei:EntityVoluntaryFilers contextRef="From2012-04-01to2012-12-31">No</dei:EntityVoluntaryFilers>
    <dei:EntityCurrentReportingStatus contextRef="From2012-04-01to2012-12-31">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityFilerCategory contextRef="From2012-04-01to2012-12-31">Smaller Reporting Company</dei:EntityFilerCategory>
    <dei:EntityPublicFloat contextRef="AsOf2013-02-12" unitRef="USD" decimals="0">8317414</dei:EntityPublicFloat>
    <dei:EntityCommonStockSharesOutstanding contextRef="AsOf2013-02-12" unitRef="Shares" decimals="INF">20091787</dei:EntityCommonStockSharesOutstanding>
    <dei:DocumentFiscalPeriodFocus contextRef="From2012-04-01to2012-12-31">Q3</dei:DocumentFiscalPeriodFocus>
    <dei:DocumentFiscalYearFocus contextRef="From2012-04-01to2012-12-31">2013</dei:DocumentFiscalYearFocus>
    <VSTA:HistoryAndOrganizationTextBlock contextRef="From2012-04-01to2012-12-31">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in"&gt;&lt;font style="font-size: 10pt"&gt;VistaGen&#13;Therapeutics, Inc., a Nevada corporation (&amp;#147;&lt;i&gt;VistaGen&lt;/i&gt;&amp;#148; or the &amp;#147;&lt;i&gt;Compan&lt;/i&gt;y&amp;#148;), is a biotechnology&#13;company applying human pluripotent stem cell technology for drug rescue and novel pharmaceutical assays for predictive heart and&#13;liver toxicology and drug metabolism screening. VistaGen's drug rescue activities are focused on combining its human pluripotent&#13;stem cell technology platform, &lt;i&gt;Human Clinical Trials in a Test Tube&lt;/i&gt;&amp;#153;, with modern medicinal chemistry to generate&#13;new chemical variants (Drug Rescue Variants) of once-promising small molecule drug candidates. These are drug candidates discontinued&#13;due to heart or liver toxicity or drug metabolism issues after substantial investment and development by large pharmaceutical&#13;companies, the U.S. National Institutes of Health (NIH) or university laboratories. VistaGen uses its pluripotent stem cell technology&#13;and novel bioassay systems to generate early indications, or predictions, of how humans will ultimately respond to new drug candidates,&#13;including Drug Rescue Variants, before they are ever tested in humans, bringing human biology to the front end of the conventional&#13;drug development process.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"&gt;&lt;font style="font-size: 10pt"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in"&gt;&lt;font style="font-size: 10pt"&gt;Additionally,&#13;VistaGen's orally-available, small molecule drug candidate, AV-101, has successfully completed Phase 1 development for treatment&#13;of neuropathic pain. Neuropathic pain, a serious and chronic condition causing pain after an injury or disease of the peripheral&#13;or central nervous system, affects millions of people worldwide. To date, the NIH has awarded VistaGen approximately $8.8 million&#13;for preclinical and clinical development of AV-101.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"&gt;&lt;font style="font-size: 10pt"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in"&gt;&lt;font style="font-size: 10pt"&gt;VistaGen&#13;is in the development stage and, since inception, has devoted substantially all of its time and efforts to stem cell research&#13;and stem-cell based bioassay development, small molecule drug development, creating, protecting and patenting intellectual property,&#13;recruiting personnel and raising working capital.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"&gt;&lt;font style="font-size: 10pt"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"&gt;&lt;font style="font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;The Merger&lt;/i&gt;&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"&gt;&lt;font style="font-size: 10pt"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in"&gt;&lt;font style="font-size: 10pt"&gt;VistaGen&#13;Therapeutics, Inc., a California corporation and a wholly-owned subsidiary of the Company (&amp;#147;&lt;i&gt;VistaGen California&lt;/i&gt;&amp;#148;),&#13;was incorporated in California on May 26, 1998. Excaliber Enterprises, Ltd. (&amp;#147;&lt;i&gt;Excaliber&lt;/i&gt;&amp;#148; or the &amp;#147;Company&amp;#148;)&#13;was organized as a Nevada corporation on October 6, 2005. On May 11, 2011, Excaliber acquired all outstanding shares of VistaGen&#13;California for 6,836,452 shares of Excaliber common stock (the &amp;#147;&lt;i&gt;Merger&lt;/i&gt;&amp;#148;), and assumed VistaGen California&amp;#146;s&#13;pre-Merger obligations to contingently issue common shares in accordance with stock option agreements, warrant agreements, and&#13;a convertible promissory note. As part of the Merger, Excaliber repurchased 5,064,207 shares of its common stock from two stockholders&#13;for a nominal amount, leaving 784,500 shares of Excaliber common stock outstanding at the date of the Merger. The 6,836,452 shares&#13;issued to VistaGen California&amp;#146;s stockholders in connection with the Merger represented approximately ninety percent (90%)&#13;of the outstanding shares of the Company&amp;#146;s common stock after the Merger. As a result of the Merger, the business of VistaGen&#13;California became the business of the Company. Shortly after the Merger:&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in"&gt;&lt;font style="font-size: 10pt"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;table align="center" cellspacing="0" cellpadding="0" style="width: 100%"&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;    &lt;td style="width: 60px; font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;font style="font-size: 10pt"&gt;&amp;#9679;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;font style="font-size: 10pt"&gt;Each of the prior directors&#13;    of VistaGen California was appointed as a director of the Company;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;font style="font-size: 10pt"&gt;&amp;#9679;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;font style="font-size: 10pt"&gt;The prior directors and&#13;    officers of Excaliber resigned as officers and directors of the Company;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"&gt;&lt;font style="font-size: 10pt"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;table align="center" cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;    &lt;td style="width: 60px; text-align: center"&gt;&lt;font style="font-size: 10pt"&gt;&amp;#9679;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font-size: 10pt"&gt;VistaGen California&amp;#146;s prior officers were appointed as officers&#13;    of like tenor of the Company;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;    &lt;td style="text-align: center"&gt;&lt;font style="font-size: 10pt"&gt;&amp;#9679;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font-size: 10pt"&gt;The Company&amp;#146;s directors approved a two-for-one (2:1) forward&#13;    stock split of the Company&amp;#146;s common stock;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"&gt;&lt;font style="font-size: 10pt"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;table align="center" cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;    &lt;td style="width: 60px; text-align: center"&gt;&lt;font style="font-size: 10pt"&gt;&amp;#9679;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: justify"&gt;&lt;font style="font-size: 10pt"&gt;The Company&amp;#146;s directors approved an increase in the number&#13;    of shares of common stock the Company was authorized to issue from 200 million to 400 million shares;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;    &lt;td style="text-align: center"&gt;&lt;font style="font-size: 10pt"&gt;&amp;#9679;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font-size: 10pt"&gt;The Company changed its name to &amp;#147;VistaGen Therapeutics, Inc.&amp;#148;;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"&gt;&lt;font style="font-size: 10pt"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;table align="center" cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;    &lt;td style="width: 60px; text-align: center"&gt;&lt;font style="font-size: 10pt"&gt;&amp;#9679;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: justify"&gt;&lt;font style="font-size: 10pt"&gt;The Company&amp;#146;s common stock began trading on the OTC Bulletin&#13;    Board under the symbol &amp;#147;VSTA&amp;#148; effective on June 21, 2011; and&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;    &lt;td style="text-align: center"&gt;&lt;font style="font-size: 10pt"&gt;&amp;#9679;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font-size: 10pt"&gt;The Company adopted VistaGen California's fiscal year-end of March&#13;    31st, with VistaGen California as the accounting acquirer.&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"&gt;&lt;font style="font-size: 10pt"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;font style="font-size: 10pt"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in"&gt;&lt;font style="font-size: 10pt"&gt;VistaGen&#13;California, as the accounting acquirer in the Merger, recorded the Merger as the issuance of common stock for the net monetary&#13;assets of the Company, accompanied by a recapitalization. This accounting for the transaction was identical to that resulting&#13;from a reverse acquisition, except that no goodwill or other intangible assets were recorded. A total of 1,569,000 shares of common&#13;stock, representing the shares held by stockholders of Excaliber immediately prior to the Merger and effected for the post-Merger&#13;two-for-one (2:1) stock split noted above, have been retroactively reflected as outstanding for all periods presented in the accompanying&#13;Condensed Consolidated Financial Statements of the Company.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in"&gt;&lt;font style="font-size: 10pt"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in"&gt;&lt;font style="font-size: 10pt"&gt;In&#13;October 2011, the Company&amp;#146;s stockholders amended the Company&amp;#146;s Articles of Incorporation to (1) reduce the number&#13;of shares of common stock the Company is authorized to issue from 400 million shares to 200 million shares; (2) authorize the&#13;Company to issue up to 10 million shares of preferred stock; and (3) authorize the Company&amp;#146;s Board of Directors to prescribe&#13;the classes, series and the number of each class or series of preferred stock and the voting powers, designations, preferences,&#13;limitations, restrictions and relative rights of each class or series of preferred stock. In December 2011, the Company&amp;#146;s&#13;Board of Directors authorized the creation of a series of up to 500,000 shares of Series A Preferred Stock, par value $0.001 (&amp;#147;&lt;i&gt;Series&#13;A Preferred&lt;/i&gt;&amp;#148;). Pursuant to the Note Exchange and Purchase Agreement of October 12, 2012 (the &amp;#147;&lt;i&gt;October 2012&#13;Agreement&lt;/i&gt;&amp;#148;) between the Company and Platinum Long Term Growth VII, LLC (&amp;#147;&lt;i&gt;Platinum&lt;/i&gt;&amp;#148;), the Company&amp;#146;s&#13;largest institutional investor, Platinum has the right and option to exchange all 500,000 shares of the Company&amp;#146;s Series&#13;A Preferred held by Platinum for (i) a total of 15,000,000 shares of the Company&amp;#146;s common stock, and (ii) a five-year warrant&#13;to purchase 7,500,000 shares of the Company&amp;#146;s common stock at an exercise price of $1.50 per share (see Note 9, &lt;i&gt;Capital&#13;Stock&lt;/i&gt;).&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in"&gt;&lt;font style="font-size: 10pt"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in"&gt;&lt;font style="font-size: 10pt"&gt;&lt;/font&gt;The Condensed Consolidated Financial Statements in this Quarterly Report represent the activity of VistaGen&#13;California from May 26, 1998, and the consolidated activity of VistaGen California and Excaliber (now VistaGen Therapeutics, Inc.,&#13;a Nevada corporation) from May 11, 2011 (the date of the Merger). The consolidated financial statements also include the accounts&#13;of VistaGen California&amp;#146;s wholly-owned subsidiaries, Artemis Neuroscience, Inc. (&amp;#147;&lt;i&gt;Artemis&lt;/i&gt;&amp;#148;), a Maryland&#13;corporation, and VistaStem Canada, Inc., an Ontario corporation.&lt;/p&gt;</VSTA:HistoryAndOrganizationTextBlock>
    <us-gaap:LiquidityDisclosureTextBlock contextRef="From2012-04-01to2012-12-31">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in"&gt;The accompanying unaudited&#13;Condensed Consolidated Financial Statements have been prepared in accordance with accounting principles generally accepted in the&#13;United States (&amp;#34;&lt;i&gt;U.S. GAAP&lt;/i&gt;&amp;#34;) for interim financial information and with the instructions to Form 10-Q and Rule&#13;8-03 of Regulation S-X. Accordingly, they do not contain all of the information and footnotes required for complete consolidated&#13;financial statements. In the opinion of management, the accompanying unaudited Condensed Consolidated Financial Statements reflect&#13;all adjustments, which include only normal recurring adjustments, necessary to present fairly the Company&amp;#146;s interim financial&#13;information. The accompanying Condensed Consolidated Balance Sheet at March 31, 2012 has been derived from the Company's audited&#13;consolidated financial statements at that date but do not include all disclosures required by U.S. GAAP. Additionally, certain&#13;reclassifications have been made to the Condensed Consolidated Balance Sheet at March 31, 2012 to conform to current year presentation.&#13;The operating results for the nine months ended December 31, 2012 are not necessarily indicative of the operating results to be&#13;expected for the Company's fiscal year ending March 31, 2013 or for any other interim period or any other future period.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in"&gt;The accompanying unaudited&#13;Condensed Consolidated Financial Statements and notes to Condensed Consolidated Financial Statements should be read in conjunction&#13;with the Company&amp;#146;s audited Consolidated Financial Statements for the fiscal year ended March 31, 2012 contained in its Annual&#13;Report on Form 10-K, as filed with the United States Securities and Exchange Commission (&amp;#147;&lt;i&gt;SEC&lt;/i&gt;&amp;#148;).&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in"&gt;The accompanying Condensed&#13;Consolidated Financial Statements have been prepared assuming the Company will continue as a going concern. As a development stage&#13;company without sustainable revenues, the Company has experienced recurring losses and negative cash flows from operations. From&#13;inception through December 31, 2012, the Company has accumulated a deficit of $63.9 million during its development stage. The&#13;Company expects these conditions to continue for the foreseeable future as it expands its &lt;i&gt;Human Clinical Trials in a Test Tube&lt;/i&gt;&amp;#153;&#13;platform and executes its drug rescue, predictive toxicology and cell therapy business programs.&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in"&gt;At December 31, 2012,&#13;the Company had $24,200 in cash and cash equivalents. The Company&amp;#146;s principal source of financing during the quarter&#13;ended December 31, 2012 was proceeds from certain financing transactions between the Company and Platinum. On July 2, 2012&#13;and on August 31, 2012, the Company issued to Platinum 10% senior secured convertible promissory notes in the principal&#13;amount of $500,000 (the &lt;i&gt;&amp;#147;July 2012 Platinum Note&lt;/i&gt;&amp;#148;) and $750,000 (the &amp;#147;&lt;i&gt;August 2012 Platinum&#13;Note&lt;/i&gt;&amp;#148;), respectively, (see Note 7, &lt;i&gt;Convertible Promissory Notes and Other Notes Payable&lt;/i&gt;). On October 11,&#13;2012, the Company and Platinum entered into the October 2012 Agreement, wherein Platinum agreed to purchase additional 10%&#13;senior secured convertible promissory notes in the aggregate principal amount of $2.0 million, issuable over four $500,000&#13;tranches between October 2012 and December 2012. The first and second $500,000 tranches, in the aggregate principal amount of&#13;$1.0 million, were purchased by Platinum on October 11, 2012 and October 19, 2012, respectively. The final two $500,000&#13;tranches, were combined into a single senior secured promissory note in the aggregate principal amount of $1.0 million (the &lt;i&gt;&amp;#147;$1.0&#13;Million Note&lt;/i&gt;&amp;#148;), pursuant to amendments to the October 2012 Agreement entered into by the Company and Platinum on&#13;November 14, 2012 and January 31, 2013 (the &amp;#147;&lt;i&gt;NEPA&lt;/i&gt; &lt;i&gt;Amendments&lt;/i&gt;&amp;#148;). Under the terms of the NEPA&#13;Amendments, Platinum agreed to purchase the $1.0 Million Note within five (5) business days of the Company's notice to&#13;Platinum of the consummation of a debt or equity financing, or combination of financings, prior to February 15,&#13;2013, resulting in gross proceeds to the Company of at least $1.0 million, (see Note 7&lt;i&gt;, Convertible Promissory Notes and&#13;Other Notes Payable,&lt;/i&gt; and Note 12, &lt;i&gt;Subsequent Events&lt;/i&gt;.)&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in"&gt;Through December 31, 2012,&#13;the Company issued 951,256 Units in private placements to accredited investors and received cash proceeds of $475,600. The Units&#13;were sold for $0.50 per Unit and each Unit consisted of one share of the Company&amp;#146;s common stock and a five year warrant to&#13;purchase one half (1/2) of one share of the Company&amp;#146;s common stock at an exercise price of $1.50 per share. At December 31,&#13;2012, the proceeds of these private placements have reduced the remaining amount of financing the Company is required to secure&#13;from $1.0 million to $524,400 to be entitled to sell the $1.0 Million Note to Platinum as described above. (See Note 12, &lt;i&gt;Subsequent&#13;Events.&lt;/i&gt;)&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in"&gt;The Company anticipates that&#13;its cash expenditures during the next twelve months will be approximately $4.0 million to $6.0 million and it plans to meet its&#13;cash needs and fund its working capital requirements through a combination of additional private placements of its securities,&#13;which may include both debt and equity securities issued to Platinum and other investors, stem cell technology-based research and&#13;development collaborations, stem cell technology and drug candidate license fees and government grant awards. If the Company is&#13;unable to obtain sufficient financing, it may be required to reduce, defer, or discontinue certain of its research and development&#13;activities or it may not be able to continue as a going concern.&lt;/p&gt;</us-gaap:LiquidityDisclosureTextBlock>
    <us-gaap:SignificantAccountingPoliciesTextBlock contextRef="From2012-04-01to2012-12-31">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"&gt;&lt;b&gt;Use of Estimates&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in"&gt;The preparation of financial&#13;statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts&#13;of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the financial statements, and the&#13;reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates. Significant&#13;estimates include those relating to revenue recognition, share-based compensation, and assumptions that have been used to value&#13;warrants, warrant modifications and previous put option and note term extension liabilities.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"&gt;&lt;b&gt;Revenue Recognition&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in"&gt;The Company generates revenue&#13;principally from collaborative research and development arrangements, technology access fees and government grants. Revenue arrangements&#13;with multiple components are divided into separate units of accounting if certain criteria are met, including whether the delivered&#13;component has stand-alone value to the customer. Consideration received is allocated among the separate units of accounting based&#13;on their respective selling prices. The selling price for each unit is based on vendor-specific objective evidence, or VSOE, if&#13;available, third party evidence if VSOE is not available, or estimated selling price if neither VSOE nor third party evidence is&#13;available. The applicable revenue recognition criteria are then applied to each of the units.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in"&gt;The Company recognizes revenue&#13;when the four basic criteria of revenue recognition are met: (1) a contractual agreement exists; (2) the transfer of technology&#13;has been completed or services have been rendered; (3) the fee is fixed or determinable; and (4) collectability is reasonably assured.&#13;For each source of revenue, the Company complies with the above revenue recognition criteria in the following manner:&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table align="center" cellspacing="0" cellpadding="0" style="width: 100%"&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;    &lt;td style="width: 48px; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 30px; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&amp;#9679;&lt;/td&gt;&#13;    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;Collaborative arrangements typically consist of non-refundable and/or exclusive technology access fees, cost reimbursements for specific research and development spending, and various milestone and future product royalty payments. If the delivered technology does not have stand-alone value, the amount of revenue allocable to the delivered technology is deferred. Non-refundable upfront fees with stand-alone value that are not dependent on future performance under these agreements are recognized as revenue when received, and are deferred if the Company has continuing performance obligations and has no objective and reliable evidence of the fair value of those obligations. The Company recognizes non-refundable upfront technology access fees under agreements in which it has a continuing performance obligation ratably, on a straight-line basis, over the period in which the Company is obligated to provide services. Cost reimbursements for research and development spending are recognized when the related costs are incurred and when collectability is reasonably assured. Payments received related to substantive, performance-based &amp;#147;at-risk&amp;#148; milestones are recognized as revenue upon achievement of the milestone event specified in the underlying contracts, which represent the culmination of the earnings process. Amounts received in advance are recorded as deferred revenue until the technology is transferred, costs are incurred, or a milestone is reached.&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table align="center" cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;    &lt;td style="width: 48px; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 30px; text-align: left"&gt;&amp;#9679;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;Technology license agreements typically consist of non-refundable upfront license fees, annual minimum access fees and/or royalty payments. Non-refundable upfront license fees and annual minimum payments received with separable stand-alone values are recognized when the technology is transferred or accessed, provided that the technology transferred or accessed is not dependent on the outcome of the continuing research and development efforts. Otherwise, revenue is recognized over the period of the Company&amp;#146;s continuing involvement.&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table align="center" cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;    &lt;td style="width: 48px; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 30px; text-align: left"&gt;&amp;#9679;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;Government grants, which support the Company&amp;#146;s research efforts on specific projects, generally provide for reimbursement of approved costs as defined in the terms of grant awards. Grant revenue is recognized when associated project costs are incurred.&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"&gt;&lt;b&gt;Research and Development Expenses&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in"&gt;Research and development expenses&#13;include internal and external costs. Internal costs include salaries and employment related expenses of scientific personnel and&#13;direct project costs. External research and development expenses consist of sponsored stem cell research and development costs,&#13;costs associated with clinical and non-clinical development of AV-101, the Company&amp;#146;s small molecule prodrug candidate, and&#13;costs related to the application and prosecution of patents related to the Company&amp;#146;s stem cell technology, &lt;i&gt;Human Clinical&#13;Trials in a Test Tube&lt;/i&gt;&amp;#153;, and AV-101. All such costs are charged to expense as incurred.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"&gt;&lt;b&gt;Stock-Based Compensation&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in"&gt;The Company recognizes compensation&#13;cost for all share-based awards to employees based on the grant date fair value of the award. Share-based compensation expense&#13;is recognized over the period during which the employee is required to perform services in exchange for the award, which generally&#13;represents the scheduled vesting period. The Company has no awards with market or performance conditions. For equity awards to&#13;non-employees, the Company re-measures the fair value of the awards as they vest and the resulting value is recognized as an expense&#13;during the period over which the services are performed.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in"&gt;The Company recorded share-based&#13;compensation costs of $813,700 and $962,000 for the three and nine month periods ended December 31, 2012, respectively and $468,100&#13;and $1,447,400 for the three and nine month periods ended December 31, 2011, respectively. At December 31, 2012, there were options&#13;outstanding to purchase 4,966,771 shares of the Company&amp;#146;s common stock at a weighted average exercise price of $1.33 per&#13;share. See Note 10, &lt;i&gt;Stock Based Compensation, &lt;/i&gt;for additional information regarding stock-based compensation.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"&gt;&lt;b&gt;Comprehensive Loss&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in"&gt;The Company has no components&#13;of other comprehensive loss other than net loss, and accordingly the Company&amp;#146;s comprehensive loss is equivalent to net loss&#13;for the periods presented.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"&gt;&lt;b&gt;Loss per Common Share&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in"&gt;Basic loss per share of common&#13;stock excludes the effect of dilution and is computed by dividing the net loss by the weighted-average number of shares of common&#13;stock outstanding for the period. Diluted loss per share of common stock reflects the potential dilution that could occur if securities&#13;or other contracts to issue shares of common stock were exercised or converted into shares of common stock. For all periods presented,&#13;potentially dilutive securities are excluded from the computation in loss periods, as their effect would be antidilutive.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in"&gt;Potentially dilutive securities&#13;excluded from the calculation of diluted net loss per common share are as follows:&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="padding-bottom: 1.35pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.35pt; text-align: left; font-weight: bold"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="6" style="border-bottom: black 1.5pt solid; text-align: center; font-weight: bold"&gt;December 31,&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-bottom: 1.35pt; text-align: left; font-weight: bold"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="padding-bottom: 1.35pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.35pt; text-align: left; font-weight: bold"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; font-weight: bold"&gt;2012&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-bottom: 1.35pt; text-align: left; font-weight: bold"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.35pt; text-align: left; font-weight: bold"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; font-weight: bold"&gt;2011&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-bottom: 1.35pt; text-align: left; font-weight: bold"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td style="width: 76%; text-align: left"&gt;Series A preferred stock issued and outstanding&lt;font style="font-size: 7pt"&gt; (1)&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 9%; text-align: right"&gt;15,000,000&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="width: 1%; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 9%; text-align: right"&gt;4,370,550&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="width: 1%; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="text-align: justify"&gt;Warrant shares issuable to Platinum upon exercise of common stock warrants by Platinum upon exchange of Series A preferred stock under the terms of the October 11, 2012 Note Purchase and Exchange Agreement&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;7,500,000&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;-&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td style="text-align: left"&gt;Outstanding options under the 2008 and 1999 Stock Incentive Plans&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;4,966,771&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;4,806,114&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="text-align: left"&gt;Outstanding warrants to purchase common stock&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;9,873,034&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;3,451,728&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td style="padding-bottom: 1.35pt; text-align: justify"&gt;October 2012 10% convertible Exchange Note and Investment Notes issued to Platinum including accrued interest through December 31, 2012 &lt;font style="font-size: 7pt"&gt;(2)&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.35pt; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: right"&gt;4,645,198&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-bottom: 1.35pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.35pt; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: right"&gt;-&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-bottom: 1.35pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td style="padding-bottom: 2.65pt; text-align: left"&gt;Total&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.65pt; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;41,895,003&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-bottom: 2.65pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.65pt; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;12,628,392&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-bottom: 2.65pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;    &lt;td style="width: 100%; text-align: left; font-size: 7pt"&gt;(1)&amp;#160;&amp;#160;at December 31, 2012, assumes exchange under the terms of the October 11, 2012&amp;#160;&amp;#160;Note Exchange and Purchase Agreement with Platinum&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;    &lt;td style="text-align: left; font-size: 7pt"&gt;(2)&amp;#160;&amp;#160;assumes conversion under the terms of the October 11, 2012&amp;#160;&amp;#160;Note Exchange and Purchase Agreement with Platinum and the terms of the individual notes&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"&gt;&lt;b&gt;Recent Accounting Pronouncements&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="letter-spacing: 9pt"&gt;&amp;#160;&amp;#160;&amp;#160;&lt;/font&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&#13;There have been no recent accounting pronouncements or changes in accounting pronouncements during the nine months ended December&#13;31, 2012, as compared to the recent accounting pronouncements described in the Company&amp;#146;s Form 10-K for the fiscal year ended&#13;March 31, 2012, that are of significance or potential significance to the Company.&lt;/p&gt;</us-gaap:SignificantAccountingPoliciesTextBlock>
    <us-gaap:FairValueDisclosuresTextBlock contextRef="From2012-04-01to2012-12-31">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in"&gt;The Company follows the principles&#13;of fair value accounting as they relate to its financial assets and financial liabilities. Fair value is defined as the estimated&#13;exit price received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the&#13;measurement date, rather than an entry price that represents the purchase price of an asset or liability. Where available, fair&#13;value is based on observable market prices or parameters, or derived from such prices or parameters. Where observable prices or&#13;inputs are not available, valuation models are applied. These valuation techniques involve some level of management estimation&#13;and judgment, the degree of which is dependent on several factors, including the instrument&amp;#146;s complexity. The required fair&#13;value hierarchy that prioritizes observable and unobservable inputs used to measure fair value into three broad levels is described&#13;as follows:&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table align="center" cellspacing="0" cellpadding="0" style="width: 100%"&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;    &lt;td style="width: 48px; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 30px; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&amp;#9679;&lt;/td&gt;&#13;    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;i&gt;Level 1&lt;/i&gt; &amp;#151; Quoted prices (unadjusted) in active markets that are accessible at the measurement date for assets or liabilities. The fair value hierarchy gives the highest priority to Level 1 inputs.&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table align="center" cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;    &lt;td style="width: 48px; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 30px; text-align: left"&gt;&amp;#9679;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;i&gt;Level 2&lt;/i&gt; &amp;#151; Inputs other than Level 1 that are observable, either directly or indirectly, such as quoted prices for similar assets or liabilities; quoted prices in markets that are not active; or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities.&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table align="center" cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;    &lt;td style="width: 48px; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 30px; text-align: left"&gt;&amp;#9679;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;i&gt;Level 3&lt;/i&gt; &amp;#151; Unobservable inputs (&lt;i&gt;i.e., &lt;/i&gt;inputs that reflect the reporting entity&amp;#146;s own assumptions about the assumptions that market participants would use in estimating the fair value of an asset or liability) are used when little or no market data is available. The fair value hierarchy gives the lowest priority to Level 3 inputs.&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in"&gt;A financial instrument&amp;#146;s&#13;categorization within the valuation hierarchy is based upon the lowest level of input that is significant to the fair value measurement.&#13;Where quoted prices are available in an active market, securities are classified as Level 1 of the valuation hierarchy. If quoted&#13;market prices are not available for the specific financial instrument, then the Company estimates fair value by using pricing models,&#13;quoted prices of financial instruments with similar characteristics or discounted cash flows. In certain cases where there is limited&#13;activity or less transparency around inputs to valuation, financial assets or liabilities are classified as Level 3 within the&#13;valuation hierarchy.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 27pt"&gt;The Company does not use&#13;derivative instruments for hedging of market risks or for trading or speculative purposes. In conjunction with the issuance&#13;of the Senior Secured Convertible Promissory Notes and related Exchange Warrant and Investment Warrants to Platinum in&#13;October 2012 (see Note 7, Convertible Promissory Notes and Other Notes Payable), and the potential issuance of the Series A&#13;Exchange Warrant (see Note 9, Capital Stock), all pursuant to the October 2012 Agreement, the Company determined that the&#13;warrants included certain exercise price adjustment features and, as a result, the Company determined that the warrants were&#13;liabilities, which were recorded at their estimated fair value. The Company determined the fair value of the&#13;warrant liability using a Monte Carlo simulation model with Level 3 inputs. Inputs used to determine fair value include the&#13;remaining contractual term of the notes and warrants, risk-free interest rates, expected volatility of the price of the&#13;underlying common stock, and the probability of a financing transaction that would trigger a reset in the warrant exercise&#13;price, and, in the case of the Series A Exchange Warrant, the probability of Platinum's exchange of the shares of Series A&#13;preferred stock it holds into shares of common stock. Changes in the fair value of these warrant liabilities have been&#13;recognized as non-cash income in other income (expense) in the Condensed Consolidated Statements of Operations and&#13;Comprehensive Income.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 27pt"&gt;The fair value hierarchy for&#13;liabilities measured at fair value on a recurring basis is as follows:&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 27pt"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="padding-bottom: 1.35pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.35pt; text-align: left; font-weight: bold"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="padding-bottom: 1.35pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-bottom: 1.35pt; text-align: left; font-weight: bold"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.35pt; text-align: left; font-weight: bold"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="10" style="border-bottom: black 1.5pt solid; text-align: center; font-weight: bold"&gt;Fair Value Measurements at Reporting Date Using&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-bottom: 1.35pt; text-align: left; font-weight: bold"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font-weight: bold"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: center; font-weight: bold"&gt;Quoted Prices&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: left; font-weight: bold"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font-weight: bold"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: center; font-weight: bold"&gt;in Active&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: left; font-weight: bold"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font-weight: bold"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: center; font-weight: bold"&gt;Significant&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: left; font-weight: bold"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font-weight: bold"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: center; font-weight: bold"&gt;Markets for&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: left; font-weight: bold"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font-weight: bold"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: center; font-weight: bold"&gt;Other&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: left; font-weight: bold"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font-weight: bold"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: center; font-weight: bold"&gt;Significant&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: left; font-weight: bold"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font-weight: bold"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: center; font-weight: bold"&gt;Total&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: left; font-weight: bold"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font-weight: bold"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: center; font-weight: bold"&gt;Identical&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: left; font-weight: bold"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font-weight: bold"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: center; font-weight: bold"&gt;Observable&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: left; font-weight: bold"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font-weight: bold"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: center; font-weight: bold"&gt;Unobservable&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: left; font-weight: bold"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font-weight: bold"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: center; font-weight: bold"&gt;Carrying&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: left; font-weight: bold"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font-weight: bold"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: center; font-weight: bold"&gt;Assets&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: left; font-weight: bold"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font-weight: bold"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: center; font-weight: bold"&gt;Inputs&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: left; font-weight: bold"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font-weight: bold"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: center; font-weight: bold"&gt;Inputs&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: left; font-weight: bold"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="padding-bottom: 1.35pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.35pt; text-align: left; font-weight: bold"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; font-weight: bold"&gt;Value&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-bottom: 1.35pt; text-align: left; font-weight: bold"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.35pt; text-align: left; font-weight: bold"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; font-weight: bold"&gt;(Level 1)&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-bottom: 1.35pt; text-align: left; font-weight: bold"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.35pt; text-align: left; font-weight: bold"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; font-weight: bold"&gt;(Level 2)&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-bottom: 1.35pt; text-align: left; font-weight: bold"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.35pt; text-align: left; font-weight: bold"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; font-weight: bold"&gt;(Level 3)&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-bottom: 1.35pt; text-align: left; font-weight: bold"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="text-align: left"&gt;December 31, 2012:&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td style="width: 40%; padding-bottom: 2.65pt; text-align: left"&gt;&amp;#160;Warrant liability&lt;/td&gt;&#13;    &lt;td style="width: 1%; padding-bottom: 2.65pt; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; border-bottom: black 2.25pt double; text-align: left"&gt;$&lt;/td&gt;&#13;    &lt;td style="width: 12%; border-bottom: black 2.25pt double; text-align: right"&gt;3,910,400&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="width: 1%; padding-bottom: 2.65pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; padding-bottom: 2.65pt; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; border-bottom: black 2.25pt double; text-align: left"&gt;$&lt;/td&gt;&#13;    &lt;td style="width: 12%; border-bottom: black 2.25pt double; text-align: right"&gt;-&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="width: 1%; padding-bottom: 2.65pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; padding-bottom: 2.65pt; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; border-bottom: black 2.25pt double; text-align: left"&gt;$&lt;/td&gt;&#13;    &lt;td style="width: 12%; border-bottom: black 2.25pt double; text-align: right"&gt;-&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="width: 1%; padding-bottom: 2.65pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; padding-bottom: 2.65pt; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; border-bottom: black 2.25pt double; text-align: left"&gt;$&lt;/td&gt;&#13;    &lt;td style="width: 12%; border-bottom: black 2.25pt double; text-align: right"&gt;3,910,400&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="width: 1%; padding-bottom: 2.65pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="text-align: left"&gt;March 31, 2012:&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td style="padding-bottom: 2.65pt; text-align: left"&gt;&amp;#160;Warrant liability&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.65pt; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: left"&gt;$&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;-&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-bottom: 2.65pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.65pt; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: left"&gt;$&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;-&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-bottom: 2.65pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.65pt; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: left"&gt;$&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;-&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-bottom: 2.65pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.65pt; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: left"&gt;$&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;-&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-bottom: 2.65pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 27pt"&gt;During the three month periods&#13;ended December 31, 2012, there were no significant changes to the valuation models used for purposes of determining the fair value&#13;of the Level 3 warrant liability.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 27pt"&gt;The changes in Level 3 liabilities&#13;measured at fair value on a recurring basis are as follows:&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 27pt"&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 27pt"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="font-weight: bold"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;Warrant&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="font-weight: bold"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="font-weight: bold"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: center"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="font-weight: bold"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1.5pt solid; font-weight: bold; text-align: center"&gt;Liability&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-bottom: 1.5pt; font-weight: bold"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1.5pt solid; font-weight: bold; text-align: center"&gt;Total&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-bottom: 1.5pt; font-weight: bold"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td style="width: 70%"&gt;Balance at March 31, 2012&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;$&lt;/td&gt;&#13;    &lt;td style="width: 12%; text-align: right"&gt;-&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;$&lt;/td&gt;&#13;    &lt;td style="width: 12%; text-align: right"&gt;-&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td colspan="3" style="text-indent: -9pt"&gt;Recognition of warrant liability upon issuance of&amp;#160;warrants to Platinum under October 2012 Agreement&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;1,200,000&lt;/td&gt;&#13;    &lt;td nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;1,200,000&lt;/td&gt;&#13;    &lt;td nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td&gt;Recognition of warrant liability in connection with Series A Exchange Warrant potentially issuable to Platinum under October 2012 Agreement&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;3,068,200&lt;/td&gt;&#13;    &lt;td nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;3,068,200&lt;/td&gt;&#13;    &lt;td nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;Mark to market gain included in net loss&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: right"&gt;(357,800&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-bottom: 1.5pt"&gt;)&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: right"&gt;(357,800&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-bottom: 1.5pt"&gt;)&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="padding-bottom: 3pt"&gt;Balance at December 31, 2012&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 3pt; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double"&gt;$&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;3,910,400&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-bottom: 3pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 3pt; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double"&gt;$&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;3,910,400&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-bottom: 3pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&amp;#160;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 27pt"&gt;No assets or other liabilities&#13;were carried at fair value at December 31, 2012 or March 31, 2012.&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="letter-spacing: 9pt"&gt;&amp;#160;&amp;#160;&amp;#160;&lt;/font&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&#13;During 2007 and 2008, the Company issued three convertible promissory notes with an aggregate principal balance of $4.0 million&#13;(the &amp;#147;&lt;i&gt;Original Platinum Notes&lt;/i&gt;&amp;#148;) to Platinum Long Term Growth VII, LLC (&amp;#147;&lt;i&gt;Platinum&lt;/i&gt;&amp;#148;). On May&#13;5, 2011, the Original Platinum Notes were amended, restated and consolidated into a single note (the &amp;#147;&lt;i&gt;May 2011&lt;/i&gt; &lt;i&gt;Platinum&#13;Note&lt;/i&gt;&amp;#148;) with a principal balance of $4.0 million (&amp;#147;&lt;i&gt;May 2011 Amendment&lt;/i&gt;&amp;#148;). In conjunction with the issuance&#13;of the Original Platinum Notes, the Company determined that i) the cash payment option or put option, which provided the lender&#13;with the right to require the Company to repay part of the debt at a 25% premium, and ii) the note term extension option, which&#13;provided the lender with the right to extend the maturity date by one year, were embedded derivatives that should be bifurcated&#13;and accounted for separately as liabilities. In conjunction with the issuance of the Original Platinum Notes, the Company also&#13;issued warrants to purchase 560,000 shares of its common stock. These warrants included certain exercise price adjustment features&#13;and, as a result, the Company determined that the warrants were liabilities, which were recorded at their estimated fair value.&#13;The Company determined the fair value of the i) put option and note term extension option using an internal valuation model with&#13;Level 3 inputs and ii) the warrant liability using a lattice model with Level 3 inputs. Inputs used to determine fair value include&#13;estimated value of the underlying common stock at the valuation measurement date, the remaining contractual term of the notes,&#13;risk-free interest rates, expected volatility of the price of the underlying common stock, and the probability of a qualified financing.&#13;Changes in the fair value of these liabilities prior to the May 2011 Amendment were recognized as a non-cash charge or income in&#13;other income (expense) in the consolidated statements of operations.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in"&gt;As a result of the May 2011&#13;Amendment, the Original Platinum Notes were amended and restated on May 5, 2011, eliminating the cash payment option. Further,&#13;concurrent with the Merger transaction described in Note 1 above, the warrants were determined not to be liabilities, since the&#13;exercise price adjustment feature ended upon the Company becoming a public company as a result of the Merger. The increase in fair&#13;value of the warrant liability of $7,000 and the increase in the put option and note term extension option liabilities of $71,000&#13;were recognized in other expense, net in the statement of operations for the quarter ended June 30, 2011. The remaining put option&#13;and note term extension option liabilities, in the amount of $161,700, were reclassified to note discount in connection with the&#13;May 2011 Amendment. The aggregated fair value of the warrants at May 11, 2011, $424,100, was reclassified from a liability to additional&#13;paid-in capital, a component of stockholders&amp;#146; deficit.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in"&gt;In December 2011, the Company&#13;and Platinum entered into a Note and Warrant Exchange Agreement pursuant to which the May 2011 Platinum Note and warrants issued&#13;to Platinum were cancelled in exchange for shares of the Company&amp;#146;s Series A Preferred.&lt;/p&gt;</us-gaap:FairValueDisclosuresTextBlock>
    <VSTA:PrepaidExpensesTextBlock contextRef="From2012-04-01to2012-12-31">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in"&gt;Prepaid expenses consist of&#13;the following at December 31, 2012 and March 31, 2012 (amounts in 100&amp;#146;s).&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: center"&gt;December 31,&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: center"&gt;March 31,&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="padding-bottom: 1.35pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.35pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"&gt;2012&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-bottom: 1.35pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.35pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"&gt;2012&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-bottom: 1.35pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td style="width: 70%; text-align: left"&gt;&amp;#160;Investor relations and awareness services paid&amp;#160;by issuance of common stock or warrants&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&#13;    &lt;td style="width: 12%; text-align: right"&gt;-&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="width: 1%; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&#13;    &lt;td style="width: 12%; text-align: right"&gt;19,700&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="width: 1%; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;Insurance&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;42,300&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;19,000&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;Legal fees&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;28,900&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;6,100&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="padding-bottom: 1.35pt; text-align: left"&gt;&amp;#160;All other&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.35pt; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: right"&gt;11,600&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-bottom: 1.35pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.35pt; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: right"&gt;6,100&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-bottom: 1.35pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="padding-bottom: 2.65pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.65pt; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: left"&gt;$&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;82,800&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-bottom: 2.65pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.65pt; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: left"&gt;$&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;50,900&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-bottom: 2.65pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;</VSTA:PrepaidExpensesTextBlock>
    <VSTA:AccruedExpensesTextBlock contextRef="From2012-04-01to2012-12-31">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in"&gt;Accrued expenses consist of&#13;the following at December 31, 2012 and March 31, 2012 (amounts in 100&amp;#146;s).&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: center"&gt;December 31,&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: center"&gt;March 31,&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="padding-bottom: 1.35pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.35pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"&gt;2012&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-bottom: 1.35pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.35pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"&gt;2012&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-bottom: 1.35pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td style="width: 70%; text-align: left"&gt;&amp;#160;Accrued professional services&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&#13;    &lt;td style="width: 12%; text-align: right"&gt;68,300&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="width: 1%; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&#13;    &lt;td style="width: 12%; text-align: right"&gt;107,400&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="width: 1%; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;Accrued research and development expenses&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;-&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;237,500&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;Accrued vacation pay and other compensation&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;223,400&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;229,900&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;Accrued placement agent fees&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;50,000&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;50,000&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;Accrued royalties and license fees&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;29,700&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;5,000&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="padding-bottom: 1.35pt; text-align: left"&gt;&amp;#160;All other&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.35pt; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: right"&gt;10,900&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-bottom: 1.35pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.35pt; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: right"&gt;27,500&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-bottom: 1.35pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="padding-bottom: 2.65pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.65pt; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: left"&gt;$&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;382,300&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-bottom: 2.65pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.65pt; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: left"&gt;$&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;657,300&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-bottom: 2.65pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;</VSTA:AccruedExpensesTextBlock>
    <us-gaap:DebtDisclosureTextBlock contextRef="From2012-04-01to2012-12-31">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in"&gt;The following table summarizes&#13;the components of the company&amp;#146;s secured and unsecured promissory notes and other notes payable at December 31, 2012 and March&#13;31, 2012 (amounts in 100&amp;#146;s).&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="padding-bottom: 1.35pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.35pt; text-align: left; font-weight: bold"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="10" style="border-bottom: black 1.5pt solid; text-align: center; font-weight: bold"&gt;December 31, 2012&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-bottom: 1.35pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.35pt; text-align: left; font-weight: bold"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="10" style="border-bottom: black 1.5pt solid; text-align: center; font-weight: bold"&gt;March 31, 2012&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-bottom: 1.35pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: center"&gt;Principal&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: center"&gt;Accrued&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: center"&gt;Principal&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: center"&gt;Accrued&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="padding-bottom: 1.35pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.35pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"&gt;Balance&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-bottom: 1.35pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.35pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"&gt;Interest&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-bottom: 1.35pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.35pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"&gt;Total&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-bottom: 1.35pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.35pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"&gt;Balance&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-bottom: 1.35pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.35pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"&gt;Interest&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-bottom: 1.35pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.35pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"&gt;Total&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-bottom: 1.35pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="text-align: left; font-style: italic; font-weight: bold"&gt;Senior Secured 10% Convertible Promissory Notes issued to Platinum:&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td style="width: 28%; text-align: left"&gt;Exchange Note issued on October 11, 2012&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&#13;    &lt;td style="width: 9%; text-align: right"&gt;1,272,600&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="width: 1%; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&#13;    &lt;td style="width: 9%; text-align: right"&gt;28,900&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="width: 1%; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&#13;    &lt;td style="width: 9%; text-align: right"&gt;1,301,500&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="width: 1%; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&#13;    &lt;td style="width: 9%; text-align: right"&gt;-&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="width: 1%; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&#13;    &lt;td style="width: 9%; text-align: right"&gt;-&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="width: 1%; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&#13;    &lt;td style="width: 9%; text-align: right"&gt;-&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="width: 1%; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="text-align: left"&gt;Investment Note issued on October 11, 2012&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;500,000&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;11,300&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;511,300&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;-&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;-&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;-&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td style="padding-bottom: 1.35pt; text-align: left"&gt;Investment Note issued on October 19, 2012&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.35pt; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: right"&gt;500,000&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-bottom: 1.35pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.35pt; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: right"&gt;10,200&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-bottom: 1.35pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.35pt; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: right"&gt;510,200&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-bottom: 1.35pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.35pt; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: right"&gt;-&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-bottom: 1.35pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.35pt; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: right"&gt;-&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-bottom: 1.35pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.35pt; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: right"&gt;-&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-bottom: 1.35pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;2,272,600&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;50,400&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;2,323,000&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;-&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;-&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;-&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td style="padding-bottom: 1.35pt; text-align: left"&gt;Aggregate note discount&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.35pt; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: right"&gt;(985,500&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-bottom: 1.35pt; text-align: left"&gt;)&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.35pt; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: right"&gt;-&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-bottom: 1.35pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.35pt; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: right"&gt;(985,500&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-bottom: 1.35pt; text-align: left"&gt;)&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.35pt; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: right"&gt;-&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-bottom: 1.35pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.35pt; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: right"&gt;-&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-bottom: 1.35pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.35pt; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: right"&gt;-&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-bottom: 1.35pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="padding-bottom: 2.65pt; text-align: left"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;Total Senior notes (non-current)&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.65pt; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: left"&gt;$&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;1,287,100&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-bottom: 2.65pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.65pt; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: left"&gt;$&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;50,400&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-bottom: 2.65pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.65pt; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: left"&gt;$&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;1,337,500&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-bottom: 2.65pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.65pt; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: left"&gt;$&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;-&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-bottom: 2.65pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.65pt; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: left"&gt;$&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;-&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-bottom: 2.65pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.65pt; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: left"&gt;$&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;-&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-bottom: 2.65pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="text-align: left; font-style: italic; font-weight: bold"&gt;Convertible Promissory Notes:&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;February 2012 12% convertible promissory notes&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;-&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;-&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;-&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;500,000&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;5,300&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;505,300&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="padding-bottom: 1.35pt; text-align: left"&gt;&amp;#160;&amp;#160;&amp;#160;Note discount&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.35pt; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: right"&gt;-&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-bottom: 1.35pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.35pt; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: right"&gt;-&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-bottom: 1.35pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.35pt; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: right"&gt;-&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-bottom: 1.35pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.35pt; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: right"&gt;(499,300&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-bottom: 1.35pt; text-align: left"&gt;)&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.35pt; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: right"&gt;-&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-bottom: 1.35pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.35pt; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: right"&gt;(499,300&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-bottom: 1.35pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td style="padding-bottom: 2.65pt; text-align: left"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;Total 12% convertible notes, net (non-current)&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.65pt; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: left"&gt;$&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;-&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-bottom: 2.65pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.65pt; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: left"&gt;$&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;-&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-bottom: 2.65pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.65pt; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: left"&gt;$&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;-&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-bottom: 2.65pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.65pt; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: left"&gt;$&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;700&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-bottom: 2.65pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.65pt; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: left"&gt;$&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;5,300&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-bottom: 2.65pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.65pt; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: left"&gt;$&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;6,000&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-bottom: 2.65pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td style="text-align: left; font-style: italic; font-weight: bold"&gt;Notes Payable to unrelated parties:&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&amp;#160;7.0%&amp;#160;Notes payable (April 2011)&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;11,500&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;100&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;11,600&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;63,800&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;400&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;64,200&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td style="padding-bottom: 1.35pt; text-align: left"&gt;&amp;#160;&amp;#160;7.0%&amp;#160;Notes payable (August 2012)&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.35pt; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: right"&gt;60,000&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-bottom: 1.35pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.35pt; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: right"&gt;1,400&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-bottom: 1.35pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.35pt; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: right"&gt;61,400&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-bottom: 1.35pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.35pt; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: right"&gt;-&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-bottom: 1.35pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.35pt; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: right"&gt;-&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-bottom: 1.35pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.35pt; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: right"&gt;-&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-bottom: 1.35pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;71,500&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;1,500&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;73,000&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;63,800&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;400&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;64,200&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td style="padding-bottom: 1.35pt; text-align: left"&gt;&amp;#160;less: current portion&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.35pt; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: right"&gt;(18,100&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-bottom: 1.35pt; text-align: left"&gt;)&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.35pt; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: right"&gt;(1,500&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-bottom: 1.35pt; text-align: left"&gt;)&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.35pt; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: right"&gt;(19,600&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-bottom: 1.35pt; text-align: left"&gt;)&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.35pt; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: right"&gt;(63,800&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-bottom: 1.35pt; text-align: left"&gt;)&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.35pt; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: right"&gt;(400&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-bottom: 1.35pt; text-align: left"&gt;)&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.35pt; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: right"&gt;(64,200&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-bottom: 1.35pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="padding-bottom: 2.65pt; text-align: left"&gt;&amp;#160;&amp;#160;7.0%&amp;#160;Notes payable - non-current portion&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.65pt; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: left"&gt;$&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;53,400&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-bottom: 2.65pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.65pt; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: left"&gt;$&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;-&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-bottom: 2.65pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.65pt; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: left"&gt;$&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;53,400&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-bottom: 2.65pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.65pt; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: left"&gt;$&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;-&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-bottom: 2.65pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.65pt; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: left"&gt;$&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;-&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-bottom: 2.65pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.65pt; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: left"&gt;$&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;-&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-bottom: 2.65pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&amp;#160;7.5%&amp;#160;Notes payable to service providers for accounts payable&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="text-align: left"&gt;converted to notes payable:&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;Burr, Pilger, Mayer&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;91,800&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;900&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;92,700&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;93,400&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;1,100&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;94,500&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;Desjardins&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;211,700&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;2,000&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;213,700&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;224,300&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;2,800&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;227,100&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;McCarthy Tetrault&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;435,900&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;200&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;436,100&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;459,400&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;5,700&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;465,100&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;May 2011 Morrison Foerster&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;-&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;-&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;-&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;2,420,100&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;37,900&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;2,458,000&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;August 2012 Morrison &amp;#38; Foerster Note A&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;964,700&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;-&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;964,700&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;-&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;-&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;-&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;August 2012 Morrison &amp;#38; Foerster Note B &lt;font style="font-size: 7pt"&gt;(1)&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;1,379,400&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;34,600&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;1,414,000&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;-&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;-&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;-&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td style="padding-bottom: 1.35pt; text-align: left"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;University Health Network&amp;#160;&amp;#160;&lt;font style="font-size: 7pt"&gt;(1)&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.35pt; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: right"&gt;549,500&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-bottom: 1.35pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.35pt; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: right"&gt;9,300&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-bottom: 1.35pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.35pt; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: right"&gt;558,800&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-bottom: 1.35pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.35pt; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: right"&gt;-&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-bottom: 1.35pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.35pt; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: right"&gt;-&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-bottom: 1.35pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.35pt; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: right"&gt;-&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-bottom: 1.35pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;3,633,000&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;47,000&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;3,680,000&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;3,197,200&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;47,500&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;3,244,700&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td style="padding-bottom: 1.35pt; text-align: left"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;Note discount&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.35pt; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: right"&gt;(1,205,500&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-bottom: 1.35pt; text-align: left"&gt;)&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.35pt; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: right"&gt;-&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-bottom: 1.35pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.35pt; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: right"&gt;(1,205,500&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-bottom: 1.35pt; text-align: left"&gt;)&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.35pt; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: right"&gt;(228,900&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-bottom: 1.35pt; text-align: left"&gt;)&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.35pt; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: right"&gt;-&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-bottom: 1.35pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.35pt; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: right"&gt;(228,900&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-bottom: 1.35pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;2,427,500&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;47,000&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;2,474,500&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;2,968,300&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;47,500&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;3,015,800&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td style="padding-bottom: 1.35pt; text-align: left"&gt;&amp;#160;less: current portion&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.35pt; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: right"&gt;(617,000&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-bottom: 1.35pt; text-align: left"&gt;)&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.35pt; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: right"&gt;(3,100&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-bottom: 1.35pt; text-align: left"&gt;)&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.35pt; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: right"&gt;(620,100&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-bottom: 1.35pt; text-align: left"&gt;)&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.35pt; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: right"&gt;(367,700&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-bottom: 1.35pt; text-align: left"&gt;)&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.35pt; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: right"&gt;-&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-bottom: 1.35pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.35pt; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: right"&gt;(367,700&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-bottom: 1.35pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="padding-bottom: 2.65pt; text-align: left"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;non-current portion and discount&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.65pt; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: left"&gt;$&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;1,810,500&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-bottom: 2.65pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.65pt; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: left"&gt;$&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;43,900&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-bottom: 2.65pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.65pt; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: left"&gt;$&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;1,854,400&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-bottom: 2.65pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.65pt; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: left"&gt;$&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;2,600,600&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-bottom: 2.65pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.65pt; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: left"&gt;$&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;47,500&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-bottom: 2.65pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.65pt; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: left"&gt;$&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;2,648,100&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-bottom: 2.65pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td colspan="4" style="text-align: left"&gt;&amp;#160;&amp;#160;&amp;#160;5.8%&amp;#160;&amp;#160;and 8% Notes payable to insurance&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="padding-bottom: 2.65pt; text-align: left"&gt;premium financing company (current)&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.65pt; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: left"&gt;$&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;15,900&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-bottom: 2.65pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.65pt; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: left"&gt;$&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;-&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-bottom: 2.65pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.65pt; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: left"&gt;$&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;15,900&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-bottom: 2.65pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.65pt; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: left"&gt;$&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;4,600&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-bottom: 2.65pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.65pt; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: left"&gt;$&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;-&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-bottom: 2.65pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.65pt; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: left"&gt;$&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;4,600&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-bottom: 2.65pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td colspan="4" style="text-align: left"&gt;&amp;#160;&amp;#160;10%&amp;#160;Notes payable to vendors for accounts&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="text-align: left"&gt;payable converted to notes payable&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;144,400&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;22,100&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;166,500&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;165,400&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;16,800&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;182,200&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td style="padding-bottom: 1.35pt; text-align: left"&gt;&amp;#160;less: current portion&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.35pt; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: right"&gt;(144,400&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-bottom: 1.35pt; text-align: left"&gt;)&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.35pt; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: right"&gt;(22,100&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-bottom: 1.35pt; text-align: left"&gt;)&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.35pt; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: right"&gt;(166,500&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-bottom: 1.35pt; text-align: left"&gt;)&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.35pt; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: right"&gt;(146,000&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-bottom: 1.35pt; text-align: left"&gt;)&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.35pt; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: right"&gt;-&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-bottom: 1.35pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.35pt; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: right"&gt;(146,000&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-bottom: 1.35pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="padding-bottom: 2.65pt; text-align: left"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;non-current portion&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.65pt; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: left"&gt;$&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;-&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-bottom: 2.65pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.65pt; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: left"&gt;$&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;-&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-bottom: 2.65pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.65pt; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: left"&gt;$&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;-&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-bottom: 2.65pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.65pt; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: left"&gt;$&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;19,400&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-bottom: 2.65pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.65pt; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: left"&gt;$&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;16,800&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-bottom: 2.65pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.65pt; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: left"&gt;$&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;36,200&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-bottom: 2.65pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;Total notes payable to unrelated paties&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;2,659,300&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;70,600&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;2,729,900&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;3,202,100&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;64,700&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;3,266,800&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td style="padding-bottom: 1.35pt; text-align: left"&gt;&amp;#160;less: current portion&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.35pt; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: right"&gt;(795,400&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-bottom: 1.35pt; text-align: left"&gt;)&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.35pt; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: right"&gt;(26,700&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-bottom: 1.35pt; text-align: left"&gt;)&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.35pt; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: right"&gt;(822,100&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-bottom: 1.35pt; text-align: left"&gt;)&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.35pt; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: right"&gt;(582,100&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-bottom: 1.35pt; text-align: left"&gt;)&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.35pt; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: right"&gt;(400&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-bottom: 1.35pt; text-align: left"&gt;)&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.35pt; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: right"&gt;(582,500&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-bottom: 1.35pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="padding-bottom: 2.65pt; text-align: left"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;non-current portion and discount&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.65pt; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: left"&gt;$&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;1,863,900&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-bottom: 2.65pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.65pt; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: left"&gt;$&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;43,900&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-bottom: 2.65pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.65pt; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: left"&gt;$&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;1,907,800&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-bottom: 2.65pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.65pt; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: left"&gt;$&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;2,620,000&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-bottom: 2.65pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.65pt; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: left"&gt;$&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;64,300&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-bottom: 2.65pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.65pt; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: left"&gt;$&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;2,684,300&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-bottom: 2.65pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="text-align: left; font-style: italic; font-weight: bold"&gt;Notes payable to related parties:&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td colspan="2" style="text-align: left"&gt;&amp;#160;&amp;#160;April 2011 7 % Note to Cato Holding Co.&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;-&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;-&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;-&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;293,300&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;6,900&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;300,200&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td colspan="2" style="text-align: left"&gt;&amp;#160;&amp;#160;October 2012 7.5% Note to Cato Holding Co.&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;293,600&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;1,900&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;295,500&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;-&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;-&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;-&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td style="padding-bottom: 1.35pt; text-align: left"&gt;&amp;#160;&amp;#160;October 2012 7.5% Note to Cato Research Ltd.&lt;font style="font-size: 7pt"&gt; (1)&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.35pt; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: right"&gt;1,009,000&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-bottom: 1.35pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.35pt; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: right"&gt;17,100&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-bottom: 1.35pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.35pt; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: right"&gt;1,026,100&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-bottom: 1.35pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.35pt; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: right"&gt;-&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-bottom: 1.35pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.35pt; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: right"&gt;-&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-bottom: 1.35pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.35pt; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: right"&gt;-&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-bottom: 1.35pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;1,302,600&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;19,000&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;1,321,600&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;293,300&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;6,900&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;300,200&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td style="padding-bottom: 1.35pt; text-align: left"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;Note discount&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.35pt; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: right"&gt;(157,900&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-bottom: 1.35pt; text-align: left"&gt;)&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.35pt; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: right"&gt;-&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-bottom: 1.35pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.35pt; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: right"&gt;(157,900&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-bottom: 1.35pt; text-align: left"&gt;)&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.35pt; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: right"&gt;(24,300&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-bottom: 1.35pt; text-align: left"&gt;)&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.35pt; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: right"&gt;-&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-bottom: 1.35pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.35pt; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: right"&gt;(24,300&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-bottom: 1.35pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="padding-bottom: 1.35pt; text-align: left"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;Total notes payable to related parties&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.35pt; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: left"&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: right"&gt;1,144,700&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-bottom: 1.35pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.35pt; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: left"&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: right"&gt;19,000&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-bottom: 1.35pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.35pt; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: left"&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: right"&gt;1,163,700&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-bottom: 1.35pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.35pt; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: left"&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: right"&gt;269,000&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-bottom: 1.35pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.35pt; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: left"&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: right"&gt;6,900&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-bottom: 1.35pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.35pt; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: left"&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: right"&gt;275,900&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-bottom: 1.35pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td style="padding-bottom: 1.35pt; text-align: left"&gt;&amp;#160;less: current portion&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.35pt; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: right"&gt;(110,100&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-bottom: 1.35pt; text-align: left"&gt;)&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.35pt; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: right"&gt;(1,900&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-bottom: 1.35pt; text-align: left"&gt;)&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.35pt; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: right"&gt;(112,000&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-bottom: 1.35pt; text-align: left"&gt;)&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.35pt; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: right"&gt;(168,200&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-bottom: 1.35pt; text-align: left"&gt;)&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.35pt; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: right"&gt;-&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-bottom: 1.35pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.35pt; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: right"&gt;(168,200&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-bottom: 1.35pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="padding-bottom: 2.65pt; text-align: left"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;non-current portion and discount&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.65pt; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: left"&gt;$&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;1,034,600&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-bottom: 2.65pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.65pt; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: left"&gt;$&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;17,100&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-bottom: 2.65pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.65pt; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: left"&gt;$&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;1,051,700&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-bottom: 2.65pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.65pt; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: left"&gt;$&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;100,800&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-bottom: 2.65pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.65pt; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: left"&gt;$&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;6,900&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-bottom: 2.65pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.65pt; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: left"&gt;$&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;107,700&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-bottom: 2.65pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="text-align: left"&gt;____________&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td colspan="24" style="text-align: left; font-size: 7pt"&gt;(1) Note and interest payable solely in restricted shares of the Company's common stock; see description of debt restructuring in Note 7.&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"&gt;&lt;font style="background-color: white"&gt;&lt;b&gt;Senior&#13;Secured Convertible Promissory Notes&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in"&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;On July 2, 2012&#13;and on August 31, 2012, the Company issued to Platinum senior secured convertible promissory notes in the principal amount of $500,000&#13;(the &lt;i&gt;&amp;#147;July 2012 Platinum Note&lt;/i&gt;&amp;#148;) and &lt;font style="background-color: white"&gt;$750,000 (the &amp;#34;&lt;i&gt;August 2012&#13;Platinum Note&lt;/i&gt;&amp;#34;), respectively. The July 2012 Platinum Note and the August 2012 Platinum Note each accrued interest at&#13;the rate of 10% per annum and were due and payable on July 2, 2015. The July 2012 Platinum Note and the August 2012 Platinum Note&#13;were each mandatorily convertible into securities that may be issued by the Company in an equity, equity-based, or debt financing,&#13;or series of financings, subsequent to the issuance of the note resulting in gross proceeds to the Company of at least $3,000,000,&#13;excluding any additional investment by Platinum. &lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;font style="background-color: white"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;On October 11, 2012,&#13;the Company and Platinum entered into a Note Exchange and Purchase Agreement (the &amp;#147;&lt;i&gt;October 2012 Agreement&lt;/i&gt;&amp;#148;)&#13;in which &lt;font style="background-color: white"&gt;the July 2012 Platinum Note and the August 2012 Platinum Note &lt;/font&gt;(together,&#13;the &amp;#147;&lt;i&gt;Existing Notes&lt;/i&gt;&amp;#148;)&lt;font style="background-color: white"&gt;, as well as the related accrued interest, were consolidated&#13;into and exchanged for a single senior secured convertible note in the amount of $1,272,577 (the &amp;#147;&lt;i&gt;Exchange Note&lt;/i&gt;&amp;#148;)&#13;and &lt;/font&gt;Platinum agreed to purchase 10% senior secured convertible promissory notes in the aggregate principal amount of $2.0&#13;million (the &amp;#147;&lt;i&gt;Investment Notes&lt;/i&gt;&amp;#148;), issuable over four $500,000 tranches between October 2012 and December 2012.&amp;#160;&amp;#160;The&#13;first and second $500,000 Investment Notes, in the aggregate principal amount of $1.0 million, were purchased by Platinum on October&#13;11, 2012 and October 19, 2012, respectively. The Company and Platinum also entered into an amended and restated Security Agreement&#13;to secure repayment of all obligations due and payable under the terms of the Investment Notes and Exchange Note.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;On November 14,&#13;2012 and January 31, 2013, the Company and Platinum entered into amendments to the October 2012 Agreement (the &amp;#147;&lt;i&gt;NEPA Amendments&lt;/i&gt;&amp;#148;),&#13;pursuant to which the final two $500,000 tranches were combined into a single Investment Note in the aggregate principal amount&#13;of $1.0 million (the &lt;i&gt;&amp;#147;$1.0 Million Note&lt;/i&gt;&amp;#148;). Under the terms and conditions of the NEPA Amendment, Platinum agreed&#13;to purchase the $1.0 Million Note within five business days of the Company's notice to Platinum of the consummation of a debt or&#13;equity financing, or combination of financings, prior to February 15, 2013, resulting in gross proceeds to the Company of at least&#13;$1.0 million (the &amp;#147;&lt;i&gt;Additional Financing Requirement&lt;/i&gt;&amp;#148;), provided, however, that the $1.0 Million Note would not&#13;be issued prior to January 1, 2013.&lt;/p&gt;&#13;&#13;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in"&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in"&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;The Exchange Note&#13;and each Investment Note (together, the &amp;#147;&lt;i&gt;Notes&lt;/i&gt;&amp;#148;) accrues interest at a rate of 10% per annum and, subject to&#13;certain limitations and exceptions set forth in the Notes, will be due and payable in shares of the Company&amp;#146;s common stock&#13;on October 11, 2015, or three years from the date of issuance, as determined by the terms of the Investment Notes. At maturity,&#13;all principal and accrued interest under the Notes shall be payable by the Company through the issuance of restricted shares of&#13;common stock to Platinum.&amp;#160;&amp;#160;Subject to certain potential adjustments set forth in the Notes, the number of shares of common&#13;stock issuable as payment in full for each note at maturity will be calculated by dividing the outstanding note balance plus accrued&#13;interest by $0.50 per share. Prior to maturity, the outstanding principal and any accrued interest on the Exchange Note and each&#13;of the Investment Notes is convertible, in whole or in part, at Platinum&amp;#146;s option into shares of the Company&amp;#146;s common&#13;stock at a conversion price of $0.50 per share, subject to certain adjustments. The conversion feature in each of the Notes constitutes&#13;a beneficial conversion feature at the date of issuance.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;As additional consideration&#13;for the purchase of the Investment Notes, the Company agreed to issue to Platinum a warrant to purchase an aggregate of 2,000,000&#13;shares of the Company&amp;#146;s common stock, issuable in separate tranches of 500,000 shares each, to be issued together with each&#13;Investment Note, of which a warrant to purchase 500,000 shares was issued to Platinum on October 11, 2012 and on October 19, 2012&#13;(each an &amp;#147;&lt;i&gt;Investment Warrant&lt;/i&gt;&amp;#148;). In addition, the Company issued Platinum a warrant to purchase 1,272,577 shares&#13;of the Company&amp;#146;s common stock in connection with the issuance of the Exchange Note (the &amp;#147;&lt;i&gt;Exchange Warrant&lt;/i&gt;&amp;#148;).&#13;Each warrant has a term of 5 years and an exercise price of $1.50, subject to certain adjustments.&lt;font style="background-color: white"&gt;&#13;The Company and Platinum also executed and subsequently amended a security agreement to secure repayment of all obligations due&#13;and payable under the terms of the Exchange Note and all Investment Notes. &amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;font style="background-color: white"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;As a result of the&#13;beneficial conversion feature in the Exchange Note and the issuance of the Exchange Warrant, the Company determined that the cancellation&#13;of the Existing Notes and the issuance of the Exchange Note should be accounted for as an extinguishment of debt. The Company determined&#13;that the fair value of the Exchange Note, including the beneficial conversion feature, was $2,355,800 using a Monte Carlo simulation&#13;model and inception-date assumptions including market price of common stock of $0.75 per share; stock price volatility of 85%;&#13;risk-free interest rate of 0.67%; conversion price of $0.50 per share; note term of 3 years; 75% probability that conversion would&#13;occur at or immediately prior to maturity; and 25% probability that an event requiring either the repayment of the Exchange Note&#13;or its conversion into common stock would occur prior to maturity. The fair value of the Exchange Note at inception represented&#13;a substantial premium over its face value. In accordance with the provisions of ASC 470-20, &lt;i&gt;Debt with Conversion and Other Options,&#13;&lt;/i&gt;the Company recognized the premium in excess of the face value, $1,083,200, as a non-cash charge to loss on early extinguishment&#13;of debt in the accompanying Condensed Consolidated Statement of Operations and Comprehensive Income and as a credit to additional&#13;paid-in capital and recorded the liability for the Exchange Note at its face value.&lt;/p&gt;&#13;&#13;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in"&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in"&gt;Subject to limited exceptions, which include issuances of common stock pursuant to&#13;the 2012 Private Placement of Units (see Note 9, Capital Stock), the Exchange Warrant and each of the Investment Warrants&#13;include certain exercise price reset and anti-dilution protection features in the event that the Company issues other shares&#13;of common stock during the five-year term of the warrants at a price less than their initial $1.50 per share exercise price.&#13;As a result of these provisions, the Exchange Warrant and the Investment Warrants do not meet the criteria set forth in ASC&#13;815, Derivatives and Hedging, to be considered indexed to the Company&amp;#146;s own stock and treated as equity instruments.&#13;Consequently, the Company recorded the Exchange Warrant and each of the Investment Warrants as liabilities at their fair value,&#13;which was estimated at the issuance date using a Monte Carlo simulation model, with assumptions including market price of&#13;common stock of $0.75 per share, stock price volatility of 85%, risk-free interest rate of 0.67%; exercise price of $1.50&#13;per share and term of 5 years. The fair value of the Exchange Warrant, $672,000 at the date of issuance, was recorded as a&#13;liability and as a corresponding charge to loss on early extinguishment of debt in the accompanying Condensed Consolidated&#13;Statement of Operations and Comprehensive Income. The fair value of each Investment Warrant, $264,000 at the date of issuance,&#13;was recorded as a liability and as a corresponding discount to the related Investment Note. Subject to limitations of the&#13;absolute amount of discount attributable to each Investment Note, the Company treated the issuance-date intrinsic value of&#13;the beneficial conversion feature embedded in each Investment Note as an additional component of the discount attributable&#13;to each Investment Note and recorded $231,000 as a discount attributable to the beneficial conversion feature for each Investment&#13;Note. The Company amortizes the aggregate discount attributable to each of the Investment Notes using the interest method&#13;over the respective term of each note. The effective interest rate on both the October 11, 2012 Investment Note and the October&#13;19, 2012 Investment Note at the issuance date was 159.05%.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in"&gt;The fair value of the Exchange Warrant and Investment Warrants was&#13;re-measured as of December 31, 2012 at an aggregate of $1,102,000 and the $98,000 reduction in fair value since inception&#13;was reflected in the accompanying Condensed Consolidated Statement of Operations and Comprehensive Income.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"&gt;&lt;b&gt;February 2012 Convertible Promissory Notes&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in"&gt;On February 28, 2012, the&#13;Company completed a private placement of convertible promissory notes to certain accredited investors in the aggregate principal&#13;amount of $500,000 (the &amp;#34;&lt;i&gt;Notes&lt;/i&gt;&amp;#34;). Each Note accrued interest at the rate of 12% per annum and was to mature on&#13;the earlier of (i) twenty-four months from the date of issuance, or (ii) the consummation of an equity, equity-based, or series&#13;of equity-based financings resulting in gross proceeds to the Company of at least $4.0 million (the &amp;#147;&lt;i&gt;Qualified Financing&#13;Threshold&lt;/i&gt;&amp;#148;). The holders of the Notes had the right to voluntarily convert the outstanding principal amount of the Notes&#13;and all accrued and unpaid interest (the &amp;#147;&lt;i&gt;Outstanding Balance&lt;/i&gt;&amp;#148;) at any time prior to maturity into that number&#13;of shares of the Company&amp;#146;s common stock equal to the Outstanding Balance, divided by $3.00 (the &amp;#34;&lt;i&gt;Conversion Shares&lt;/i&gt;&amp;#34;).&#13;In addition, in the event the Company consummated a financing equal to or exceeding the Qualified Financing Threshold, and the&#13;price per unit of the securities sold, or price per share of common stock issuable in connection with such financing, was at least&#13;$2.00 (a &amp;#147;&lt;i&gt;Qualified Financing&lt;/i&gt;&amp;#148;), the Outstanding Balance would have automatically converted into such securities,&#13;including warrants, that were issued in the Qualified Financing, the amount of which would have been determined according to the&#13;following formula: (Outstanding Balance at the closing date of the Qualified Financing) x (1.25) / (the per security price of the&#13;securities sold in the Qualified Financing). The purchaser of each Note was issued a five-year warrant to purchase, for $2.75 per&#13;share, the number of shares of the Company&amp;#146;s common stock equal to 150% of the total principal amount of the Notes purchased&#13;by such purchaser, divided by $2.75, resulting in the potential issuance of an aggregate of 272,724 shares of the Company&amp;#146;s&#13;common stock upon exercise of the warrants (the &amp;#147;&lt;i&gt;Warrant Shares&lt;/i&gt;&amp;#148;).&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in"&gt;The Company entered into a&#13;Registration Rights Agreement with the purchasers of the February 2012 Notes pursuant to which the Company agreed to register for&#13;resale the Conversion Shares and the Warrant Shares. The Company agreed to file a registration statement no later than ninety days&#13;from the February 28, 2012 closing date, or by May 28, 2012 (the &amp;#147;&lt;i&gt;Filing Deadline&lt;/i&gt;&amp;#148;). Should the Company not&#13;have filed the registration statement by the Filing Deadline or if the registration statement had not been declared effective by&#13;the agreed upon effectiveness deadline, the Company was required to make aggregate payments to the purchasers in an amount equal&#13;to 1% of the $500,000 aggregate face amount of the February 2012 Notes for each 30-day period following the Filing Deadline, or&#13;pro-rata portion thereof, with an aggregate limitation of $50,000.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in"&gt;On November 15, 2012, the&#13;holders of the February 2012 Notes entered into an Exchange Agreement with the Company (the &amp;#34;&lt;i&gt;Exchange Agreement&lt;/i&gt;&amp;#34;).&#13;Under the terms of the Exchange Agreement, (i) the current amount due under the terms of the February 2012 Notes, $678,600, which&#13;amount included all accrued interest as well as additional consideration for the conversion, was exchanged for a total of 1,357,281&#13;unregistered shares of the Company's common stock and five-year warrants to purchase 678,641 unregistered shares of the Company's&#13;common stock at an exercise price of $1.50 per share (the &amp;#34;&lt;i&gt;Note Exchange Securities&lt;/i&gt;&amp;#34;); and (ii) the Registration&#13;Rights Agreement was terminated. Additionally, the Company issued a five-year warrant to purchase 72,000 unregistered shares of&#13;the Company&amp;#146;s common stock at an exercise price of $1.50 per share as partial compensation to an investment bank that had&#13;placed certain of the Notes. The Company recorded the issuance of the warrants with a charge to interest expense of $28,200 and&#13;a corresponding credit to additional paid-in capital.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in"&gt;The Company determined&#13;that the exchange of the Notes into shares of its common stock should be accounted for as an extinguishment of debt. The&#13;Company recognized as consideration in the exchange the sum of (i) the fair value of the common stock issued in the exchange&#13;at the quoted market price of $0.70 per share on the date of the exchange, or $950,100, and (ii) the fair value of the&#13;warrants, which was determined to be $0.39 per share, or $265,500, using the Black Scholes Option Pricing Model and the&#13;following assumptions: market price per share: $0.70; exercise price per share: $1.50; risk-free interest rate: 0.62%;&#13;contractual term: 5 years; volatility: 89.5%; expected dividend rate: 0%. The aggregate consideration less the net carrying&#13;value of the Notes, including accrued interest, resulted in the recognition of $1,145,100 as a non-cash loss on early&#13;extinguishment of debt in the accompanying Condensed Consolidated Statements of Operations and Comprehensive Income. The&#13;warrants issued to the investment bank were valued using the same assumptions as used for the warrants issued to the&#13;exchanging note holders.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"&gt;&lt;b&gt;August 2010 Short-Term Note Converted to 7%&#13;Note Payable&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in"&gt;In August 2010, the Company&#13;issued short-term, non-interest bearing, unsecured promissory notes (the &amp;#147;&lt;i&gt;August 2010 Short-Term Notes&lt;/i&gt;&amp;#148;) having&#13;an aggregate principal amount, as adjusted, of $1,120,000. In May 2011, a total of $840,000 of the aggregate principal amount of&#13;the August 2010 Short-Term Notes were converted into Units consisting of shares of the Company&amp;#146;s common stock and three-year&#13;warrants to purchase shares of the Company&amp;#146;s common stock at an exercise price of $2.50 per share. Of the remaining balance&#13;of the August 2010 Short Term Notes; $105,000 of such amount was converted into a long-term note issued to Cato Holding Company,&#13;doing business as Cato BioVentures; and $175,000 of such amount was amended into a note bearing interest at 7% per annum, as described&#13;below.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in"&gt;In April 2011, the Company&#13;and the holder of the $175,000 August 2010 Short-Term Note amended the note, whereby the Company paid $50,000 of the note balance&#13;in May 2011 and was to make four monthly payments of $5,000 between May 2011 and August 2011, an additional nine monthly payments&#13;of $11,125 per month for the period from September 1, 2011 through May 1, 2012, plus a final payment on May 2, 2012 equal to any&#13;remaining balance. In September 2011, the Company and the holder agreed to modify the payment schedule to require payments of $5,000&#13;per month through November 1, 2011, six monthly payments of $11,125 for the period from December 1, 2011 through May 1, 2012, an&#13;additional payment of $11,125 on May 2, 2012, plus a final payment on June 30, 2012 equal to any remaining balance. For strategic&#13;purposes, the Company did not make the February 2012 and March 2012 payments as scheduled. In March 2012, the Company and the note&#13;holder again agreed to modify the payment schedule to require seven monthly payments of $9,171 beginning June 1, 2012 with the&#13;final payment due on December 1, 2012 to include interest accrued after March 2012. The Company made payments totaling $55,000&#13;during the period from June 1, 2012 to December 31, 2012.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"&gt;&lt;b&gt;Issuance and Restructuring of Long-Term Promissory&#13;Note to Cato Holding Company&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in"&gt;In April 2011, all amounts&#13;owed by the Company to Cato Holding Company (&amp;#34;&lt;i&gt;CHC&lt;/i&gt;&amp;#34;) and its affiliates, which included the $105,000 balance of&#13;the August 2010 Short-Term Note issued to Cato BioVentures discussed above, were consolidated into a single note, in the principal&#13;amount of $352,273 (the &amp;#147;&lt;i&gt;2011 CHC Note&lt;/i&gt;&amp;#148;). Concurrently, CHC released all of its security interests in certain&#13;of the Company&amp;#146;s personal property. The 2011 CHC note bears interest at 7% per annum, compounded monthly. Under the terms&#13;of the note, the Company was to make six monthly payments of $10,000 each beginning June 1, 2011, and thereafter to make payments&#13;of $12,500 monthly until the note was repaid in full. The Company had the option to prepay the outstanding balance under this note&#13;in full or in part at any time during its term without penalty.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in"&gt;On October 10, 2012, the Company&#13;and CHC restructured the 2011 CHC Note. The 2011 CHC Note was cancelled and exchanged for a new unsecured promissory note in the&#13;principal amount of $310,443 (the &amp;#147;&lt;i&gt;2012 CHC Note&lt;/i&gt;&amp;#148;) and a five-year warrant to purchase 250,000 shares of the&#13;Company&amp;#146;s common stock at a price of $1.50 per share (the &amp;#147;&lt;i&gt;CHC Warrant&lt;/i&gt;&amp;#148;). The 2012 CHC Note accrues interest&#13;at a rate of 7.5% per annum and is due and payable in monthly installments of $10,000, beginning November 1, 2012 and continuing&#13;until the outstanding balance is paid in full.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in"&gt;The Company determined&#13;that the cancellation of the 2011 CHC Note and the issuance of the 2012 CHC Note should be accounted for as an extinguishment&#13;of debt.&amp;#160;&amp;#160;Accordingly, the Company recorded the 2012 CHC Note at its fair value of $291,100 based on the present&#13;value of its scheduled cash flows and assumptions regarding market interest rates for unsecured debt of similar quality. The&#13;Company determined the fair value of the CHC Warrant to be $0.48 per share, or $120,462, using the Black Scholes Option&#13;Pricing Model and the following assumptions: market price per share: $0.75; exercise price per share: $1.00; risk-free&#13;interest rate: 0.66%; contractual term: 5 years; volatility: 89.9%; expected dividend rate: 0%. The Company recognized the&#13;difference between the sum of the fair values of the 2012 CHC Note and the CHC Warrant less the carrying value of the 2011&#13;CHC Note, $119,100, as a non-cash loss on early extinguishment of debt in the accompanying Condensed Consolidated Statements&#13;of Operations and Comprehensive Income.&amp;#160;&amp;#160;The fair value of the warrant, $120,462, which is treated as an equity&#13;instrument, was credited to additional paid in capital at the issuance date. The difference between the face value of the&#13;2012 CHC Note and its fair value, $19,343, has been treated as a discount to the note and is being amortized over the term of&#13;the note using the interest method, resulting in an effective interest rate of 11.9% on the CHC 2012 Note.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"&gt;&lt;b&gt;Issuance of Long-Term Notes and Cancellation&#13;of Amounts Payable&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in"&gt;On February 25, 2011, the&#13;Company issued to Burr, Pilger, and Mayer, LLC (&amp;#147;&lt;i&gt;BPM&lt;/i&gt;&amp;#148;) an unsecured promissory note in the principal amount&#13;of $98,674 for amounts payable in connection with valuation services provided to the Company by BPM. The BPM note bears interest&#13;at the rate of 7.5% per annum and has payment terms of $1,000 per month, beginning March 1, 2011 and continuing until all principal&#13;and interest are paid in full. In addition, a payment of $25,000 shall be due upon the sale of the Company or upon the Company&#13;completing a financing transaction of at least $5.0 million during any three-month period, with the payment increasing to $50,000&#13;(or the amount then owed under the note, if less) upon the Company completing a financing of over $10.0 million.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in"&gt;On April 29, 2011, the Company&#13;issued to Desjardins Securities, Inc. (&amp;#147;&lt;i&gt;Desjardins&lt;/i&gt;&amp;#148;) an unsecured promissory note in the principal amount of&#13;CDN $236,000 for amounts payable for legal fees incurred by Desjardins in connection with investment banking services provided&#13;to the Company by Desjardins. The Desjardins note bears interest at 7.5% and will be due, along with all accrued but unpaid interest&#13;on the earliest of (i) June 30, 2014, (ii) the consummation of a Change of Control, as defined in the Desjardins note, and (iii)&#13;any failure to pay principal or interest when due. The Company was required to make payments of CDN $4,000 per month beginning&#13;May 31, 2011, increasing to CDN $6,000 per month on January 31, 2012. Beginning on January 1, 2012, the Company shall also make&#13;payments equal to one-half percent (0.5%) of the net proceeds of all private or public equity financings closed during the term&#13;of the note. At September 30, 2012, the Company had not made the monthly payments required for February through September 2012.&#13;However, the Company resumed such monthly payments in October 2012.&lt;font style="font-size: 8pt"&gt;&amp;#160; &lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in"&gt;On May 5, 2011, the Company&#13;issued to McCarthy Tetrault LLP (&amp;#147;&lt;i&gt;McCarthy&lt;/i&gt;&amp;#148;) an unsecured promissory note in the principal amount of CDN $502,797&#13;for the amounts payable in connection with Canadian legal services provided to the Company. The McCarthy note bears interest at&#13;7.5% and will be due, along with all accrued but unpaid interest on the earliest of (i) June 30, 2014, (ii) the consummation of&#13;a Change of Control, as defined in the McCarthy note, and (iii) any failure to pay principal or interest when due. The Company&#13;was required to make payments of CDN $10,000 per month beginning May 31, 2011, which payment amounts increased to CDN $15,000 per&#13;month on January 31, 2012. Beginning on January 1, 2012, the Company is also required to make payments equal to one percent (1%)&#13;of the net proceeds of all private or public equity financings closed during the term of the note. At September 30, 2012, the Company&#13;had not made the monthly payments required for February through September 2012. In October 2012, the Company and McCarthy agreed&#13;to extend the term of the note through March 2015 and the Company resumed the monthly payments.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in"&gt;On August 30, 2012, the Company&#13;issued a promissory note in the principal amount of $60,000 and 15,000 shares of its common stock valued at a market price of $0.94&#13;per share to Progressive Medical Research in settlement of past due obligations for clinical research services in the amount of&#13;$79,900. Under the terms of the settlement, the company also agreed to make monthly cash payments of $5,000 in August 2012 through&#13;December 2012. The promissory note bears interest at 7% per annum and requires payments of $1,000 per month beginning January 15,&#13;2013 until all principal and interest is paid in full. The note requires payment in full upon the sale of all or substantially&#13;all of the Company&amp;#146;s assets or upon the Company completing a financing transaction, or series of transactions, resulting&#13;in gross proceeds to the Company of at least $4.0 million in any three-month period, excluding proceeds from stock option or warrant&#13;exercises. The Company charged the loss on the settlement to interest expense.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"&gt;&lt;b&gt;Restructuring of Note Payable to Morrison &amp;#38;&#13;Foerster&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in"&gt;On May 5, 2011, the Company&#13;and Morrison &amp;#38; Foerster LLP (&amp;#147;&lt;i&gt;Morrison &amp;#38; Foerster&lt;/i&gt;&amp;#148;), the Company&amp;#146;s legal and intellectual property&#13;counsel, amended a previously outstanding note (the &amp;#147;&lt;i&gt;Original Note&lt;/i&gt;&amp;#148;) issued by the Company in payment of legal&#13;services (the &amp;#147;&lt;i&gt;Amended Note&lt;/i&gt;&amp;#148;). Under the Amended Note, the principal balance of the Original Note was increased&#13;to $2,200,000, &lt;font style="background-color: white"&gt;interest accrued at the rate of 7.5% per annum, and the Company was required&#13;to make &lt;/font&gt;an additional payment of $100,000 within three business days of the date of the Amended Note. The Company made the&#13;required $100,000 payment in a timely manner.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in"&gt;&lt;font style="background-color: white"&gt;On&#13;August 31, 2012, the Company restructured the Amended Note (the &amp;#147;&lt;i&gt;Restructuring Agreement&lt;/i&gt;&amp;#148;). Pursuant to the&#13;Restructuring Agreement, the Company issued to Morrison &amp;#38; Foerster two new unsecured promissory notes to replace the Amended&#13;Note, one in the principal amount of $1,000,000 (&amp;#34;&lt;i&gt;Replacement Note A&lt;/i&gt;&amp;#34;) and the other in the principal amount of&#13;$1,379,400 (&amp;#34;&lt;i&gt;Replacement Note B&lt;/i&gt;&amp;#34;) (together, the &amp;#34;&lt;i&gt;Replacement Notes&lt;/i&gt;&amp;#34;); amended an outstanding&#13;warrant to purchase shares of the Company&amp;#146;s common stock (the &lt;i&gt;&amp;#147;Amended M&amp;#38;F Warrant&amp;#148;)&lt;/i&gt;; and issued a&#13;new warrant to purchase shares of the Company&amp;#146;s common stock (the &amp;#147;&lt;i&gt;New M&amp;#38;F Warrant&amp;#148;). &lt;/i&gt;Under the terms&#13;of the Restructuring Agreement, the Amended Note was cancelled and all of the Company's past due payment obligations under the&#13;Amended Note were satisfied. The Company made a payment of $155,000 to Morrison &amp;#38; Foerster on August 31, 2012 pursuant to the&#13;terms of the Amended Note, and issued the Replacement Notes, each dated as of August 31, 2012. Both Replacement Notes accrue interest&#13;at the rate of 7.5% per annum and are due and payable on March 31, 2016. Replacement Note A requires &lt;/font&gt;monthly payments of&#13;$15,000 per month through March 31, 2013, and $25,000 per month thereafter until maturity. &lt;font style="background-color: white"&gt;Payment&#13;of the principal and interest on Replacement Note B will be made solely in shares of the Company&amp;#146;s common stock pursuant&#13;to Morrison &amp;#38; Foerster&amp;#146;s surrender from time to time of all or a portion of the principal and interest balance due on&#13;Replacement Note B in connection with its exercise of the New M&amp;#38;F Warrant, at an exercise price of $1.00 per share,&lt;i&gt; &lt;/i&gt;and&#13;concurrent cancellation of indebtedness and surrender of Replacement Note B; provided, however, that Morrison &amp;#38; Foerster shall&#13;have the option to require payment of Replacement Note B in cash upon the occurrence of a change in control of the Company or an&#13;event of default, and only in such circumstances. &lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in"&gt;The Company treated the aggregate&#13;of the incremental value of the Amended M&amp;#38;F Warrant and the fair value of the New M&amp;#38;F Warrant as a discount to the Replacement&#13;Notes. Under the terms of the Amended M&amp;#38;F Warrant, the Company amended the warrant to purchase 425,000 shares of its common&#13;stock originally issued to Morrison &amp;#38; Foerster on March 15, 2010 to extend the expiration date of the warrant from December&#13;31, 2014 to September 15, 2017 and to provide for exercise by paying cash or by the cancellation in whole or in part of the Company&amp;#146;s&#13;indebtedness under either of the Replacement Notes. The Company determined that the incremental value of the Amended M&amp;#38;F Warrant&#13;was $121,650 at the modification date using the Black-Scholes Option Pricing Model and the following assumptions:&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: left; font-weight: bold"&gt;Assumption:&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.35pt; text-align: left; font-weight: bold"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; font-weight: bold"&gt;Pre-modification&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-bottom: 1.35pt; text-align: left; font-weight: bold"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.35pt; text-align: left; font-weight: bold"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; font-weight: bold"&gt;Post-modification&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-bottom: 1.35pt; text-align: left; font-weight: bold"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td style="width: 64%; text-align: left"&gt;Market price per share&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&#13;    &lt;td style="width: 15%; text-align: right"&gt;0.94&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="width: 1%; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&#13;    &lt;td style="width: 15%; text-align: right"&gt;0.94&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="width: 1%; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="text-align: left"&gt;Exercise price per share&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;2.00&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;2.00&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td style="text-align: left"&gt;Risk-free interest rate&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;0.25&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: left"&gt;%&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;0.60&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="text-align: left"&gt;Expected term (years)&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;2.33&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;5.04&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td style="text-align: left"&gt;Volatility&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;77.9&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: left"&gt;%&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;88.8&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="text-align: left"&gt;Dividend rate&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;0.0&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: left"&gt;%&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;0.0&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="text-align: left; font-weight: bold"&gt;Fair Value per share&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.65pt; text-align: left; font-weight: bold"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font-weight: bold"&gt;$&lt;/td&gt;&#13;    &lt;td style="text-align: right; font-weight: bold"&gt;0.24&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-bottom: 2.65pt; text-align: left; font-weight: bold"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.65pt; text-align: left; font-weight: bold"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font-weight: bold"&gt;$&lt;/td&gt;&#13;    &lt;td style="text-align: right; font-weight: bold"&gt;0.52&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-bottom: 2.65pt; text-align: left; font-weight: bold"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in"&gt;The New M&amp;#38;F Warrant is&#13;exercisable for the number of shares of the Company&amp;#146;s common stock equal to the principal and accrued interest due under&#13;the terms of Replacement Note B divided by the warrant exercise price of $1.00 per share. At the August 31, 2012 date of grant,&#13;the New M&amp;#38;F Warrant was exercisable to purchase 1,379,376 shares of the Company&amp;#146;s common stock. The New M&amp;#38;F Warrant&#13;effectively permits exercise only by the cancellation in whole or in part of the Company&amp;#146;s indebtedness under either of the&#13;Replacement Notes. The New M&amp;#38;F Warrant expires on September 15, 2017. The Company determined the fair value of the New M&amp;#38;F&#13;Warrant to be $0.64 per share, or $876,800, at the date of grant using the Black Scholes Option Pricing Model and the following&#13;assumptions: market price per share: $0.94; exercise price per share: $1.00; risk-free interest rate: 0.61%; contractual term:&#13;5.04 years; volatility: 88.8%; expected dividend rate: 0%. The note discounts totaling $1,197,900, including the $199,500 remaining&#13;unamortized discount recorded prior to the modification, will be amortized to interest expense using the effective interest method&#13;over the term of the Replacement Notes. The aggregate amount of the incremental fair value of the Amended M&amp;#38;F Warrant and the&#13;fair value of the New M&amp;#38;F Warrant, $998,450, was recognized as equity and was credited to additional paid-in capital in the&#13;accompanying Condensed Consolidated Balance Sheets. The effective interest rate on the Replacement Notes at the date of issuance&#13;was 32.3%, based on the stated interest rate, the amount of discount, and the term of the Replacement Notes. Through December 31,&#13;2012, the Company has adjusted the New M&amp;#38;F Warrant to increase the number of shares available for purchase by 34,579 shares,&#13;based on interest accrued on Replacement Note B through that date. The Company has recorded the fair value of the additional shares&#13;as a charge to interest expense and a corresponding credit to additional paid-in capital.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"&gt;&lt;b&gt;Restructuring of Accounts Payable to Cato&#13;Research Ltd. (&amp;#147;&lt;i&gt;CRL&lt;/i&gt;&amp;#148;)&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in"&gt;On October 10, 2012, the Company&#13;issued to CRL: (i) an unsecured promissory note in the initial principal amount of $1,009,000, which is payable solely in restricted&#13;shares of the Company&amp;#146;s common stock and which accrues interest at the rate of 7.5% per annum, compounded monthly (the &amp;#147;&lt;i&gt;CRL&#13;Note&lt;/i&gt;&amp;#148;), as payment in full for all contract research and development services and regulatory advice (&amp;#147;&lt;i&gt;CRO Services&lt;/i&gt;&amp;#148;)&#13;rendered by CRL to the Company and its affiliates through December 31, 2012 with respect to the preclinical and clinical development&#13;of AV-101, and (ii) a five-year warrant to purchase, at a price of $1.00 per share, 1,009,000 restricted shares of the Company&amp;#146;s&#13;common stock, the amount equal to the sum of the principal amount of the CRL Note, plus all accrued interest thereon, divided by&#13;$1.00 per share (the &amp;#147;&lt;i&gt;CRL Warrant&lt;/i&gt;&amp;#148;). The principal amount of the CRL Note may, at the Company&amp;#146;s option,&#13;be automatically increased as a result of future CRO Services rendered by CRL to the Company and its affiliates from January 1,&#13;2013 to June 30, 2013. The CRL Note is due and payable on March 31, 2016 and is payable solely by CRL's surrender from time to&#13;time of all or a portion of the principal and interest balance due on the CRL Note in connection with its concurrent exercise of&#13;the CRL Warrant, provided, however, that CRL will have the option to require payment of the CRL Note in cash upon the occurrence&#13;of a change in control of the Company or an event of default, and only in such circumstances.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in"&gt;The Company determined&#13;that the cancellation of the accounts payable to CRL for CRO Services and the related issuance of the CRL Note should be&#13;accounted for as an extinguishment of debt.&amp;#160;&amp;#160;Accordingly, the Company recorded the CRL Note at its fair value of&#13;$857,900 based on the present value of its scheduled cash flows and assumptions regarding market interest rates for unsecured&#13;debt of similar quality. The Company determined the fair value of the CRL Warrant to be $0.48 per share, or $486,164, using&#13;the Black Scholes Option Pricing Model and the following assumptions: market price per share: $0.75; exercise price per&#13;share: $1.00; risk-free interest rate: 0.66%; contractual term: 5 years; volatility: 89.9%; expected dividend rate:&#13;0%.&amp;#160;&amp;#160;The Company recognized the difference between the sum of the fair values of the CRL Note and the CRL Warrant&#13;less the accounts payable balance due to CRL, $335,100, as a non-cash loss on early extinguishment of debt in the&#13;accompanying Condensed Consolidated Statements of Operations and Comprehensive Income.&amp;#160;&amp;#160;The fair value of the&#13;warrant, $486,164, which is treated as an equity instrument, was credited to additional paid in capital at the issuance date.&#13;The difference between the face value of the CRL Note and its fair value, $151,100, has been treated as a discount to the&#13;note and is being amortized over the term of the note using the interest method, resulting in an effective interest rate of&#13;12.1% on the CRL Note.&amp;#160;&amp;#160;Through December 31, 2012, the Company has adjusted the CRL Warrant to increase the&#13;number of shares available for purchase by 17,095 shares, based on interest accrued on the CRL Note through that date. The&#13;Company has recorded the fair value of the additional shares as a charge to interest expense and a corresponding credit to&#13;additional paid-in capital.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"&gt;&lt;b&gt;Restructuring of Accounts Payable to University&#13;Health Network (&amp;#147;&lt;i&gt;UHN&lt;/i&gt;&amp;#148;)&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in"&gt;On October 10, 2012, the Company&#13;issued to UHN: (i) an unsecured promissory note in the principal amount of $549,500, which is payable solely in restricted shares&#13;of the Company&amp;#146;s common stock and which accrues interest at the rate of 7.5% per annum, as payment in full for all sponsored&#13;stem cell research and development activities by UHN and Gordon Keller, Ph.D. under the SCRA through September 30, 2012 (the &amp;#147;&lt;i&gt;UHN&#13;Note&lt;/i&gt;&amp;#148;), and (ii) a five-year warrant to purchase, at a price of $1.00 per share, 549,500 restricted shares of the Company&amp;#146;s&#13;common stock, the amount equal to the sum of the principal amount of the UHN Note, plus all accrued interest thereon, divided by&#13;$1.00 per share (the &amp;#147;&lt;i&gt;UHN Warrant&lt;/i&gt;&amp;#148;). The UHN Note is due and payable on March 31, 2016 and is payable solely&#13;by UHN's surrender from time to time of all or a portion of the principal and interest balance due on the UHN Note in connection&#13;with its concurrent exercise of the UHN Warrant, provided, however, that UHN will have the option to require payment of the UHN&#13;Note in cash upon the occurrence of a change in control of the Company or an event of default, and only in such circumstances.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in"&gt;The Company determined&#13;that the restructuring of the accounts payable to UHN under the SRCA, defined below, and the related issuance of the UHN Note&#13;should be accounted for as an extinguishment of debt. Accordingly, the Company recorded the UHN Note at its fair value of&#13;$467,211 based on the present value of its scheduled cash flows and assumptions regarding market interest rates for unsecured&#13;debt of similar quality. The Company determined the fair value of the UHN Warrant to be $0.48 per share, or $264,775, using&#13;the Black Scholes Option Pricing Model and the following assumptions: market price per share: $0.75; exercise price per&#13;share: $1.00; risk-free interest rate: 0.66%; contractual term: 5 years; volatility: 89.9%; expected dividend rate: 0%. The&#13;Company recognized the difference between the sum of the fair values of the UHN Note and the UHN Warrant less the accounts&#13;payable balance due to UHN, $182,500, as a non-cash loss on early extinguishment of debt in the accompanying Condensed&#13;Consolidated Statements of Operations and Comprehensive Income. The fair value of the warrant, $264,775, which is treated as&#13;an equity instrument, was credited to additional paid in capital at the issuance date. The difference between the face value&#13;of the UHN Note and its fair value has been treated as a discount to the note and is being amortized over the term of the&#13;note using the interest rate method, resulting in an effective interest rate of 11.3% on the UHN Note. Through December 31,&#13;2012, the Company has adjusted the UHN Warrant to increase the number of shares available for purchase by 9,259 shares, based&#13;on interest accrued on the UHN Note through that date. The Company has recorded the fair value of the additional shares as a&#13;charge to interest expense and a corresponding credit to additional paid-in capital.&lt;/p&gt;</us-gaap:DebtDisclosureTextBlock>
    <VSTA:LicensingAndCollaborativeAgreementsTextBlock contextRef="From2012-04-01to2012-12-31">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"&gt;&lt;b&gt;University Health Network&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"&gt;&lt;font style="letter-spacing: 9pt"&gt;&amp;#160;&amp;#160;&amp;#160;&lt;/font&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&#13;On September 17, 2007, the Company and UHN entered into a Sponsored Research Collaboration Agreement (&amp;#147;&lt;i&gt;SRCA&lt;/i&gt;&amp;#148;)&#13;to develop certain stem cell technologies for drug discovery and drug rescue technologies. The SRCA was amended on April 19, 2010&#13;to extend the term to five years and give the Company various options to extend the term for an additional three years. On December&#13;15, 2010, the Company and UHN entered into a second amendment to expand the scope of work to include induced pluripotent stem cell&#13;technology and to further expand the scope of research and term extension options. On April 25, 2011, the Company and UHN amended&#13;the SRCA a third time to expand the scope to include therapeutic and stem cell therapy applications of induced pluripotent cells&#13;and to extend the date during which the Company may elect to fund additional projects to April 30, 2012. On October 24, 2011, the&#13;Company and UHN amended the SRCA a fourth time to identify five key programs that will further support the Company&amp;#146;s core&#13;drug rescue initiatives and potential cell therapy applications. Under the terms of the fourth amendment, the Company committed&#13;to making monthly payments of $50,000 per month from October 2011 through September 2012 to fund these programs. As disclosed in&#13;Note 7, &lt;i&gt;Convertible Notes and Other Notes Payable&lt;/i&gt;, in October 2012, the Company issued a promissory note in the principal&#13;amount of $549,500 and a warrant to UHN as payment in full for services rendered under the fourth amendment. Additionally, the&#13;Company and UHN entered into Amendment No. 5 to the SRCA establishing the sponsored research projects and the sponsored research&#13;budgets under the SRCA from October 1, 2012 to September 30, 2013, as well as a schedule of the Company&amp;#146;s sponsored research&#13;payments for such period totaling $309,000, including an initial payment of $75,000 applicable to services for the period from&#13;October 1, 2012 to December 31, 2012.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in"&gt;Concurrent with the execution&#13;of the fourth amendment to the SRCA, the Company and UHN entered into a License Agreement under the terms of which UHN granted&#13;the Company exclusive rights to the use of a novel molecule that can be employed in the identification and isolation of mature&#13;and immature human cardiomyocytes from pluripotent stem cells, as well as methods for the production of cardiomyocytes from pluripotent&#13;stem cells that express this marker. In consideration for the grant of the license, the Company has agreed to make payments to&#13;UHN totaling $3.9 million, if, and when, it achieves certain commercial milestones set forth in the License Agreement, and to pay&#13;UHN royalties based on the receipt of revenue by the Company attributable to the licensed patents.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"&gt;&lt;b&gt;U.S. National Institutes of Health&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in"&gt;During fiscal years 2006 through&#13;2008, the U.S. National Institutes of Health (&amp;#34;&lt;i&gt;NIH&lt;/i&gt;&amp;#34;) awarded the Company a $4.2 million grant to support preclinical&#13;development of AV-101, the Company&amp;#146;s lead drug candidate for treatment of neuropathic pain and other neurodegenerative diseases&#13;such as Huntington&amp;#146;s and Parkinson&amp;#146;s diseases. In June 2009, the NIH awarded the Company a $4.2 million grant to support&#13;the Phase I clinical development of AV-101, which amount was subsequently increased to a total of $4.6 million in July 2010. The&#13;Company recognized NIH grant revenue related to AV-101 in the amounts of $187,000 and $714,000 in the nine-month periods ended&#13;December 31, 2012 and 2011, respectively. The grant expired in the ordinary course on June 30, 2012 and has not been extended or&#13;renewed.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"&gt;&lt;b&gt;Cato Research Ltd.&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in"&gt;The Company has a long-term&#13;strategic development relationship with Cato Research Ltd. (&amp;#147;&lt;i&gt;CRL&lt;/i&gt;&amp;#148;), a global contract research and development&#13;organization, or CRO. CRL has provided the Company with access to essential CRO services and regulatory expertise supporting its&#13;AV-101 preclinical and clinical development programs and other projects. The Company recorded research and development expenses&#13;for CRO services provided by CRL in the amounts of $124,700 and $639,300 in the three month and nine month periods ended December&#13;31, 2012, respectively, and $360,000 and $1,019,000 in the three month and nine month periods ended December 31, 2011, respectively.&#13;As described in Note 7, &lt;i&gt;Convertible Promissory&lt;/i&gt; &lt;i&gt;Notes and Other Notes Payable&lt;/i&gt;, in October 2012, the Company issued&#13;an unsecured promissory note in the principal amount of $1,009,000, and a warrant exercisable for 1,009,000 shares of the Company&amp;#146;s&#13;common stock, as payment in full of all amounts owed to CRL for CRO services rendered to the Company through December 31, 2012.&lt;/p&gt;</VSTA:LicensingAndCollaborativeAgreementsTextBlock>
    <VSTA:CapitalStockTextBlock contextRef="From2012-04-01to2012-12-31">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"&gt;&lt;b&gt;2012 Exchange Agreement with Platinum and Deemed&#13;Dividend&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in"&gt;On June 29, 2012, the Company&#13;and Platinum entered into an Exchange Agreement (the &amp;#147;&lt;i&gt;2012 Platinum Exchange Agreement&lt;/i&gt;&amp;#148;) pursuant to which the&#13;Company agreed to issue Platinum 62,945 shares of its Series A Preferred Stock (&amp;#147;&lt;i&gt;Series A Preferred&lt;/i&gt;&amp;#148;) in exchange&#13;for 629,450 shares of common stock owned by Platinum, in consideration for Platinum&amp;#146;s agreement to purchase from the Company&#13;the July 2012 Platinum Note, as described in Note 7, &lt;i&gt;Convertible Promissory Notes and Other Notes Payable&lt;/i&gt;. Under the terms&#13;of the 2012 Platinum Exchange Agreement, Platinum, at its option, may exchange all or a portion of its Series A Preferred for the&#13;securities issued in connection with a qualified financing, an equity or equity-based financing, or series of financing transactions&#13;resulting in gross proceeds to the Company of at least $3.0 million, based on the stated value of $15.00 per share of Series A&#13;Preferred. The Company estimated the fair value of the shares of Series A Preferred tendered to Platinum under the terms of the&#13;2012 Platinum Exchange Agreement at $736,500 ($1.17 per share on a common share equivalent basis). Following the issuance of the&#13;Series A Preferred pursuant to the 2012 Platinum Exchange Agreement, Platinum owns all 500,000 authorized and outstanding shares&#13;of the Company&amp;#146;s Series A Preferred, each share of which, in accordance with the certificate of designations, is convertible&#13;into ten shares of the Company&amp;#146;s common stock. The common shares exchanged for shares of Series A Preferred are treated as&#13;Treasury Stock in the accompanying Condensed Consolidated Balance Sheet at December 31, 2012.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in"&gt;Pursuant to the October 2012 Agreement described in Note 7, Convertible Promissory Notes and Other Notes Payable, Platinum&amp;#146;s&#13;exchange rights in the Series A Preferred were modified such that Platinum now has the right and option to exchange all 500,000&#13;shares of the Company&amp;#146;s Series A Preferred held by Platinum for (i) a total of 15,000,000 shares of the Company&amp;#146;s&#13;common stock, and (ii) a five-year warrant to purchase 7,500,000 shares of the Company&amp;#146;s common stock at an exercise&#13;price of $1.50 per share. The modification of the exchange ratio resulted in a deemed dividend of $7,125,000 to Platinum for&#13;accounting purposes, which has been reflected in the accompanying Condensed Consolidated Statement of Operations and Comprehensive&#13;Loss for the quarter and nine months ended December 31, 2012. The amount of the deemed dividend was determined based on the&#13;value of the 10 million incremental shares to which Platinum is entitled pursuant to the October 2012 Agreement valued at&#13;the $0.75 per share quoted market price for the Company&amp;#146;s common stock on the date of the agreement, an aggregate of&#13;$7.5 million, adjusted for an expected 95% probability of exercise of the exchange rights by Platinum. The fair value of the&#13;five-year warrant, determined to be $0.43 per share, or $3,228,700, using the Black Scholes Option Pricing Model and the following&#13;assumptions: market price per share: $0.75; exercise price per share: $1.50; risk-free interest rate: 0.67%; contractual term:&#13;5 years; volatility: 89.9%; expected dividend rate: 0%; and adjusted for an expected 95% probability of exercise of the exchange&#13;rights by Platinum, was recognized as a liability in the amount of $3,068,200 at the date of the October 2012 Agreement, with&#13;a corresponding charge to Additional paid-in capital in the accompanying Condensed Consolidated Balance Sheet.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in"&gt;The fair value&#13;of the Series A Exchange Warrant was re-measured as of December 31, 2012 at $2,808,400 and the $259,800 reduction in fair&#13;value since the date of the October 2012 Agreement was reflected in the accompanying Condensed Consolidated Statement of Operations&#13;and Comprehensive Income.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"&gt;&lt;b&gt;2012 Private Placement of Units&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in"&gt;Between September 2012 and&#13;December 31, 2012, the Company sold 951,256 Units in private placements to accredited investor and received cash proceeds of $475,600.&#13;The Units were sold for $0.50 per Unit and each Unit consisted of one share of the Company&amp;#146;s common stock and a five year&#13;warrant to purchase one half (1/2) of one share of the Company&amp;#146;s common stock at an exercise price of $1.50 per share. In&#13;addition, in November 2012, pursuant to an Exchange Agreement, the holders of the February 2012 Notes exchanged the aggregate amount&#13;of $678,600 due under the terms of such notes for a total of 678,641 Units, consisting of 1,357,281 unregistered shares of the&#13;Company's common stock and five-year warrants to purchase 678,641 unregistered shares of the Company's common stock at an exercise&#13;price of $1.50 per share. At December 31, 2012, the gross proceeds from these private placements of Units for cash have reduced&#13;the remaining amount of financing the Company is required to secure from $1.0 million to $524,400 to be entitled to sell an additional&#13;senior secured convertible promissory note to Platinum in February 2013 under the terms of the amended Note Exchange and Purchase&#13;Agreement described in Note 7, &lt;i&gt;Convertible Promissory Notes and Other Notes Payable&lt;/i&gt;. See Note 12, &lt;i&gt;Subsequent Events&lt;/i&gt;,&#13;for information regarding additional Unit sales after December 31, 2012.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"&gt;&lt;b&gt;Warrants and Stock Grants&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in"&gt;In April 2012, the Company&#13;entered into a contract for investor relations consulting services pursuant to which it granted three-year warrants to purchase&#13;50,000 shares of the Company&amp;#146;s common stock at an exercise price of $2.80 per share. The Company valued the warrant at $69,200&#13;using the Black Scholes Option Pricing Model and the following assumptions: market price per share: $2.74; exercise price per share:&#13;$2.80; risk-free interest rate: 0.50%; contractual term: 3 years; volatility: 79.09%; expected dividend rate: 0%. The fair value&#13;of the warrant was initially recorded as a prepaid expense and was being expensed over one year in accordance with the terms of&#13;the contract. The contract and related warrant were cancelled in October 2012 and the remaining amount attributable to the fair&#13;value of the warrant was expensed.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in"&gt;In June 2012, the Company&#13;entered into a contract for investor relations and public company support services through December 31, 2012 pursuant to which&#13;it granted 280,000 restricted shares of its common stock valued at $238,000 based on the grant date quoted market price of $0.85&#13;per share and warrants to purchase 100,000 shares of its common stock at an exercise price of $3.00 per share through December&#13;31, 2015. The Company valued the warrant at $25,800 using the Black Scholes Option Pricing Model and the following assumptions:&#13;market price per share: $0.85; exercise price per share: $3.00; risk-free interest rate: 0.46%; contractual term: 3.53 years; volatility:&#13;84.279%; expected dividend rate: 0%. The fair value of the stock and the warrant was recorded as a prepaid expense and is being&#13;expensed over the approximately six-month term of the contract.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in"&gt;In June 2012, the Company&#13;entered into a contract for investor relations consulting services pursuant to which it granted 120,000 shares of its common stock&#13;valued at $102,000 based on the grant date quoted market price of $0.85 per share. The fair value of the stock was recorded as&#13;a prepaid expense and is being expensed over the approximately six-month term of the contract.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in"&gt;In August 2012, the Company&#13;modified an existing warrant and issued a new warrant to Morrison &amp;#38; Foerster as additional consideration for the Restructuring&#13;Agreement, as disclosed in Note 7, &lt;i&gt;Convertible Promissory Notes and Other Notes Payable&lt;/i&gt;. As described in Note 7, the Company&#13;has treated the aggregate of the incremental value of the Amended M&amp;#38;F Warrant and the fair value of the New M&amp;#38;F Warrant&#13;as a discount to the Replacement Notes, which discount is being amortized to interest expense using the effective interest rate&#13;method over the term of the Replacement Notes.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in"&gt;During August 2012, the Company&#13;issued 88,235 shares of its common stock valued at a market price of $1.01 per share in settlement of a past-due obligation for&#13;business development consulting services in the amount of $25,000. The Company charged the loss on the settlement to interest expense.&#13;As disclosed in Note 7, &lt;i&gt;Convertible Promissory Notes and Other Notes Payable&lt;/i&gt;, in August 2012, the Company issued a promissory&#13;note in the principal amount of $60,000 and 15,000 shares of its common stock valued at $0.94 per share in settlement of its past&#13;due obligation for AV-101 clinical development services.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"&gt;&lt;b&gt;Warrant Modifications&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in"&gt;Between May and June 30, 2012,&#13;the Company offered certain warrant holders the opportunity to exercise their warrants to purchase shares of the Company&amp;#146;s&#13;common stock at reduced exercise prices. The Company subsequently extended the offer through August 2012. Warrant holders exercised&#13;warrants to purchase an aggregate of 524,056 shares of the Company&amp;#146;s common stock and the Company received cash proceeds&#13;of $262,000. In addition, certain warrant holders exercised warrants to purchase 25,000 shares of the Company&amp;#146;s common stock&#13;in lieu of payment by the Company in satisfaction of amounts due for services in the aggregate amount of $12,500. For every three&#13;discounted warrant shares exercised by the warrant holders, the Company granted a three-year warrant to purchase one share of its&#13;common stock at an exercise price of $3.00 per share.&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in"&gt;The Company calculated the&#13;fair value of the warrants exercised immediately before and after the May 18, 2012 Board of Directors approval of the modification&#13;offer, and on the exercise date for the exercises occurring after June 30, 2012, and determined that the increase in the fair value&#13;of the warrants exercised was $440,700, which is reflected in general and administrative expense in the accompanying Condensed&#13;Consolidated Statements of Operations and Comprehensive Loss. The warrants subject to the exercise price modifications were valued&#13;using the Black-Scholes Option Pricing Model and the following assumptions:&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: left; font-weight: bold"&gt;Assumption:&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.35pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; font-weight: bold"&gt;Pre-modification&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.35pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.35pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; font-weight: bold"&gt;Post-modification&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.35pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td style="width: 64%; text-align: left"&gt;Market price per share (weighted average)&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&#13;    &lt;td style="width: 15%; text-align: right"&gt;1.95&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&#13;    &lt;td style="width: 15%; text-align: right"&gt;1.95&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="text-align: left"&gt;Exercise price per share (weighted average)&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;2.75&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;0.50&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td style="text-align: left"&gt;Risk-free interest rate (weighted average)&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;0.29%&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;0.06%&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="text-align: left"&gt;Expected term in years (weighted average)&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;1.93&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;0.12&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td style="text-align: left"&gt;Volatility (weighted average)&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;78.0%&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;85.7%&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="text-align: left"&gt;Dividend rate&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;0.0%&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;0.0%&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="text-align: left; font-weight: bold"&gt;Weighted Average Fair Value per share&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font-weight: bold"&gt;$&lt;/td&gt;&#13;    &lt;td style="text-align: right; font-weight: bold"&gt;0.64&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font-weight: bold"&gt;$&lt;/td&gt;&#13;    &lt;td style="text-align: right; font-weight: bold"&gt;1.45&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in"&gt;The market price per share&#13;is based on the quoted market price of the Company&amp;#146;s common stock on the Over-the-Counter Bulletin Board on the date of the&#13;modification. Because of its short history as a public company, the Company has estimated volatility based on the historical volatilities&#13;of a peer group of public companies over the expected term of the option. The risk-free rate of interest is based on the quoted&#13;constant maturity rate for U.S Treasury Bills on the date of the modification for the term corresponding with the expected term&#13;of the warrant. The expected dividend rate is zero as the Company has not paid and does not expect to pay dividends in the near&#13;future.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in"&gt;In connection with the foregoing&#13;exercises, the Company issued three-year warrants to purchase 183,025 shares of the Company&amp;#146;s common stock at an exercise&#13;price of $3.00 per share. The Company valued these warrants at $35,900 using the Black Scholes Option Pricing Model and the following&#13;assumptions: weighted average market price per share: $0.89; exercise price per share: $3.00; risk-free interest rate: 0.42%; contractual&#13;term: 3.0 years; volatility: 78.04%; expected dividend rate: 0%. The fair value of the warrants was charged to interest expense.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in"&gt;Following the warrant exercises&#13;and grants described above, at December 31, 2012, the Company had outstanding warrants to purchase shares of its common stock at&#13;a weighted average exercise price of $1.58 per share as follows:&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table align="center" cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td colspan="2" style="text-align: center; font-weight: bold"&gt;Exercise&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: left; font-weight: bold"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: center; font-weight: bold"&gt;Expiration&lt;/td&gt;&#13;    &lt;td style="text-align: left; font-weight: bold"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: center; font-weight: bold"&gt;December 31,&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: left; font-weight: bold"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; font-weight: bold"&gt;Price&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-bottom: 1.35pt; text-align: left; font-weight: bold"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: center; font-weight: bold"&gt;Date&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.35pt; text-align: left; font-weight: bold"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; font-weight: bold"&gt;2012&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-bottom: 1.35pt; text-align: left; font-weight: bold"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td colspan="2" style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&#13;    &lt;td style="width: 25%; text-align: right"&gt;0.88&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="width: 1%; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 45%; text-align: center"&gt;5/11/2014&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 25%; text-align: right"&gt;15,428&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="width: 1%; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;1.00&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: center"&gt;9/15/2017 to 9/30/2017&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;2,998,809&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;1.25&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: center"&gt;5/11/2014 to 12/31/2014&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;120,280&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;1.50&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: center"&gt;2/28/2017 to 12/13/2017&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;4,021,570&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;1.75&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: center"&gt;12/31/2013&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;577,784&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;2.00&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: center"&gt;8/3/2013 to 9/15/2017&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;604,000&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;2.50&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: center"&gt;5/11/2014&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;492,004&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;2.625&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: center"&gt;12/31/2013&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;480,134&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.35pt; text-align: right"&gt;3.00&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-bottom: 1.35pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.35pt; text-align: center"&gt;5/11/2015 to 2/13/2016&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.35pt; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: right"&gt;563,025&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-bottom: 1.35pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.65pt; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-bottom: 2.65pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.65pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.65pt; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;9,873,034&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-bottom: 2.65pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"&gt;&lt;b&gt;Modification of Note Receivable for Purchase&#13;of Common Stock&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"&gt;In connection with the Company&amp;#146;s May 2011&#13;private placement of units at $1.75 per unit, with each unit consisting of one share of the Company&amp;#146;s common stock and a&#13;three-year warrant to purchase one quarter (1/4) of one share of the Company&amp;#146;s common stock at $2.50 per share, the Company&#13;accepted a short term note receivable from an investor in the face amount of $500,000 that was due on September 6, 2011 in payment&#13;for 285,714 units purchased in the private placement. In October 2011, the Company modified the note to extend the repayment term&#13;through September 1, 2012 and to increase the interest rate to 5% per annum. On November 8, 2012 the Company and the investor again&#13;amended the note to require payment of the outstanding balance of $256,000, reflecting unpaid principal and accrued interest, in&#13;twenty-four monthly payments of $11,000 beginning in December 2012 and continuing through November 2014, with a final payment of&#13;the remaining unpaid principal and interest due in December 2014.&lt;/p&gt;</VSTA:CapitalStockTextBlock>
    <us-gaap:DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock contextRef="From2012-04-01to2012-12-31">&lt;p style="margin: 0pt"&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in"&gt;During the quarter ended&#13;December 31, 2012, when the quoted market price of the Company&amp;#146;s common stock was $0.71 per share, the Company cancelled&#13;outstanding options to purchase an aggregate of 870,550 shares of its common stock at exercise prices between $1.13 per share&#13;and $2.58 per share held by certain employees, excluding the Company&amp;#146;s Chief Executive Officer and President and Chief&#13;Scientific Officer, and consultants and granted those persons new options to purchase an aggregate of 920,550 shares at an&#13;exercise price of $0.75 per share. Options granted during the third quarter have a contractual term of 10 years and options&#13;to purchase 604,699 shares were granted as immediately vested, with the remaining option shares vesting over a period of two&#13;years. During the first quarter of fiscal 2013, when the quoted market price of the Company&amp;#146;s common stock was $0.51,&#13;the Company granted options to purchase an aggregate of 155,000 shares of its common stock at an exercise price of $0.51 per&#13;share to certain of its employees, excluding the Company&amp;#146;s Chief Executive Officer and President and Chief Scientific&#13;Officer, and certain scientific consultants. Options granted during the first quarter have a contractual term of 10 years and&#13;vest over a period of 4 years. During the nine months ended December 31, 2011, the Company granted options to purchase an&#13;aggregate of 1,020,000 shares of its common stock at exercise prices ranging from $1.75 per share to $2.99 per share to&#13;certain of its employees and scientific and business consultants, including members of the Company's Board of Directors and&#13;Scientific Advisory Board, and one of the Company&amp;#146;s officers exercised options to purchase 113,636 shares of its common&#13;stock at an exercise price of $0.88 per share. As a result of the modification of the option grants during the quarter ended&#13;December 31, 2012 described above, the Company recorded share-based compensation costs of $813,700 and $962,000 for the three&#13;and nine month periods ended December 31, 2012, respectively  compared with $468,100 and $1,447,400 for the three and nine&#13;month periods ended December 31, 2011, respectively.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in"&gt;The Company used the Black-Scholes&#13;option valuation model with the following assumptions to determine share-based compensation expense related to option grants during&#13;the nine months ended December 31, 2012:&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table align="center" cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white"&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td style="width: 57%; text-align: left"&gt;Expected dividend yield&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: center"&gt;0%&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="width: 1%; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="text-align: left"&gt;Exercise price&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: center"&gt;$0.51 and $0.75&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td style="text-align: left"&gt;Market price on date of grant&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: center"&gt;$0.51 and $0.71&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="text-align: left"&gt;Risk-free interest rate&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: center"&gt;0.895% to 1.74%&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td style="text-align: left"&gt;Expected (years)&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: center"&gt;6.25 to 10.0&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="text-align: left"&gt;Volatility&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: center"&gt;82.9% to 85.4%&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td style="text-align: left"&gt;Fair value per share at grant date&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: center"&gt;$0.36 to $0.59&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in"&gt;The expected dividend yield&#13;is zero, as the Company has not paid any dividends and does not anticipate paying dividends in the near future. The risk-free interest&#13;rate for periods related to the expected life of the options is based on the U.S. Treasury yield curve in effect at the time of&#13;grant. The expected volatility is based on the historical volatilities of a peer group of public companies&amp;#146; stock over the&#13;expected term of the option. The expected term of options represents the period that the Company&amp;#146;s share-based compensation&#13;awards are expected to be outstanding. The Company used the simplified method provided in SEC Staff Accounting Bulletin 107 to&#13;estimate the expected term. The Company calculated the forfeiture rate based on an analysis of historical data as it reasonably&#13;approximates the currently anticipated rate of forfeitures for granted and outstanding options that have not vested.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in"&gt;The following table summarizes&#13;activity for the nine months ended December 31, 2012 under the Company&amp;#146;s stock option plans:&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="6" style="text-align: center"&gt;Nine Months Ended&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="padding-bottom: 1.35pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.35pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="6" style="border-bottom: black 1.5pt solid; text-align: center"&gt;December 31, 2012&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-bottom: 1.35pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: center"&gt;Number of&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: center"&gt;Weighted Average&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="padding-bottom: 1.35pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.35pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"&gt;Shares&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-bottom: 1.35pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.35pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"&gt;Exercise Price&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-bottom: 1.35pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td style="width: 64%; text-align: left"&gt;&amp;#160;Options outstanding at beginning of period&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 15%; text-align: right"&gt;4,805,771&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="width: 1%; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&#13;    &lt;td style="width: 15%; text-align: right"&gt;1.53&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="width: 1%; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="padding-left: 67.3pt; text-align: left"&gt;&amp;#160;Options granted&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;1,075,550&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;0.72&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td style="padding-left: 67.3pt; text-align: left"&gt;&amp;#160;Options exercised&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;-&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;-&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="padding-left: 67.3pt; text-align: left"&gt;&amp;#160;Options cancelled&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;(870,550&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: left"&gt;)&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;1.72&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td style="padding-bottom: 1.35pt; padding-left: 67.3pt; text-align: left"&gt;&amp;#160;Options expired&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.35pt; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: right"&gt;(44,000&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-bottom: 1.35pt; text-align: left"&gt;)&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.35pt; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.35pt; text-align: right"&gt;0.79&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-bottom: 1.35pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td style="padding-bottom: 2.65pt; text-align: left"&gt;&amp;#160;Options outstanding at end of period&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.65pt; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;4,966,771&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-bottom: 2.65pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.65pt; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.65pt; text-align: right"&gt;1.33&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-bottom: 2.65pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="padding-bottom: 2.65pt; text-align: left"&gt;&amp;#160;Options exercisable at end of period&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.65pt; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;4,169,822&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-bottom: 2.65pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.65pt; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.65pt; text-align: right"&gt;1.36&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-bottom: 2.65pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;Weighted average grant-date fair value of&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td style="padding-bottom: 2.65pt; padding-left: 0.85in; text-align: left"&gt;&amp;#160;options granted during the period&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.65pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.65pt; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-bottom: 2.65pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.65pt; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: left"&gt;$&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;0.52&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-bottom: 2.65pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in"&gt;The following table summarizes&#13;information on stock options outstanding and exercisable under the Company&amp;#146;s option plans as of December 31, 2012:&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td colspan="2" style="padding-bottom: 1.35pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-bottom: 1.35pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.35pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="6" style="border-bottom: black 1.5pt solid; text-align: center"&gt;Options Outstanding&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-bottom: 1.35pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.35pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1.5pt solid; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-bottom: 1.35pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.35pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="6" style="border-bottom: black 1.5pt solid; text-align: center"&gt;Options Exercisable&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-bottom: 1.35pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td colspan="2" style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: center"&gt;Weighted&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="6" style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td colspan="2" style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: center"&gt;Average&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: center"&gt;Weighted&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: center"&gt;Weighted&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td colspan="2" style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: center"&gt;Remaining&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: center"&gt;Average&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: center"&gt;Average&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td colspan="2" style="text-align: center"&gt;Exercise&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: center"&gt;Number&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: center"&gt;Years until&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: center"&gt;Exercise&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: center"&gt;Number&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: center"&gt;Exercise&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"&gt;Price&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-bottom: 1.35pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.35pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="3" style="border-bottom: black 1.5pt solid; text-align: center"&gt;Outstanding&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.35pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"&gt;Expiration&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-bottom: 1.35pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.35pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"&gt;Price&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-bottom: 1.35pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.35pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="3" style="border-bottom: black 1.5pt solid; text-align: center"&gt;Exercisable&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.35pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"&gt;Price&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-bottom: 1.35pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&#13;    &lt;td style="width: 23%; text-align: right"&gt;0.51 - $0.72&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="width: 1%; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 12%; text-align: right"&gt;267,540&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="width: 1%; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 12%; text-align: right"&gt;7.30&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="width: 1%; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&#13;    &lt;td style="width: 12%; text-align: right"&gt;0.60&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="width: 1%; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 12%; text-align: right"&gt;112,540&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="width: 1%; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&#13;    &lt;td style="width: 12%; text-align: right"&gt;0.72&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="width: 1%; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;0.75&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;920,550&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;9.84&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;0.75&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;631,010&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;0.75&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;0.80 - $1.13&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;455,776&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;4.08&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;1.00&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;445,458&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;0.99&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;1.50&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;2,413,250&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;6.93&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;1.50&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;2,413,250&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;1.50&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;1.65 - $1.925&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;725,000&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;6.32&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;1.76&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;382,909&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;1.73&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.35pt; text-align: right"&gt;2.10 - $2.99&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-bottom: 1.35pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.35pt; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: right"&gt;184,655&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-bottom: 1.35pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.35pt; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.35pt; text-align: right"&gt;4.62&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-bottom: 1.35pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.35pt; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.35pt; text-align: right"&gt;2.18&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-bottom: 1.35pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.35pt; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: right"&gt;184,655&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-bottom: 1.35pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.35pt; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.35pt; text-align: right"&gt;2.18&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-bottom: 1.35pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.65pt; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-bottom: 2.65pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.65pt; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;4,966,771&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-bottom: 2.65pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.65pt; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.65pt; text-align: right"&gt;7.05&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-bottom: 2.65pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.65pt; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.65pt; text-align: right"&gt;1.33&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-bottom: 2.65pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.65pt; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;4,169,822&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-bottom: 2.65pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.65pt; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.65pt; text-align: right"&gt;1.36&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-bottom: 2.65pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="letter-spacing: 9pt"&gt;&amp;#160;&amp;#160;&amp;#160;&lt;/font&gt;&amp;#160;&amp;#160;&amp;#160;&#13;At December 31, 2012, there were 228,700 shares of the Company&amp;#146;s common stock remaining available for grant under its stock&#13;option plans.&lt;/p&gt;&#13;&#13;&#13;&#13;&lt;p style="margin: 0pt"&gt;&lt;/p&gt;</us-gaap:DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock>
    <us-gaap:RelatedPartyTransactionsDisclosureTextBlock contextRef="From2012-04-01to2012-12-31">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in"&gt;Cato Holding Company, doing&#13;business as Cato BioVentures (&amp;#34;&lt;i&gt;CBV&lt;/i&gt;&amp;#34;), the parent of CRL, is the Company&amp;#146;s second largest institutional stockholder.&#13;Pursuant to a loan agreement dated as of February 3, 2004 between CBV and VistaGen, as amended, CBV extended to the Company a $400,000&#13;revolving line of credit. As of April 29, 2011, the outstanding balance under the line of credit agreement was terminated and the&#13;Company issued to CHC an unsecured promissory note in the principal amount of $352,273 (the &amp;#147;&lt;i&gt;2011 CHC Note&lt;/i&gt;&amp;#148;),&#13;which principal amount included the $242,273 outstanding balance on the line of credit as of April 29, 2011, and $105,000 of indebtedness&#13;owed to CBV under an August 2010 Short-Term Note. As described in Note 7, &lt;i&gt;Convertible Promissory Notes and Other Notes Payable,&lt;/i&gt;&#13;in October 2012,&lt;i&gt; &lt;/i&gt;the 2011 CHC Note was cancelled and exchanged for the 2012 CHC Note and the CHC Warrant. The 2012 CHC Note&#13;bears interest at the rate of 7.5% compounded monthly and is payable in monthly installments of $10,000 beginning November 1, 2012&#13;until the balance is paid in full, with the final monthly payment to be made in the amount equal to the then current outstanding&#13;balance of principal and interest due under the 2012 Cato Note. Total interest expense on notes payable to CHC was $34,700 and&#13;$51,400 in the three month and nine month periods ended December 31, 2012, respectively, and $9,000 and $85,000 in the three month&#13;and nine month periods ended December 31, 2011, respectively.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in"&gt;During fiscal year 2007, the&#13;Company entered into a contract research organization arrangement with CRL related to the development of its lead drug candidate,&#13;AV-101, and subsequent other projects under which the Company incurred expenses of $124,700 and $639,300 in the three month and&#13;nine month periods ended December 31, 2012, respectively, and $360,000 and $1,019,000 in the three month and nine month periods&#13;ended December 31, 2011, respectively. As described in Note 7, &lt;i&gt;Convertible Promissory Notes and Other Notes Payable&lt;/i&gt;, in&lt;i&gt;&#13;&lt;/i&gt;October 2012, the Company issued to CRL (i) the CRL Note as payment in full for all contract research and development services&#13;and regulatory advice (&amp;#147;&lt;i&gt;CRO Services&lt;/i&gt;&amp;#148;) rendered by CRL to the Company and its affiliates through December 31,&#13;2012 with respect to the preclinical and clinical development of AV-101, and (ii) the CRL Warrant. The principal amount of the&#13;CRL Note may, at the Company&amp;#146;s option, be automatically increased as a result of future CRO Services rendered by CRL to the&#13;Company and its affiliates from January 1, 2013 to June 30, 2013. The CRL Note accrues interest at a rate of 7.5% compounded monthly,&#13;is due and payable on March 31, 2016 and is payable solely by CRL's surrender from time to time of all or a portion of the principal&#13;and interest balance due on the CRL Note in connection with its concurrent exercise of the CRL Warrant. Total interest expense&#13;on the CRL Note for the three and nine month periods ended December 31, 2012 was $26,300.&lt;/p&gt;</us-gaap:RelatedPartyTransactionsDisclosureTextBlock>
    <us-gaap:BasisOfAccountingPolicyPolicyTextBlock contextRef="From2012-04-01to2012-12-31">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in"&gt;The accompanying unaudited&#13;Condensed Consolidated Financial Statements have been prepared in accordance with accounting principles generally accepted in the&#13;United States (&amp;#34;&lt;i&gt;U.S. GAAP&lt;/i&gt;&amp;#34;) for interim financial information and with the instructions to Form 10-Q and Rule&#13;8-03 of Regulation S-X. Accordingly, they do not contain all of the information and footnotes required for complete consolidated&#13;financial statements. In the opinion of management, the accompanying unaudited Condensed Consolidated Financial Statements reflect&#13;all adjustments, which include only normal recurring adjustments, necessary to present fairly the Company&amp;#146;s interim financial&#13;information. The accompanying Condensed Consolidated Balance Sheet at March 31, 2012 has been derived from the Company's audited&#13;consolidated financial statements at that date but do not include all disclosures required by U.S. GAAP. Additionally, certain&#13;reclassifications have been made to the Condensed Consolidated Balance Sheet at March 31, 2012 to conform to current year presentation.&#13;The operating results for the nine months ended December 31, 2012 are not necessarily indicative of the operating results to be&#13;expected for the Company's fiscal year ending March 31, 2013 or for any other interim period or any other future period.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in"&gt;The accompanying unaudited&#13;Condensed Consolidated Financial Statements and notes to Condensed Consolidated Financial Statements should be read in conjunction&#13;with the Company&amp;#146;s audited Consolidated Financial Statements for the fiscal year ended March 31, 2012 contained in its Annual&#13;Report on Form 10-K, as filed with the United States Securities and Exchange Commission (&amp;#147;SEC&amp;#148;).&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in"&gt;The accompanying Condensed&#13;Consolidated Financial Statements have been prepared assuming the Company will continue as a going concern. As a development stage&#13;company without sustainable revenues, the Company has experienced recurring losses and negative cash flows from operations. From&#13;inception through December 31, 2012, the Company has accumulated a deficit of $64.2 million during its development stage. The&#13;Company expects these conditions to continue for the foreseeable future as it expands its &lt;i&gt;Human Clinical Trials in a Test Tube&lt;/i&gt;&amp;#153;&#13;platform and executes its drug rescue, predictive toxicology and cell therapy business programs.&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in"&gt;At December 31, 2012, the&#13;Company had $24,200 in cash and cash equivalents. The Company&amp;#146;s principal source of financing during the quarter ended December&#13;31, 2012 was proceeds from certain financing transactions between the Company and Platinum. On July 2, 2012 and on August 31, 2012,&#13;the Company issued to Platinum 10% senior secured convertible promissory notes in the principal amount of $500,000 (the &lt;i&gt;&amp;#147;July&#13;2012 Platinum Note&lt;/i&gt;&amp;#148;) and $750,000 (the &amp;#147;&lt;i&gt;August 2012 Platinum Note&lt;/i&gt;&amp;#148;), respectively, (see Note 7, &lt;i&gt;Convertible&#13;Promissory Notes and Notes Payable&lt;/i&gt;). On October 11, 2012, the Company and Platinum entered into the October 2012 Agreement,&#13;wherein Platinum agreed to purchase additional 10% senior secured convertible promissory notes in the aggregate principal amount&#13;of $2.0 million, issuable over four $500,000 tranches between October 2012 and December 2012. The first and second $500,000 tranches,&#13;in the aggregate principal amount of $1.0 million, were purchased by Platinum on October 11, 2012 and October 19, 2012, respectively.&#13;The final two $500,000 tranches, were combined into a single senior secured promissory note in the aggregate principal amount of&#13;$1.0 million (the &lt;i&gt;&amp;#147;$1.0 Million Note&lt;/i&gt;&amp;#148;), pursuant to amendments to the October 2012 Agreement entered into by&#13;the Company and Platinum on November 14, 2012 and January 31, 2013 (the &amp;#147;&lt;i&gt;NEPA&lt;/i&gt; &lt;i&gt;Amendments&lt;/i&gt;&amp;#148;). Under the&#13;terms of the NEPA Amendments, Platinum agreed to purchase the $1.0 Million Note within five (5) business days of the Company's&#13;notice to Platinum of the consummation of a debt or equity financing, or combination of financings, prior to February 15, 2013,&#13;resulting in gross proceeds to the Company of at least $1.0 million, (see Note 7&lt;i&gt;, Convertible Promissory Notes and Other Notes&#13;Payable,&lt;/i&gt; and Note 12, &lt;i&gt;Subsequent Events&lt;/i&gt;.)&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in"&gt;Through December 31, 2012,&#13;the Company issued 951,256 Units in private placements to accredited investors and received cash proceeds of $475,600. The Units&#13;were sold for $0.50 per Unit and each Unit consisted of one share of the Company&amp;#146;s common stock and a five year warrant to&#13;purchase one half (1/2) of one share of the Company&amp;#146;s common stock at an exercise price of $1.50 per share. At December 31,&#13;2012, the proceeds of these private placements have reduced the remaining amount of financing the Company is required to secure&#13;from $1.0 million to $524,400 to be entitled to sell the $1.0 Million Note to Platinum as described above. (See Note 12, &lt;i&gt;Subsequent&#13;Events.&lt;/i&gt;)&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in"&gt;The Company anticipates that&#13;its cash expenditures during the next twelve months will be approximately $4.0 million to $6.0 million and it plans to meet its&#13;cash needs and fund its working capital requirements through a combination of additional private placements of its securities,&#13;which may include both debt and equity securities issued to Platinum and other investors, stem cell technology-based research and&#13;development collaborations, stem cell technology and drug candidate license fees and government grant awards. If the Company is&#13;unable to obtain sufficient financing, it may be required to reduce, defer, or discontinue certain of its research and development&#13;activities or it may not be able to continue as a going concern.&lt;/p&gt;</us-gaap:BasisOfAccountingPolicyPolicyTextBlock>
    <us-gaap:UseOfEstimates contextRef="From2012-04-01to2012-12-31">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in"&gt;The preparation of financial&#13;statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts&#13;of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the financial statements, and the&#13;reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates. Significant&#13;estimates include those relating to revenue recognition, share-based compensation, and assumptions that have been used to value&#13;warrants, warrant modifications and previous put option and note term extension liabilities.&lt;/p&gt;</us-gaap:UseOfEstimates>
    <us-gaap:RevenueRecognitionPolicyTextBlock contextRef="From2012-04-01to2012-12-31">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in"&gt;The Company generates revenue&#13;principally from collaborative research and development arrangements, technology access fees and government grants. Revenue arrangements&#13;with multiple components are divided into separate units of accounting if certain criteria are met, including whether the delivered&#13;component has stand-alone value to the customer. Consideration received is allocated among the separate units of accounting based&#13;on their respective selling prices. The selling price for each unit is based on vendor-specific objective evidence, or VSOE, if&#13;available, third party evidence if VSOE is not available, or estimated selling price if neither VSOE nor third party evidence is&#13;available. The applicable revenue recognition criteria are then applied to each of the units.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in"&gt;The Company recognizes revenue&#13;when the four basic criteria of revenue recognition are met: (1) a contractual agreement exists; (2) the transfer of technology&#13;has been completed or services have been rendered; (3) the fee is fixed or determinable; and (4) collectability is reasonably assured.&#13;For each source of revenue, the Company complies with the above revenue recognition criteria in the following manner:&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table align="center" cellspacing="0" cellpadding="0" style="width: 100%"&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;    &lt;td style="width: 48px; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 30px; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&amp;#9679;&lt;/td&gt;&#13;    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;Collaborative arrangements typically consist of non-refundable and/or exclusive technology access fees, cost reimbursements for specific research and development spending, and various milestone and future product royalty payments. If the delivered technology does not have stand-alone value, the amount of revenue allocable to the delivered technology is deferred. Non-refundable upfront fees with stand-alone value that are not dependent on future performance under these agreements are recognized as revenue when received, and are deferred if the Company has continuing performance obligations and has no objective and reliable evidence of the fair value of those obligations. The Company recognizes non-refundable upfront technology access fees under agreements in which it has a continuing performance obligation ratably, on a straight-line basis, over the period in which the Company is obligated to provide services. Cost reimbursements for research and development spending are recognized when the related costs are incurred and when collectability is reasonably assured. Payments received related to substantive, performance-based &amp;#147;at-risk&amp;#148; milestones are recognized as revenue upon achievement of the milestone event specified in the underlying contracts, which represent the culmination of the earnings process. Amounts received in advance are recorded as deferred revenue until the technology is transferred, costs are incurred, or a milestone is reached.&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table align="center" cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;    &lt;td style="width: 48px; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 30px; text-align: left"&gt;&amp;#9679;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;Technology license agreements typically consist of non-refundable upfront license fees, annual minimum access fees and/or royalty payments. Non-refundable upfront license fees and annual minimum payments received with separable stand-alone values are recognized when the technology is transferred or accessed, provided that the technology transferred or accessed is not dependent on the outcome of the continuing research and development efforts. Otherwise, revenue is recognized over the period of the Company&amp;#146;s continuing involvement.&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table align="center" cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;    &lt;td style="width: 48px; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 30px; text-align: left"&gt;&amp;#9679;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;Government grants, which support the Company&amp;#146;s research efforts on specific projects, generally provide for reimbursement of approved costs as defined in the terms of grant awards. Grant revenue is recognized when associated project costs are incurred.&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;</us-gaap:RevenueRecognitionPolicyTextBlock>
    <us-gaap:ResearchAndDevelopmentExpensePolicy contextRef="From2012-04-01to2012-12-31">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in"&gt;Research and development expenses&#13;include internal and external costs. Internal costs include salaries and employment related expenses of scientific personnel and&#13;direct project costs. External research and development expenses consist of sponsored stem cell research and development costs,&#13;costs associated with clinical and non-clinical development of AV-101, the Company&amp;#146;s small molecule prodrug candidate, and&#13;costs related to the application and prosecution of patents related to the Company&amp;#146;s stem cell technology, &lt;i&gt;Human Clinical&#13;Trials in a Test Tube&lt;/i&gt;&amp;#153;, and AV-101. All such costs are charged to expense as incurred.&lt;/p&gt;</us-gaap:ResearchAndDevelopmentExpensePolicy>
    <us-gaap:CompensationRelatedCostsPolicyTextBlock contextRef="From2012-04-01to2012-12-31">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in"&gt;The Company recognizes compensation&#13;cost for all share-based awards to employees based on the grant date fair value of the award. Share-based compensation expense&#13;is recognized over the period during which the employee is required to perform services in exchange for the award, which generally&#13;represents the scheduled vesting period. The Company has no awards with market or performance conditions. For equity awards to&#13;non-employees, the Company re-measures the fair value of the awards as they vest and the resulting value is recognized as an expense&#13;during the period over which the services are performed.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in"&gt;The Company recorded share-based&#13;compensation costs of $813,700 and $962,000 for the three and nine month periods ended December 31, 2012, respectively and $468,100&#13;and $1,447,400 for the three and nine month periods ended December 31, 2011, respectively. At December 31, 2012, there were options&#13;outstanding to purchase 4,966,771 shares of the Company&amp;#146;s common stock at a weighted average exercise price of $1.33 per&#13;share. See Note 10, &lt;i&gt;Stock Based Compensation, &lt;/i&gt;for additional information regarding stock-based compensation.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"&gt;&amp;#160;&lt;/p&gt;</us-gaap:CompensationRelatedCostsPolicyTextBlock>
    <us-gaap:ComprehensiveIncomePolicyPolicyTextBlock contextRef="From2012-04-01to2012-12-31">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in"&gt;The Company has no components&#13;of other comprehensive loss other than net loss, and accordingly the Company&amp;#146;s comprehensive loss is equivalent to net loss&#13;for the periods presented.&lt;/p&gt;</us-gaap:ComprehensiveIncomePolicyPolicyTextBlock>
    <us-gaap:EarningsPerSharePolicyTextBlock contextRef="From2012-04-01to2012-12-31">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in"&gt;Basic loss per share of common&#13;stock excludes the effect of dilution and is computed by dividing the net loss by the weighted-average number of shares of common&#13;stock outstanding for the period. Diluted loss per share of common stock reflects the potential dilution that could occur if securities&#13;or other contracts to issue shares of common stock were exercised or converted into shares of common stock. For all periods presented,&#13;potentially dilutive securities are excluded from the computation in loss periods, as their effect would be antidilutive.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in"&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in"&gt;Basic loss per share of common&#13;stock excludes the effect of dilution and is computed by dividing the net loss by the weighted-average number of shares of common&#13;stock outstanding for the period. Diluted loss per share of common stock reflects the potential dilution that could occur if securities&#13;or other contracts to issue shares of common stock were exercised or converted into shares of common stock. For all periods presented,&#13;potentially dilutive securities are excluded from the computation in loss periods, as their effect would be antidilutive.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in"&gt;Basic loss per share of common&#13;stock excludes the effect of dilution and is computed by dividing the net loss by the weighted-average number of shares of common&#13;stock outstanding for the period. Diluted loss per share of common stock reflects the potential dilution that could occur if securities&#13;or other contracts to issue shares of common stock were exercised or converted into shares of common stock. For all periods presented,&#13;potentially dilutive securities are excluded from the computation in loss periods, as their effect would be antidilutive.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in"&gt;Potentially dilutive securities&#13;excluded from the calculation of diluted net loss per common share are as follows:&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="padding-bottom: 1.35pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.35pt; text-align: left; font-weight: bold"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="6" style="border-bottom: black 1.5pt solid; text-align: center; font-weight: bold"&gt;December 31,&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-bottom: 1.35pt; text-align: left; font-weight: bold"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="padding-bottom: 1.35pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.35pt; text-align: left; font-weight: bold"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; font-weight: bold"&gt;2012&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-bottom: 1.35pt; text-align: left; font-weight: bold"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.35pt; text-align: left; font-weight: bold"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; font-weight: bold"&gt;2011&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-bottom: 1.35pt; text-align: left; font-weight: bold"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td style="width: 76%; text-align: left"&gt;Series A preferred stock issued and outstanding&lt;font style="font-size: 7pt"&gt; (1)&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 9%; text-align: right"&gt;15,000,000&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="width: 1%; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 9%; text-align: right"&gt;4,370,550&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="width: 1%; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="text-align: justify"&gt;Warrant shares issuable to Platinum upon exercise of common stock warrants by Platinum upon exchange of Series A preferred stock under the terms of the October 11, 2012 Note Purchase and Exchange Agreement&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;7,500,000&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;-&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td style="text-align: left"&gt;Outstanding options under the 2008 and 1999 Stock Incentive Plans&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;4,966,771&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;4,806,114&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="text-align: left"&gt;Outstanding warrants to purchase common stock&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;9,873,034&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;3,451,728&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td style="padding-bottom: 1.35pt; text-align: justify"&gt;October 2012 10% convertible Exchange Note and Investment Notes issued to Platinum including accrued interest through December 31, 2012 &lt;font style="font-size: 7pt"&gt;(2)&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.35pt; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: right"&gt;4,645,198&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-bottom: 1.35pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.35pt; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: right"&gt;-&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-bottom: 1.35pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td style="padding-bottom: 2.65pt; text-align: left"&gt;Total&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.65pt; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;41,895,003&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-bottom: 2.65pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.65pt; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;12,628,392&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-bottom: 2.65pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;    &lt;td style="width: 100%; text-align: left; font-size: 7pt"&gt;(1)&amp;#160;&amp;#160;at December 31, 2012, assumes exchange under the terms of the October 11, 2012&amp;#160;&amp;#160;Note Exchange and Purchase Agreement with Platinum&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;    &lt;td style="text-align: left; font-size: 7pt"&gt;(2)&amp;#160;&amp;#160;assumes conversion under the terms of the October 11, 2012&amp;#160;&amp;#160;Note Exchange and Purchase Agreement with Platinum and the terms of the individual notes&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"&gt;&lt;/p&gt;</us-gaap:EarningsPerSharePolicyTextBlock>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock contextRef="From2012-04-01to2012-12-31">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="letter-spacing: 9pt"&gt;&amp;#160;&amp;#160;&amp;#160;&lt;/font&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&#13;There have been no recent accounting pronouncements or changes in accounting pronouncements during the nine months ended December&#13;31, 2012, as compared to the recent accounting pronouncements described in the Company&amp;#146;s Form 10-K for the fiscal year ended&#13;March 31, 2012, that are of significance or potential significance to the Company.&lt;/p&gt;</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <us-gaap:FairValueMeasurementPolicyPolicyTextBlock contextRef="From2012-04-01to2012-12-31">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in"&gt;The Company follows the principles&#13;of fair value accounting as they relate to its financial assets and financial liabilities. Fair value is defined as the estimated&#13;exit price received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the&#13;measurement date, rather than an entry price that represents the purchase price of an asset or liability. Where available, fair&#13;value is based on observable market prices or parameters, or derived from such prices or parameters. Where observable prices or&#13;inputs are not available, valuation models are applied. These valuation techniques involve some level of management estimation&#13;and judgment, the degree of which is dependent on several factors, including the instrument&amp;#146;s complexity. The required fair&#13;value hierarchy that prioritizes observable and unobservable inputs used to measure fair value into three broad levels is described&#13;as follows:&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table align="center" cellspacing="0" cellpadding="0" style="width: 100%"&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;    &lt;td style="width: 48px; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 30px; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&amp;#9679;&lt;/td&gt;&#13;    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;i&gt;Level 1&lt;/i&gt; &amp;#151; Quoted prices (unadjusted) in active markets that are accessible at the measurement date for assets or liabilities. The fair value hierarchy gives the highest priority to Level 1 inputs.&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table align="center" cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;    &lt;td style="width: 48px; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 30px; text-align: left"&gt;&amp;#9679;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;i&gt;Level 2&lt;/i&gt; &amp;#151; Inputs other than Level 1 that are observable, either directly or indirectly, such as quoted prices for similar assets or liabilities; quoted prices in markets that are not active; or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities.&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table align="center" cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;    &lt;td style="width: 48px; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 30px; text-align: left"&gt;&amp;#9679;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;i&gt;Level 3&lt;/i&gt; &amp;#151; Unobservable inputs (&lt;i&gt;i.e., &lt;/i&gt;inputs that reflect the reporting entity&amp;#146;s own assumptions about the assumptions that market participants would use in estimating the fair value of an asset or liability) are used when little or no market data is available. The fair value hierarchy gives the lowest priority to Level 3 inputs.&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in"&gt;A financial instrument&amp;#146;s&#13;categorization within the valuation hierarchy is based upon the lowest level of input that is significant to the fair value measurement.&#13;Where quoted prices are available in an active market, securities are classified as Level 1 of the valuation hierarchy. If quoted&#13;market prices are not available for the specific financial instrument, then the Company estimates fair value by using pricing models,&#13;quoted prices of financial instruments with similar characteristics or discounted cash flows. In certain cases where there is limited&#13;activity or less transparency around inputs to valuation, financial assets or liabilities are classified as Level 3 within the&#13;valuation hierarchy.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 27pt"&gt;The Company does not use derivative&#13;instruments for hedging of market risks or for trading or speculative purposes. In conjunction with the issuance of the Senior&#13;Secured Convertible Promissory Notes and related warrants to Platinum in October 2012 (see Note 7, &lt;i&gt;Convertible Promissory Notes&#13;and Other Notes Payable&lt;/i&gt;), the Company determined that the warrants included certain exercise price adjustment features and,&#13;as a result, the Company determined that the warrants were liabilities, which were recorded at their estimated fair value. The&#13;Company determined the fair value of the warrant liability using a Monte Carlo simulation model with Level 3 inputs. Inputs used&#13;to determine fair value include estimated value of the underlying common stock at the valuation measurement date, the remaining&#13;contractual term of the notes and warrants, risk-free interest rates, expected volatility of the price of the underlying common&#13;stock, and the probability of a financing transaction that would trigger a reset in the warrant exercise price. Changes in the&#13;fair value of this liability have been recognized as non-cash income in other income (expense) in the Condensed Consolidated Statements&#13;of Operations and Comprehensive Income.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 27pt"&gt;The fair value hierarchy for&#13;liabilities measured at fair value on a recurring basis is as follows:&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 27pt"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="padding-bottom: 1.35pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.35pt; text-align: left; font-weight: bold"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="padding-bottom: 1.35pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-bottom: 1.35pt; text-align: left; font-weight: bold"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.35pt; text-align: left; font-weight: bold"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="10" style="border-bottom: black 1.5pt solid; text-align: center; font-weight: bold"&gt;Fair Value Measurements at Reporting Date Using&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-bottom: 1.35pt; text-align: left; font-weight: bold"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font-weight: bold"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: center; font-weight: bold"&gt;Quoted Prices&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: left; font-weight: bold"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font-weight: bold"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: center; font-weight: bold"&gt;in Active&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: left; font-weight: bold"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font-weight: bold"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: center; font-weight: bold"&gt;Significant&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: left; font-weight: bold"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font-weight: bold"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: center; font-weight: bold"&gt;Markets for&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: left; font-weight: bold"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font-weight: bold"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: center; font-weight: bold"&gt;Other&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: left; font-weight: bold"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font-weight: bold"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: center; font-weight: bold"&gt;Significant&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: left; font-weight: bold"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font-weight: bold"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: center; font-weight: bold"&gt;Total&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: left; font-weight: bold"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font-weight: bold"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: center; font-weight: bold"&gt;Identical&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: left; font-weight: bold"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font-weight: bold"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: center; font-weight: bold"&gt;Observable&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: left; font-weight: bold"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font-weight: bold"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: center; font-weight: bold"&gt;Unobservable&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: left; font-weight: bold"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font-weight: bold"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: center; font-weight: bold"&gt;Carrying&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: left; font-weight: bold"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font-weight: bold"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: center; font-weight: bold"&gt;Assets&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: left; font-weight: bold"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font-weight: bold"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: center; font-weight: bold"&gt;Inputs&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: left; font-weight: bold"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font-weight: bold"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: center; font-weight: bold"&gt;Inputs&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: left; font-weight: bold"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="padding-bottom: 1.35pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.35pt; text-align: left; font-weight: bold"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; font-weight: bold"&gt;Value&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-bottom: 1.35pt; text-align: left; font-weight: bold"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.35pt; text-align: left; font-weight: bold"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; font-weight: bold"&gt;(Level 1)&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-bottom: 1.35pt; text-align: left; font-weight: bold"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.35pt; text-align: left; font-weight: bold"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; font-weight: bold"&gt;(Level 2)&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-bottom: 1.35pt; text-align: left; font-weight: bold"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.35pt; text-align: left; font-weight: bold"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; font-weight: bold"&gt;(Level 3)&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-bottom: 1.35pt; text-align: left; font-weight: bold"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="text-align: left"&gt;December 31, 2012:&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td style="width: 40%; padding-bottom: 2.65pt; text-align: left"&gt;&amp;#160;Warrant liability&lt;/td&gt;&#13;    &lt;td style="width: 1%; padding-bottom: 2.65pt; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; border-bottom: black 2.25pt double; text-align: left"&gt;$&lt;/td&gt;&#13;    &lt;td style="width: 12%; border-bottom: black 2.25pt double; text-align: right"&gt;3,910,400&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="width: 1%; padding-bottom: 2.65pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; padding-bottom: 2.65pt; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; border-bottom: black 2.25pt double; text-align: left"&gt;$&lt;/td&gt;&#13;    &lt;td style="width: 12%; border-bottom: black 2.25pt double; text-align: right"&gt;-&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="width: 1%; padding-bottom: 2.65pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; padding-bottom: 2.65pt; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; border-bottom: black 2.25pt double; text-align: left"&gt;$&lt;/td&gt;&#13;    &lt;td style="width: 12%; border-bottom: black 2.25pt double; text-align: right"&gt;-&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="width: 1%; padding-bottom: 2.65pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; padding-bottom: 2.65pt; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; border-bottom: black 2.25pt double; text-align: left"&gt;$&lt;/td&gt;&#13;    &lt;td style="width: 12%; border-bottom: black 2.25pt double; text-align: right"&gt;3,910,400&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="width: 1%; padding-bottom: 2.65pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="text-align: left"&gt;March 31, 2012:&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td style="padding-bottom: 2.65pt; text-align: left"&gt;&amp;#160;Warrant liability&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.65pt; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: left"&gt;$&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;-&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-bottom: 2.65pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.65pt; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: left"&gt;$&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;-&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-bottom: 2.65pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.65pt; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: left"&gt;$&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;-&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-bottom: 2.65pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.65pt; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: left"&gt;$&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;-&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-bottom: 2.65pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 27pt"&gt;During the three month periods&#13;ended December 31, 2012, there were no significant changes to the valuation models used for purposes of determining the fair value&#13;of the Level 3 warrant liability.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 27pt"&gt;The changes in Level 3 liabilities&#13;measured at fair value on a recurring basis are as follows:&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 27pt"&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 27pt"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="font-weight: bold"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;Warrant&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="font-weight: bold"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="font-weight: bold"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: center"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="font-weight: bold"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1.5pt solid; font-weight: bold; text-align: center"&gt;Liability&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-bottom: 1.5pt; font-weight: bold"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1.5pt solid; font-weight: bold; text-align: center"&gt;Total&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-bottom: 1.5pt; font-weight: bold"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td style="width: 70%"&gt;Balance at March 31, 2012&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;$&lt;/td&gt;&#13;    &lt;td style="width: 12%; text-align: right"&gt;-&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;$&lt;/td&gt;&#13;    &lt;td style="width: 12%; text-align: right"&gt;-&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td colspan="3" style="text-indent: -9pt"&gt;Recognition of warrant liability upon issuance of&amp;#160;warrants to Platinum under October 2012 Agreement&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;1,200,000&lt;/td&gt;&#13;    &lt;td nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;1,200,000&lt;/td&gt;&#13;    &lt;td nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td&gt;Recognition of warrant liability in connection with Series A Exchange Warrant potentially issuable to Platinum under October 2012 Agreement&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;3,068,200&lt;/td&gt;&#13;    &lt;td nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;3,068,200&lt;/td&gt;&#13;    &lt;td nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;Mark to market gain included in net loss&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: right"&gt;(357,800&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-bottom: 1.5pt"&gt;)&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: right"&gt;(357,800&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-bottom: 1.5pt"&gt;)&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="padding-bottom: 3pt"&gt;Balance at December 31, 2012&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 3pt; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double"&gt;$&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;3,910,400&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-bottom: 3pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 3pt; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double"&gt;$&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;3,910,400&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-bottom: 3pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 27pt"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 27pt"&gt;No assets or other liabilities&#13;were carried at fair value at December 31, 2012 or March 31, 2012.&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="letter-spacing: 9pt"&gt;&amp;#160;&amp;#160;&amp;#160;&lt;/font&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&#13;During 2007 and 2008, the Company issued three convertible promissory notes with an aggregate principal balance of $4.0 million&#13;(the &amp;#147;&lt;i&gt;Original Platinum Notes&lt;/i&gt;&amp;#148;) to Platinum Long Term Growth VII, LLC (&amp;#147;&lt;i&gt;Platinum&lt;/i&gt;&amp;#148;). On May&#13;5, 2011, the Original Platinum Notes were amended, restated and consolidated into a single note (the &amp;#147;&lt;i&gt;May 2011&lt;/i&gt; &lt;i&gt;Platinum&#13;Note&lt;/i&gt;&amp;#148;) with a principal balance of $4.0 million (&amp;#147;&lt;i&gt;May 2011 Amendment&lt;/i&gt;&amp;#148;). In conjunction with the issuance&#13;of the Original Platinum Notes, the Company determined that i) the cash payment option or put option, which provided the lender&#13;with the right to require the Company to repay part of the debt at a 25% premium, and ii) the note term extension option, which&#13;provided the lender with the right to extend the maturity date by one year, were embedded derivatives that should be bifurcated&#13;and accounted for separately as liabilities. In conjunction with the issuance of the Original Platinum Notes, the Company also&#13;issued warrants to purchase 560,000 shares of its common stock. These warrants included certain exercise price adjustment features&#13;and, as a result, the Company determined that the warrants were liabilities, which were recorded at their estimated fair value.&#13;The Company determined the fair value of the i) put option and note term extension option using an internal valuation model with&#13;Level 3 inputs and ii) the warrant liability using a lattice model with Level 3 inputs. Inputs used to determine fair value include&#13;estimated value of the underlying common stock at the valuation measurement date, the remaining contractual term of the notes,&#13;risk-free interest rates, expected volatility of the price of the underlying common stock, and the probability of a qualified financing.&#13;Changes in the fair value of these liabilities prior to the May 2011 Amendment were recognized as a non-cash charge or income in&#13;other income (expense) in the consolidated statements of operations.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in"&gt;As a result of the May 2011&#13;Amendment, the Original Platinum Notes were amended and restated on May 5, 2011, eliminating the cash payment option. Further,&#13;concurrent with the Merger transaction described in Note 1 above, the warrants were determined not to be liabilities, since the&#13;exercise price adjustment feature ended upon the Company becoming a public company as a result of the Merger. The increase in fair&#13;value of the warrant liability of $7,000 and the increase in the put option and note term extension option liabilities of $71,000&#13;were recognized in other expense, net in the statement of operations for the quarter ended June 30, 2011. The remaining put option&#13;and note term extension option liabilities, in the amount of $161,700, were reclassified to note discount in connection with the&#13;May 2011 Amendment. The aggregated fair value of the warrants at May 11, 2011, $424,100, was reclassified from a liability to additional&#13;paid-in capital, a component of stockholders&amp;#146; deficit.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in"&gt;In December 2011, the Company&#13;and Platinum entered into a Note and Warrant Exchange Agreement pursuant to which the May 2011 Platinum Note and warrants issued&#13;to Platinum were cancelled in exchange for shares of the Company&amp;#146;s Series A Preferred.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"&gt;&amp;#160;&lt;/p&gt;</us-gaap:FairValueMeasurementPolicyPolicyTextBlock>
    <us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock contextRef="From2012-04-01to2012-12-31">&lt;p style="margin: 0pt"&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in"&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in"&gt;Potentially dilutive securities&#13;excluded from the calculation of diluted net loss per common share are as follows:&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="padding-bottom: 1.35pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.35pt; text-align: left; font-weight: bold"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="6" style="border-bottom: black 1.5pt solid; text-align: center; font-weight: bold"&gt;December 31,&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-bottom: 1.35pt; text-align: left; font-weight: bold"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="padding-bottom: 1.35pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.35pt; text-align: left; font-weight: bold"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; font-weight: bold"&gt;2012&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-bottom: 1.35pt; text-align: left; font-weight: bold"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.35pt; text-align: left; font-weight: bold"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; font-weight: bold"&gt;2011&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-bottom: 1.35pt; text-align: left; font-weight: bold"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td style="width: 76%; text-align: left"&gt;Series A preferred stock issued and outstanding&lt;font style="font-size: 7pt"&gt; (1)&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 9%; text-align: right"&gt;15,000,000&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="width: 1%; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 9%; text-align: right"&gt;4,370,550&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="width: 1%; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="text-align: justify"&gt;Warrant shares issuable to Platinum upon exercise of common stock warrants by Platinum upon exchange of Series A preferred stock under the terms of the October 11, 2012 Note Purchase and Exchange Agreement&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;7,500,000&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;-&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td style="text-align: left"&gt;Outstanding options under the 2008 and 1999 Stock Incentive Plans&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;4,966,771&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;4,806,114&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="text-align: left"&gt;Outstanding warrants to purchase common stock&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;9,873,034&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;3,451,728&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td style="padding-bottom: 1.35pt; text-align: justify"&gt;October 2012 10% convertible Exchange Note and Investment Notes issued to Platinum including accrued interest through December 31, 2012 &lt;font style="font-size: 7pt"&gt;(2)&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.35pt; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: right"&gt;4,645,198&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-bottom: 1.35pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.35pt; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: right"&gt;-&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-bottom: 1.35pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td style="padding-bottom: 2.65pt; text-align: left"&gt;Total&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.65pt; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;41,895,003&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-bottom: 2.65pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.65pt; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;12,628,392&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-bottom: 2.65pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;    &lt;td style="width: 100%; text-align: left; font-size: 7pt"&gt;(1)&amp;#160;&amp;#160;at December 31, 2012, assumes exchange under the terms of the October 11, 2012&amp;#160;&amp;#160;Note Exchange and Purchase Agreement with Platinum&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;    &lt;td style="text-align: left; font-size: 7pt"&gt;(2)&amp;#160;&amp;#160;assumes conversion under the terms of the October 11, 2012&amp;#160;&amp;#160;Note Exchange and Purchase Agreement with Platinum and the terms of the individual notes&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="margin: 0pt"&gt;&lt;/p&gt;</us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock>
    <us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock contextRef="From2012-04-01to2012-12-31">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 27pt"&gt;The fair value hierarchy for&#13;liabilities measured at fair value on a recurring basis is as follows:&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 27pt"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="padding-bottom: 1.35pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.35pt; text-align: left; font-weight: bold"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="padding-bottom: 1.35pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-bottom: 1.35pt; text-align: left; font-weight: bold"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.35pt; text-align: left; font-weight: bold"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="10" style="border-bottom: black 1.5pt solid; text-align: center; font-weight: bold"&gt;Fair Value Measurements at Reporting Date Using&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-bottom: 1.35pt; text-align: left; font-weight: bold"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font-weight: bold"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: center; font-weight: bold"&gt;Quoted Prices&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: left; font-weight: bold"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font-weight: bold"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: center; font-weight: bold"&gt;in Active&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: left; font-weight: bold"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font-weight: bold"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: center; font-weight: bold"&gt;Significant&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: left; font-weight: bold"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font-weight: bold"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: center; font-weight: bold"&gt;Markets for&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: left; font-weight: bold"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font-weight: bold"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: center; font-weight: bold"&gt;Other&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: left; font-weight: bold"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font-weight: bold"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: center; font-weight: bold"&gt;Significant&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: left; font-weight: bold"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font-weight: bold"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: center; font-weight: bold"&gt;Total&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: left; font-weight: bold"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font-weight: bold"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: center; font-weight: bold"&gt;Identical&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: left; font-weight: bold"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font-weight: bold"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: center; font-weight: bold"&gt;Observable&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: left; font-weight: bold"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font-weight: bold"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: center; font-weight: bold"&gt;Unobservable&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: left; font-weight: bold"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font-weight: bold"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: center; font-weight: bold"&gt;Carrying&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: left; font-weight: bold"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font-weight: bold"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: center; font-weight: bold"&gt;Assets&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: left; font-weight: bold"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font-weight: bold"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: center; font-weight: bold"&gt;Inputs&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: left; font-weight: bold"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font-weight: bold"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: center; font-weight: bold"&gt;Inputs&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: left; font-weight: bold"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="padding-bottom: 1.35pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.35pt; text-align: left; font-weight: bold"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; font-weight: bold"&gt;Value&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-bottom: 1.35pt; text-align: left; font-weight: bold"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.35pt; text-align: left; font-weight: bold"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; font-weight: bold"&gt;(Level 1)&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-bottom: 1.35pt; text-align: left; font-weight: bold"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.35pt; text-align: left; font-weight: bold"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; font-weight: bold"&gt;(Level 2)&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-bottom: 1.35pt; text-align: left; font-weight: bold"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.35pt; text-align: left; font-weight: bold"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; font-weight: bold"&gt;(Level 3)&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-bottom: 1.35pt; text-align: left; font-weight: bold"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="text-align: left"&gt;December 31, 2012:&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td style="width: 40%; padding-bottom: 2.65pt; text-align: left"&gt;&amp;#160;Warrant liability&lt;/td&gt;&#13;    &lt;td style="width: 1%; padding-bottom: 2.65pt; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; border-bottom: black 2.25pt double; text-align: left"&gt;$&lt;/td&gt;&#13;    &lt;td style="width: 12%; border-bottom: black 2.25pt double; text-align: right"&gt;3,910,400&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="width: 1%; padding-bottom: 2.65pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; padding-bottom: 2.65pt; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; border-bottom: black 2.25pt double; text-align: left"&gt;$&lt;/td&gt;&#13;    &lt;td style="width: 12%; border-bottom: black 2.25pt double; text-align: right"&gt;-&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="width: 1%; padding-bottom: 2.65pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; padding-bottom: 2.65pt; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; border-bottom: black 2.25pt double; text-align: left"&gt;$&lt;/td&gt;&#13;    &lt;td style="width: 12%; border-bottom: black 2.25pt double; text-align: right"&gt;-&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="width: 1%; padding-bottom: 2.65pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; padding-bottom: 2.65pt; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; border-bottom: black 2.25pt double; text-align: left"&gt;$&lt;/td&gt;&#13;    &lt;td style="width: 12%; border-bottom: black 2.25pt double; text-align: right"&gt;3,910,400&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="width: 1%; padding-bottom: 2.65pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="text-align: left"&gt;March 31, 2012:&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td style="padding-bottom: 2.65pt; text-align: left"&gt;&amp;#160;Warrant liability&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.65pt; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: left"&gt;$&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;-&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-bottom: 2.65pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.65pt; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: left"&gt;$&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;-&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-bottom: 2.65pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.65pt; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: left"&gt;$&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;-&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-bottom: 2.65pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.65pt; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: left"&gt;$&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;-&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-bottom: 2.65pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"&gt;&amp;#160;&lt;/p&gt;</us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock>
    <VSTA:ChangesInLevel3Liabilities contextRef="From2012-04-01to2012-12-31">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 27pt"&gt;The changes in Level 3 liabilities&#13;measured at fair value on a recurring basis are as follows:&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 27pt"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 27pt"&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 27pt"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="font-weight: bold"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;Warrant&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="font-weight: bold"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="font-weight: bold"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: center"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="font-weight: bold"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1.5pt solid; font-weight: bold; text-align: center"&gt;Liability&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-bottom: 1.5pt; font-weight: bold"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1.5pt solid; font-weight: bold; text-align: center"&gt;Total&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-bottom: 1.5pt; font-weight: bold"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td style="width: 70%"&gt;Balance at March 31, 2012&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;$&lt;/td&gt;&#13;    &lt;td style="width: 12%; text-align: right"&gt;-&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;$&lt;/td&gt;&#13;    &lt;td style="width: 12%; text-align: right"&gt;-&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td colspan="3" style="text-indent: -9pt"&gt;Recognition of warrant liability upon issuance of&amp;#160;warrants to Platinum under October 2012 Agreement&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;1,200,000&lt;/td&gt;&#13;    &lt;td nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;1,200,000&lt;/td&gt;&#13;    &lt;td nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td&gt;Recognition of warrant liability in connection with Series A Exchange Warrant potentially issuable to Platinum under October 2012 Agreement&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;3,068,200&lt;/td&gt;&#13;    &lt;td nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;3,068,200&lt;/td&gt;&#13;    &lt;td nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;Mark to market gain included in net loss&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: right"&gt;(357,800&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-bottom: 1.5pt"&gt;)&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: right"&gt;(357,800&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-bottom: 1.5pt"&gt;)&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="padding-bottom: 3pt"&gt;Balance at December 31, 2012&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 3pt; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double"&gt;$&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;3,910,400&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-bottom: 3pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 3pt; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double"&gt;$&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;3,910,400&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-bottom: 3pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&amp;#160;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 27pt"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 27pt"&gt;&amp;#160;&lt;/p&gt;</VSTA:ChangesInLevel3Liabilities>
    <VSTA:PrepaidExpensesTableTextBlock contextRef="From2012-04-01to2012-12-31">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in"&gt;Prepaid expenses consist of&#13;the following at December 31, 2012 and March 31, 2012 (amounts in 100&amp;#146;s).&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: center"&gt;December 31,&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: center"&gt;March 31,&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="padding-bottom: 1.35pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.35pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"&gt;2012&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-bottom: 1.35pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.35pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"&gt;2012&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-bottom: 1.35pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td style="width: 70%; text-align: left"&gt;&amp;#160;Investor relations and awareness services paid&amp;#160;by issuance of common stock or warrants&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&#13;    &lt;td style="width: 12%; text-align: right"&gt;-&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="width: 1%; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&#13;    &lt;td style="width: 12%; text-align: right"&gt;19,700&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="width: 1%; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;Insurance&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;42,300&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;19,000&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;Legal fees&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;28,900&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;6,100&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="padding-bottom: 1.35pt; text-align: left"&gt;&amp;#160;All other&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.35pt; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: right"&gt;11,600&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-bottom: 1.35pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.35pt; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: right"&gt;6,100&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-bottom: 1.35pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="padding-bottom: 2.65pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.65pt; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: left"&gt;$&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;82,800&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-bottom: 2.65pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.65pt; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: left"&gt;$&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;50,900&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-bottom: 2.65pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;</VSTA:PrepaidExpensesTableTextBlock>
    <us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock contextRef="From2012-04-01to2012-12-31">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in"&gt;Accrued expenses consist of&#13;the following at December 31, 2012 and March 31, 2012 (amounts in 100&amp;#146;s).&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: center"&gt;December 31,&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: center"&gt;March 31,&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="padding-bottom: 1.35pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.35pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"&gt;2012&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-bottom: 1.35pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.35pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"&gt;2012&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-bottom: 1.35pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td style="width: 70%; text-align: left"&gt;&amp;#160;Accrued professional services&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&#13;    &lt;td style="width: 12%; text-align: right"&gt;68,300&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="width: 1%; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&#13;    &lt;td style="width: 12%; text-align: right"&gt;107,400&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="width: 1%; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;Accrued research and development expenses&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;-&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;237,500&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;Accrued vacation pay and other compensation&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;223,400&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;229,900&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;Accrued placement agent fees&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;50,000&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;50,000&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;Accrued royalties and license fees&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;29,700&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;5,000&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="padding-bottom: 1.35pt; text-align: left"&gt;&amp;#160;All other&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.35pt; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: right"&gt;10,900&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-bottom: 1.35pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.35pt; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: right"&gt;27,500&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-bottom: 1.35pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="padding-bottom: 2.65pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.65pt; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: left"&gt;$&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;382,300&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-bottom: 2.65pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.65pt; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: left"&gt;$&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;657,300&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-bottom: 2.65pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;</us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock>
    <VSTA:ConvertiblePromissoryNotesAndOtherNotesPayableTableTextBlock contextRef="From2012-04-01to2012-12-31">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in"&gt;The following table summarizes&#13;the components of the company&amp;#146;s secured and unsecured promissory notes and other notes payable at December 31, 2012 and March&#13;31, 2012 (amounts in 100&amp;#146;s).&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="padding-bottom: 1.35pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.35pt; text-align: left; font-weight: bold"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="10" style="border-bottom: black 1.5pt solid; text-align: center; font-weight: bold"&gt;December 31, 2012&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-bottom: 1.35pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.35pt; text-align: left; font-weight: bold"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="10" style="border-bottom: black 1.5pt solid; text-align: center; font-weight: bold"&gt;March 31, 2012&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-bottom: 1.35pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: center"&gt;Principal&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: center"&gt;Accrued&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: center"&gt;Principal&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: center"&gt;Accrued&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="padding-bottom: 1.35pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.35pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"&gt;Balance&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-bottom: 1.35pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.35pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"&gt;Interest&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-bottom: 1.35pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.35pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"&gt;Total&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-bottom: 1.35pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.35pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"&gt;Balance&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-bottom: 1.35pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.35pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"&gt;Interest&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-bottom: 1.35pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.35pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"&gt;Total&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-bottom: 1.35pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="text-align: left; font-style: italic; font-weight: bold"&gt;Senior Secured 10% Convertible Promissory Notes issued to Platinum:&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td style="width: 28%; text-align: left"&gt;Exchange Note issued on October 11, 2012&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&#13;    &lt;td style="width: 9%; text-align: right"&gt;1,272,600&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="width: 1%; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&#13;    &lt;td style="width: 9%; text-align: right"&gt;28,900&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="width: 1%; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&#13;    &lt;td style="width: 9%; text-align: right"&gt;1,301,500&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="width: 1%; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&#13;    &lt;td style="width: 9%; text-align: right"&gt;-&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="width: 1%; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&#13;    &lt;td style="width: 9%; text-align: right"&gt;-&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="width: 1%; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&#13;    &lt;td style="width: 9%; text-align: right"&gt;-&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="width: 1%; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="text-align: left"&gt;Investment Note issued on October 11, 2012&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;500,000&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;11,300&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;511,300&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;-&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;-&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;-&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td style="padding-bottom: 1.35pt; text-align: left"&gt;Investment Note issued on October 19, 2012&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.35pt; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: right"&gt;500,000&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-bottom: 1.35pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.35pt; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: right"&gt;10,200&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-bottom: 1.35pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.35pt; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: right"&gt;510,200&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-bottom: 1.35pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.35pt; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: right"&gt;-&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-bottom: 1.35pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.35pt; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: right"&gt;-&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-bottom: 1.35pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.35pt; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: right"&gt;-&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-bottom: 1.35pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;2,272,600&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;50,400&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;2,323,000&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;-&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;-&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;-&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td style="padding-bottom: 1.35pt; text-align: left"&gt;Aggregate note discount&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.35pt; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: right"&gt;(985,500&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-bottom: 1.35pt; text-align: left"&gt;)&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.35pt; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: right"&gt;-&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-bottom: 1.35pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.35pt; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: right"&gt;(985,500&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-bottom: 1.35pt; text-align: left"&gt;)&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.35pt; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: right"&gt;-&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-bottom: 1.35pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.35pt; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: right"&gt;-&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-bottom: 1.35pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.35pt; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: right"&gt;-&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-bottom: 1.35pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="padding-bottom: 2.65pt; text-align: left"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;Total Senior notes (non-current)&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.65pt; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: left"&gt;$&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;1,287,100&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-bottom: 2.65pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.65pt; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: left"&gt;$&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;50,400&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-bottom: 2.65pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.65pt; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: left"&gt;$&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;1,337,500&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-bottom: 2.65pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.65pt; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: left"&gt;$&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;-&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-bottom: 2.65pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.65pt; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: left"&gt;$&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;-&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-bottom: 2.65pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.65pt; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: left"&gt;$&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;-&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-bottom: 2.65pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="text-align: left; font-style: italic; font-weight: bold"&gt;Convertible Promissory Notes:&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;February 2012 12% convertible promissory notes&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;-&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;-&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;-&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;500,000&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;5,300&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;505,300&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="padding-bottom: 1.35pt; text-align: left"&gt;&amp;#160;&amp;#160;&amp;#160;Note discount&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.35pt; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: right"&gt;-&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-bottom: 1.35pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.35pt; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: right"&gt;-&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-bottom: 1.35pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.35pt; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: right"&gt;-&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-bottom: 1.35pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.35pt; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: right"&gt;(499,300&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-bottom: 1.35pt; text-align: left"&gt;)&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.35pt; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: right"&gt;-&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-bottom: 1.35pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.35pt; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: right"&gt;(499,300&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-bottom: 1.35pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td style="padding-bottom: 2.65pt; text-align: left"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;Total 12% convertible notes, net (non-current)&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.65pt; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: left"&gt;$&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;-&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-bottom: 2.65pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.65pt; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: left"&gt;$&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;-&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-bottom: 2.65pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.65pt; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: left"&gt;$&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;-&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-bottom: 2.65pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.65pt; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: left"&gt;$&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;700&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-bottom: 2.65pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.65pt; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: left"&gt;$&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;5,300&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-bottom: 2.65pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.65pt; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: left"&gt;$&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;6,000&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-bottom: 2.65pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td style="text-align: left; font-style: italic; font-weight: bold"&gt;Notes Payable to unrelated parties:&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&amp;#160;7.0%&amp;#160;Notes payable (April 2011)&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;11,500&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;100&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;11,600&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;63,800&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;400&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;64,200&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td style="padding-bottom: 1.35pt; text-align: left"&gt;&amp;#160;&amp;#160;7.0%&amp;#160;Notes payable (August 2012)&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.35pt; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: right"&gt;60,000&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-bottom: 1.35pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.35pt; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: right"&gt;1,400&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-bottom: 1.35pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.35pt; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: right"&gt;61,400&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-bottom: 1.35pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.35pt; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: right"&gt;-&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-bottom: 1.35pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.35pt; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: right"&gt;-&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-bottom: 1.35pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.35pt; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: right"&gt;-&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-bottom: 1.35pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;71,500&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;1,500&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;73,000&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;63,800&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;400&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;64,200&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td style="padding-bottom: 1.35pt; text-align: left"&gt;&amp;#160;less: current portion&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.35pt; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: right"&gt;(18,100&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-bottom: 1.35pt; text-align: left"&gt;)&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.35pt; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: right"&gt;(1,500&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-bottom: 1.35pt; text-align: left"&gt;)&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.35pt; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: right"&gt;(19,600&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-bottom: 1.35pt; text-align: left"&gt;)&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.35pt; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: right"&gt;(63,800&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-bottom: 1.35pt; text-align: left"&gt;)&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.35pt; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: right"&gt;(400&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-bottom: 1.35pt; text-align: left"&gt;)&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.35pt; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: right"&gt;(64,200&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-bottom: 1.35pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="padding-bottom: 2.65pt; text-align: left"&gt;&amp;#160;&amp;#160;7.0%&amp;#160;Notes payable - non-current portion&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.65pt; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: left"&gt;$&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;53,400&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-bottom: 2.65pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.65pt; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: left"&gt;$&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;-&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-bottom: 2.65pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.65pt; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: left"&gt;$&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;53,400&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-bottom: 2.65pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.65pt; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: left"&gt;$&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;-&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-bottom: 2.65pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.65pt; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: left"&gt;$&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;-&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-bottom: 2.65pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.65pt; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: left"&gt;$&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;-&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-bottom: 2.65pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&amp;#160;7.5%&amp;#160;Notes payable to service providers for accounts payable&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="text-align: left"&gt;converted to notes payable:&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;Burr, Pilger, Mayer&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;91,800&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;900&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;92,700&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;93,400&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;1,100&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;94,500&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;Desjardins&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;211,700&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;2,000&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;213,700&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;224,300&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;2,800&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;227,100&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;McCarthy Tetrault&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;435,900&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;200&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;436,100&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;459,400&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;5,700&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;465,100&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;May 2011 Morrison Foerster&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;-&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;-&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;-&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;2,420,100&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;37,900&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;2,458,000&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;August 2012 Morrison &amp;#38; Foerster Note A&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;964,700&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;-&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;964,700&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;-&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;-&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;-&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;August 2012 Morrison &amp;#38; Foerster Note B &lt;font style="font-size: 7pt"&gt;(1)&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;1,379,400&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;34,600&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;1,414,000&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;-&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;-&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;-&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td style="padding-bottom: 1.35pt; text-align: left"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;University Health Network&amp;#160;&amp;#160;&lt;font style="font-size: 7pt"&gt;(1)&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.35pt; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: right"&gt;549,500&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-bottom: 1.35pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.35pt; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: right"&gt;9,300&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-bottom: 1.35pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.35pt; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: right"&gt;558,800&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-bottom: 1.35pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.35pt; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: right"&gt;-&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-bottom: 1.35pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.35pt; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: right"&gt;-&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-bottom: 1.35pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.35pt; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: right"&gt;-&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-bottom: 1.35pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;3,633,000&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;47,000&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;3,680,000&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;3,197,200&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;47,500&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;3,244,700&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td style="padding-bottom: 1.35pt; text-align: left"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;Note discount&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.35pt; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: right"&gt;(1,205,500&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-bottom: 1.35pt; text-align: left"&gt;)&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.35pt; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: right"&gt;-&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-bottom: 1.35pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.35pt; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: right"&gt;(1,205,500&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-bottom: 1.35pt; text-align: left"&gt;)&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.35pt; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: right"&gt;(228,900&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-bottom: 1.35pt; text-align: left"&gt;)&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.35pt; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: right"&gt;-&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-bottom: 1.35pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.35pt; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: right"&gt;(228,900&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-bottom: 1.35pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;2,427,500&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;47,000&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;2,474,500&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;2,968,300&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;47,500&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;3,015,800&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td style="padding-bottom: 1.35pt; text-align: left"&gt;&amp;#160;less: current portion&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.35pt; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: right"&gt;(617,000&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-bottom: 1.35pt; text-align: left"&gt;)&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.35pt; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: right"&gt;(3,100&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-bottom: 1.35pt; text-align: left"&gt;)&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.35pt; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: right"&gt;(620,100&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-bottom: 1.35pt; text-align: left"&gt;)&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.35pt; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: right"&gt;(367,700&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-bottom: 1.35pt; text-align: left"&gt;)&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.35pt; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: right"&gt;-&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-bottom: 1.35pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.35pt; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: right"&gt;(367,700&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-bottom: 1.35pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="padding-bottom: 2.65pt; text-align: left"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;non-current portion and discount&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.65pt; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: left"&gt;$&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;1,810,500&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-bottom: 2.65pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.65pt; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: left"&gt;$&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;43,900&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-bottom: 2.65pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.65pt; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: left"&gt;$&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;1,854,400&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-bottom: 2.65pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.65pt; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: left"&gt;$&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;2,600,600&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-bottom: 2.65pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.65pt; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: left"&gt;$&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;47,500&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-bottom: 2.65pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.65pt; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: left"&gt;$&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;2,648,100&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-bottom: 2.65pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td colspan="4" style="text-align: left"&gt;&amp;#160;&amp;#160;&amp;#160;5.8%&amp;#160;&amp;#160;and 8% Notes payable to insurance&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="padding-bottom: 2.65pt; text-align: left"&gt;premium financing company (current)&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.65pt; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: left"&gt;$&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;15,900&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-bottom: 2.65pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.65pt; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: left"&gt;$&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;-&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-bottom: 2.65pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.65pt; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: left"&gt;$&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;15,900&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-bottom: 2.65pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.65pt; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: left"&gt;$&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;4,600&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-bottom: 2.65pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.65pt; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: left"&gt;$&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;-&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-bottom: 2.65pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.65pt; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: left"&gt;$&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;4,600&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-bottom: 2.65pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td colspan="4" style="text-align: left"&gt;&amp;#160;&amp;#160;10%&amp;#160;Notes payable to vendors for accounts&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="text-align: left"&gt;payable converted to notes payable&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;144,400&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;22,100&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;166,500&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;165,400&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;16,800&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;182,200&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td style="padding-bottom: 1.35pt; text-align: left"&gt;&amp;#160;less: current portion&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.35pt; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: right"&gt;(144,400&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-bottom: 1.35pt; text-align: left"&gt;)&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.35pt; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: right"&gt;(22,100&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-bottom: 1.35pt; text-align: left"&gt;)&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.35pt; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: right"&gt;(166,500&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-bottom: 1.35pt; text-align: left"&gt;)&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.35pt; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: right"&gt;(146,000&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-bottom: 1.35pt; text-align: left"&gt;)&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.35pt; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: right"&gt;-&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-bottom: 1.35pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.35pt; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: right"&gt;(146,000&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-bottom: 1.35pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="padding-bottom: 2.65pt; text-align: left"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;non-current portion&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.65pt; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: left"&gt;$&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;-&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-bottom: 2.65pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.65pt; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: left"&gt;$&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;-&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-bottom: 2.65pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.65pt; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: left"&gt;$&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;-&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-bottom: 2.65pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.65pt; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: left"&gt;$&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;19,400&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-bottom: 2.65pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.65pt; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: left"&gt;$&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;16,800&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-bottom: 2.65pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.65pt; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: left"&gt;$&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;36,200&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-bottom: 2.65pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;Total notes payable to unrelated paties&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;2,659,300&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;70,600&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;2,729,900&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;3,202,100&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;64,700&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;3,266,800&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td style="padding-bottom: 1.35pt; text-align: left"&gt;&amp;#160;less: current portion&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.35pt; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: right"&gt;(795,400&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-bottom: 1.35pt; text-align: left"&gt;)&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.35pt; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: right"&gt;(26,700&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-bottom: 1.35pt; text-align: left"&gt;)&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.35pt; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: right"&gt;(822,100&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-bottom: 1.35pt; text-align: left"&gt;)&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.35pt; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: right"&gt;(582,100&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-bottom: 1.35pt; text-align: left"&gt;)&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.35pt; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: right"&gt;(400&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-bottom: 1.35pt; text-align: left"&gt;)&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.35pt; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: right"&gt;(582,500&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-bottom: 1.35pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="padding-bottom: 2.65pt; text-align: left"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;non-current portion and discount&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.65pt; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: left"&gt;$&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;1,863,900&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-bottom: 2.65pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.65pt; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: left"&gt;$&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;43,900&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-bottom: 2.65pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.65pt; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: left"&gt;$&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;1,907,800&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-bottom: 2.65pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.65pt; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: left"&gt;$&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;2,620,000&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-bottom: 2.65pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.65pt; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: left"&gt;$&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;64,300&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-bottom: 2.65pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.65pt; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: left"&gt;$&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;2,684,300&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-bottom: 2.65pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="text-align: left; font-style: italic; font-weight: bold"&gt;Notes payable to related parties:&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td colspan="2" style="text-align: left"&gt;&amp;#160;&amp;#160;April 2011 7 % Note to Cato Holding Co.&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;-&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;-&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;-&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;293,300&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;6,900&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;300,200&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td colspan="2" style="text-align: left"&gt;&amp;#160;&amp;#160;October 2012 7.5% Note to Cato Holding Co.&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;293,600&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;1,900&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;295,500&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;-&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;-&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;-&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td style="padding-bottom: 1.35pt; text-align: left"&gt;&amp;#160;&amp;#160;October 2012 7.5% Note to Cato Research Ltd.&lt;font style="font-size: 7pt"&gt; (1)&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.35pt; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: right"&gt;1,009,000&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-bottom: 1.35pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.35pt; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: right"&gt;17,100&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-bottom: 1.35pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.35pt; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: right"&gt;1,026,100&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-bottom: 1.35pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.35pt; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: right"&gt;-&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-bottom: 1.35pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.35pt; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: right"&gt;-&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-bottom: 1.35pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.35pt; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: right"&gt;-&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-bottom: 1.35pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;1,302,600&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;19,000&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;1,321,600&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;293,300&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;6,900&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;300,200&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td style="padding-bottom: 1.35pt; text-align: left"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;Note discount&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.35pt; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: right"&gt;(157,900&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-bottom: 1.35pt; text-align: left"&gt;)&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.35pt; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: right"&gt;-&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-bottom: 1.35pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.35pt; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: right"&gt;(157,900&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-bottom: 1.35pt; text-align: left"&gt;)&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.35pt; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: right"&gt;(24,300&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-bottom: 1.35pt; text-align: left"&gt;)&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.35pt; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: right"&gt;-&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-bottom: 1.35pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.35pt; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: right"&gt;(24,300&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-bottom: 1.35pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="padding-bottom: 1.35pt; text-align: left"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;Total notes payable to related parties&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.35pt; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: left"&gt;$&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: right"&gt;1,144,700&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-bottom: 1.35pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.35pt; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: left"&gt;$&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: right"&gt;19,000&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-bottom: 1.35pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.35pt; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: left"&gt;$&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: right"&gt;1,163,700&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-bottom: 1.35pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.35pt; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: left"&gt;$&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: right"&gt;269,000&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-bottom: 1.35pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.35pt; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: left"&gt;$&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: right"&gt;6,900&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-bottom: 1.35pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.35pt; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: left"&gt;$&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: right"&gt;275,900&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-bottom: 1.35pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td style="padding-bottom: 1.35pt; text-align: left"&gt;&amp;#160;less: current portion&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.35pt; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: right"&gt;(110,100&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-bottom: 1.35pt; text-align: left"&gt;)&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.35pt; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: right"&gt;(1,900&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-bottom: 1.35pt; text-align: left"&gt;)&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.35pt; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: right"&gt;(112,000&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-bottom: 1.35pt; text-align: left"&gt;)&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.35pt; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: right"&gt;(168,200&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-bottom: 1.35pt; text-align: left"&gt;)&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.35pt; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: right"&gt;-&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-bottom: 1.35pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.35pt; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: right"&gt;(168,200&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-bottom: 1.35pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="padding-bottom: 2.65pt; text-align: left"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;non-current portion and discount&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.65pt; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: left"&gt;$&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;1,034,600&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-bottom: 2.65pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.65pt; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: left"&gt;$&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;17,100&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-bottom: 2.65pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.65pt; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: left"&gt;$&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;1,051,700&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-bottom: 2.65pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.65pt; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: left"&gt;$&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;100,800&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-bottom: 2.65pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.65pt; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: left"&gt;$&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;6,900&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-bottom: 2.65pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.65pt; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: left"&gt;$&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;107,700&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-bottom: 2.65pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="text-align: left"&gt;____________&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td colspan="24" style="text-align: left; font-size: 7pt"&gt;(1) Note and interest payable solely in restricted shares of the Company's common stock; see description of debt restructuring in Note 7.&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;</VSTA:ConvertiblePromissoryNotesAndOtherNotesPayableTableTextBlock>
    <VSTA:IncrementalValueOfAmendedMfWarrant contextRef="From2012-04-01to2012-12-31">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in"&gt;The Company determined that&#13;the incremental value of the Amended M&amp;#38;F Warrant was $121,650 at the modification date using the Black-Scholes Option Pricing&#13;Model and the following assumptions:&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: left; font-weight: bold"&gt;Assumption:&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.35pt; text-align: left; font-weight: bold"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; font-weight: bold"&gt;Pre-modification&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-bottom: 1.35pt; text-align: left; font-weight: bold"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.35pt; text-align: left; font-weight: bold"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; font-weight: bold"&gt;Post-modification&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-bottom: 1.35pt; text-align: left; font-weight: bold"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td style="width: 64%; text-align: left"&gt;Market price per share&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&#13;    &lt;td style="width: 15%; text-align: right"&gt;0.94&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="width: 1%; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&#13;    &lt;td style="width: 15%; text-align: right"&gt;0.94&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="width: 1%; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="text-align: left"&gt;Exercise price per share&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;2.00&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;2.00&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td style="text-align: left"&gt;Risk-free interest rate&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;0.25&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: left"&gt;%&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;0.60&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="text-align: left"&gt;Expected term (years)&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;2.33&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;5.04&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td style="text-align: left"&gt;Volatility&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;77.9&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: left"&gt;%&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;88.8&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="text-align: left"&gt;Dividend rate&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;0.0&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: left"&gt;%&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;0.0&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="text-align: left; font-weight: bold"&gt;Fair Value per share&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.65pt; text-align: left; font-weight: bold"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font-weight: bold"&gt;$&lt;/td&gt;&#13;    &lt;td style="text-align: right; font-weight: bold"&gt;0.24&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-bottom: 2.65pt; text-align: left; font-weight: bold"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.65pt; text-align: left; font-weight: bold"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font-weight: bold"&gt;$&lt;/td&gt;&#13;    &lt;td style="text-align: right; font-weight: bold"&gt;0.52&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-bottom: 2.65pt; text-align: left; font-weight: bold"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;</VSTA:IncrementalValueOfAmendedMfWarrant>
    <VSTA:BlackscholesOptionPricingModelTableTextBlock contextRef="From2012-04-01to2012-12-31">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"&gt;The warrants subject to the exercise price modifications&#13;were valued using the Black-Scholes Option Pricing Model and the following assumptions:&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: left; font-weight: bold"&gt;Assumption:&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.35pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; font-weight: bold"&gt;Pre-modification&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.35pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.35pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; font-weight: bold"&gt;Post-modification&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.35pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td style="width: 64%; text-align: left"&gt;Market price per share (weighted average)&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&#13;    &lt;td style="width: 15%; text-align: right"&gt;1.95&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&#13;    &lt;td style="width: 15%; text-align: right"&gt;1.95&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="text-align: left"&gt;Exercise price per share (weighted average)&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;2.75&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;0.50&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td style="text-align: left"&gt;Risk-free interest rate (weighted average)&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;0.29%&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;0.06%&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="text-align: left"&gt;Expected term in years (weighted average)&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;1.93&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;0.12&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td style="text-align: left"&gt;Volatility (weighted average)&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;78.0%&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;85.7%&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="text-align: left"&gt;Dividend rate&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;0.0%&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;0.0%&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="text-align: left; font-weight: bold"&gt;Weighted Average Fair Value per share&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font-weight: bold"&gt;$&lt;/td&gt;&#13;    &lt;td style="text-align: right; font-weight: bold"&gt;0.64&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font-weight: bold"&gt;$&lt;/td&gt;&#13;    &lt;td style="text-align: right; font-weight: bold"&gt;1.45&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"&gt;&amp;#160;&lt;/p&gt;</VSTA:BlackscholesOptionPricingModelTableTextBlock>
    <VSTA:WarrantExercisesAndGrantsTableTextBlock contextRef="From2012-04-01to2012-12-31">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in"&gt;Following the warrant exercises&#13;and grants described above, at December 31, 2012, the Company had outstanding warrants to purchase shares of its common stock at&#13;a weighted average exercise price of $1.58 per share as follows:&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table align="center" cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td colspan="2" style="text-align: center; font-weight: bold"&gt;Exercise&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: left; font-weight: bold"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: center; font-weight: bold"&gt;Expiration&lt;/td&gt;&#13;    &lt;td style="text-align: left; font-weight: bold"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: center; font-weight: bold"&gt;December 31,&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: left; font-weight: bold"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; font-weight: bold"&gt;Price&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-bottom: 1.35pt; text-align: left; font-weight: bold"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: center; font-weight: bold"&gt;Date&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.35pt; text-align: left; font-weight: bold"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; font-weight: bold"&gt;2012&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-bottom: 1.35pt; text-align: left; font-weight: bold"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td colspan="2" style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&#13;    &lt;td style="width: 25%; text-align: right"&gt;0.88&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="width: 1%; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 45%; text-align: center"&gt;5/11/2014&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 25%; text-align: right"&gt;15,428&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="width: 1%; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;1.00&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: center"&gt;9/15/2017 to 9/30/2017&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;2,998,809&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;1.25&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: center"&gt;5/11/2014 to 12/31/2014&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;120,280&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;1.50&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: center"&gt;2/28/2017 to 12/13/2017&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;4,021,570&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;1.75&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: center"&gt;12/31/2013&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;577,784&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;2.00&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: center"&gt;8/3/2013 to 9/15/2017&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;604,000&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;2.50&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: center"&gt;5/11/2014&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;492,004&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;2.625&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: center"&gt;12/31/2013&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;480,134&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.35pt; text-align: right"&gt;3.00&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-bottom: 1.35pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.35pt; text-align: center"&gt;5/11/2015 to 2/13/2016&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.35pt; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: right"&gt;563,025&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-bottom: 1.35pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.65pt; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-bottom: 2.65pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.65pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.65pt; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;9,873,034&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-bottom: 2.65pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"&gt;&lt;/p&gt;</VSTA:WarrantExercisesAndGrantsTableTextBlock>
    <VSTA:BlackscholesOptionPricingModelTableAssumptionsTextBlock contextRef="From2012-04-01to2012-12-31">&lt;table align="center" cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white"&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td style="width: 57%; text-align: left"&gt;Expected dividend yield&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: center"&gt;0%&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="width: 1%; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="text-align: left"&gt;Exercise price&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: center"&gt;$0.51 and $0.75&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td style="text-align: left"&gt;Market price on date of grant&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: center"&gt;$0.51 and $0.71&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="text-align: left"&gt;Risk-free interest rate&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: center"&gt;0.895% to 1.74%&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td style="text-align: left"&gt;Expected (years)&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: center"&gt;6.25 to 10.0&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="text-align: left"&gt;Volatility&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: center"&gt;82.9% to 85.4%&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td style="text-align: left"&gt;Fair value per share at grant date&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: center"&gt;$0.36 to $0.59&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;</VSTA:BlackscholesOptionPricingModelTableAssumptionsTextBlock>
    <VSTA:StockOptionActivitySummaryTextBlock contextRef="From2012-04-01to2012-12-31">&lt;table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="6" style="text-align: center"&gt;Nine Months Ended&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="padding-bottom: 1.35pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.35pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="6" style="border-bottom: black 1.5pt solid; text-align: center"&gt;December 31, 2012&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-bottom: 1.35pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: center"&gt;Number of&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: center"&gt;Weighted Average&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="padding-bottom: 1.35pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.35pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"&gt;Shares&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-bottom: 1.35pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.35pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"&gt;Exercise Price&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-bottom: 1.35pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td style="width: 64%; text-align: left"&gt;&amp;#160;Options outstanding at beginning of period&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 15%; text-align: right"&gt;4,805,771&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="width: 1%; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&#13;    &lt;td style="width: 15%; text-align: right"&gt;1.53&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="width: 1%; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="padding-left: 67.3pt; text-align: left"&gt;&amp;#160;Options granted&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;1,075,550&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;0.72&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td style="padding-left: 67.3pt; text-align: left"&gt;&amp;#160;Options exercised&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;-&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;-&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="padding-left: 67.3pt; text-align: left"&gt;&amp;#160;Options cancelled&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;(870,550&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: left"&gt;)&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;1.72&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td style="padding-bottom: 1.35pt; padding-left: 67.3pt; text-align: left"&gt;&amp;#160;Options expired&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.35pt; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: right"&gt;(44,000&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-bottom: 1.35pt; text-align: left"&gt;)&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.35pt; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.35pt; text-align: right"&gt;1.79&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-bottom: 1.35pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td style="padding-bottom: 2.65pt; text-align: left"&gt;&amp;#160;Options outstanding at end of period&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.65pt; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;4,966,771&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-bottom: 2.65pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.65pt; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.65pt; text-align: right"&gt;1.33&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-bottom: 2.65pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="padding-bottom: 2.65pt; text-align: left"&gt;&amp;#160;Options exercisable at end of period&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.65pt; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;4,169,822&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-bottom: 2.65pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.65pt; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.65pt; text-align: right"&gt;1.36&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-bottom: 2.65pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;Weighted average grant-date fair value of&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td style="padding-bottom: 2.65pt; padding-left: 0.85in; text-align: left"&gt;&amp;#160;options granted during the period&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.65pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.65pt; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-bottom: 2.65pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.65pt; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: left"&gt;$&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;0.52&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-bottom: 2.65pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;</VSTA:StockOptionActivitySummaryTextBlock>
    <VSTA:StockOptionsOutstandingAndExercisableUnderCompanysOptionPlanTextBlock contextRef="From2012-04-01to2012-12-31">&lt;table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td colspan="2" style="padding-bottom: 1.35pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-bottom: 1.35pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.35pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="6" style="border-bottom: black 1.5pt solid; text-align: center"&gt;Options Outstanding&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-bottom: 1.35pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.35pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1.5pt solid; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-bottom: 1.35pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.35pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="6" style="border-bottom: black 1.5pt solid; text-align: center"&gt;Options Exercisable&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-bottom: 1.35pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td colspan="2" style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: center"&gt;Weighted&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="6" style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td colspan="2" style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: center"&gt;Average&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: center"&gt;Weighted&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: center"&gt;Weighted&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td colspan="2" style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: center"&gt;Remaining&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: center"&gt;Average&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: center"&gt;Average&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td colspan="2" style="text-align: center"&gt;Exercise&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: center"&gt;Number&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: center"&gt;Years until&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: center"&gt;Exercise&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: center"&gt;Number&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: center"&gt;Exercise&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"&gt;Price&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-bottom: 1.35pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.35pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="3" style="border-bottom: black 1.5pt solid; text-align: center"&gt;Outstanding&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.35pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"&gt;Expiration&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-bottom: 1.35pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.35pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"&gt;Price&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-bottom: 1.35pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.35pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="3" style="border-bottom: black 1.5pt solid; text-align: center"&gt;Exercisable&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.35pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"&gt;Price&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-bottom: 1.35pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&#13;    &lt;td style="width: 23%; text-align: right"&gt;0.51 - $0.72&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="width: 1%; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 12%; text-align: right"&gt;267,540&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="width: 1%; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 12%; text-align: right"&gt;7.30&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="width: 1%; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&#13;    &lt;td style="width: 12%; text-align: right"&gt;0.60&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="width: 1%; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 12%; text-align: right"&gt;112,540&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="width: 1%; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&#13;    &lt;td style="width: 12%; text-align: right"&gt;0.72&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="width: 1%; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;0.75&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;920,550&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;9.84&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;0.75&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;631,010&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;0.75&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;0.80 - $1.13&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;455,776&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;4.08&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;1.00&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;445,458&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;0.99&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;1.50&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;2,413,250&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;6.93&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;1.50&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;2,413,250&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;1.50&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;1.65 - $1.925&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;725,000&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;6.32&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;1.76&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;382,909&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;1.73&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.35pt; text-align: right"&gt;2.10 - $2.99&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-bottom: 1.35pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.35pt; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: right"&gt;184,655&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-bottom: 1.35pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.35pt; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.35pt; text-align: right"&gt;4.62&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-bottom: 1.35pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.35pt; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.35pt; text-align: right"&gt;2.18&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-bottom: 1.35pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.35pt; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: right"&gt;184,655&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-bottom: 1.35pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.35pt; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.35pt; text-align: right"&gt;2.18&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-bottom: 1.35pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.65pt; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-bottom: 2.65pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.65pt; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;4,966,771&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-bottom: 2.65pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.65pt; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.65pt; text-align: right"&gt;7.05&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-bottom: 2.65pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.65pt; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.65pt; text-align: right"&gt;1.33&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-bottom: 2.65pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.65pt; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;4,169,822&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-bottom: 2.65pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.65pt; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.65pt; text-align: right"&gt;1.36&lt;/td&gt;&#13;    &lt;td nowrap="nowrap" style="padding-bottom: 2.65pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;</VSTA:StockOptionsOutstandingAndExercisableUnderCompanysOptionPlanTextBlock>
    <VSTA:ChangeInFairValueOfTheWarrantLiability contextRef="From2012-10-01to2012-12-31" unitRef="USD" decimals="0">7000</VSTA:ChangeInFairValueOfTheWarrantLiability>
    <VSTA:IncreaseInPutOptionAndNoteTermExtensionOptionLiabilities contextRef="From2012-10-01to2012-12-31" unitRef="USD" decimals="0">71000</VSTA:IncreaseInPutOptionAndNoteTermExtensionOptionLiabilities>
    <VSTA:RemainingPutOptionAndNoteTermExtensionOptionLiabilities contextRef="From2012-10-01to2012-12-31" unitRef="USD" decimals="0">161700</VSTA:RemainingPutOptionAndNoteTermExtensionOptionLiabilities>
    <VSTA:FinancingRequirement contextRef="From2012-10-01to2012-12-31" unitRef="USD" decimals="0">1000000</VSTA:FinancingRequirement>
    <VSTA:SeniorSecuredConvertibleNoteValue contextRef="From2012-10-01to2012-12-31" unitRef="USD" decimals="0">1000000</VSTA:SeniorSecuredConvertibleNoteValue>
    <VSTA:CashProceeds contextRef="From2012-10-01to2012-12-31" unitRef="USD" decimals="0">1000000</VSTA:CashProceeds>
    <VSTA:RequiredCommitmentSecuringDate contextRef="From2012-10-01to2012-12-31">2013-02-14</VSTA:RequiredCommitmentSecuringDate>
    <VSTA:PlatinumNote contextRef="From2012-10-01to2012-12-31" unitRef="USD" decimals="0">1000000</VSTA:PlatinumNote>
    <us-gaap:PartnersCapitalAccountPrivatePlacementOfUnits contextRef="From2012-10-01to2012-12-31" unitRef="USD" decimals="0">525000</us-gaap:PartnersCapitalAccountPrivatePlacementOfUnits>
    <VSTA:PrivatePlacementFebruaryUnitPerShareValue contextRef="From2012-10-01to2012-12-31" unitRef="USDPShares" decimals="INF">0.5</VSTA:PrivatePlacementFebruaryUnitPerShareValue>
    <VSTA:PrivatePlacementUnitExercisePrice contextRef="From2012-10-01to2012-12-31" unitRef="USDPShares" decimals="INF">1.5</VSTA:PrivatePlacementUnitExercisePrice>
    <link:footnoteLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
      <link:loc xlink:type="locator" xlink:href="#Foot-00-0" xlink:label="Foot-00_loc" />
      <link:footnoteArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="Foot-00_loc" xlink:to="Footnote-01" order="1" />
      <link:footnote xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:label="Footnote-01" xml:lang="en-US">assumes mandatory conversion in connection with a qualified financing at $2.00 per share, plus fee warrants to placement agent</link:footnote>
    </link:footnoteLink>
</xbrli:xbrl>
